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Abstract 
Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are two major types 
of primary liver cancers (PLC), ranking among the deadliest cancers worldwide with 
poor overall survival rates. Lack of clinical symptoms and effective biomarkers for early 
detection are main causes of late diagnosis. Despite identification of several potentially 
drugable targets and subsequent development of next-generation targeted therapies, 
translation of these findings into clinical practice remains challenging. Further, there is 
a lack of models that truly and accurately represent morphological and molecular 
heterogeneity of original tumors. Therefore, development of primary culture models that 
closely recapitulate phenotypic and molecular diversities of PLC is urgently needed to 
support a translation from laboratory studies to the bedside and improve patient 
outcome. 
In the here presented thesis, we report successful establishment and detailed 
characterization of seven patient-derived liver cancer cell lines (PDCL) from HCC and 
intrahepatic CCA. Morphological and histological characteristics of obtained cell lines 
and xenograft tumors were analyzed and compared to original tumors. Tumor grading 
and genomic stability were further assessed to determine background setting for 
successful PDCL establishment. Time course analyses of transcriptomic and genomic 
changes were performed using next-generation sequencing (NGS) to characterize and 
generate molecular profiles of newly derived PDCL and investigate how accurately they 
recapitulate original cancer tissue. Key oncogenic alterations were identified by targeted 
NGS and cell lines carrying potentially actionable mutations were treated with 
corresponding specific inhibitors. Long-term cultivation effect on treatment response to 
classic chemotherapeutics was monitored. 
Our results show that PDCL fully resembled morphological features of the primary 
cancers in vitro and in vivo over extended period in culture. We also provide evidence 
that less differentiated tumors with higher genomic instability possess a higher likelihood 
of successful PDCL establishment. Genomic analyses confirmed that PDCL retain 
similar profile as corresponding primary tumors during long-term culturing. Targeted-
NGS demonstrated that key oncogenic alterations such as TP53, KRAS, CTNNB1 as 
well as actionable mutations (e.g. MET, KIT, KDR) were highly conserved in PDCL and 
amenable for individualized therapeutic approaches. Integrative genomic and 
transcriptomic approaches further demonstrated that PDCL more closely resemble 
molecular and prognostic features of PLC than established cell lines.  
Our integrative analysis demonstrates that PDCL represents refined model for 
discovery of relevant molecular subgroups and exploration of precision medicine 
approaches for the treatment of primary liver cancer. 
 
  
Zusammenfassung 
Primäre Lebertumore (PLC) zählen zu den häufigsten und tödlichsten Krebsarten 
weltweit. Klinisch werden PLCs in Hepatozelluläre Karzinome (HCC) und 
Cholangiokarzinome (CCA) unterteilt. Fehlende spezifische Symptome und 
verlässliche Biomarker für eine Früherkennung sind Hauptgründe für eine späte 
Diagnose, so dass die Möglichkeit von kurativen Therapieverfahren meist begrenzt ist. 
Trotz der Identifizierung mehrerer potenzieller Zielmoleküle und Entwicklung 
zielgerichteter Therapien bleibt die Translation dieser Ergebnisse in die klinische Praxis 
eine Herausforderung. Zudem gibt es keine verlässlichen Modelle, die morphologische 
und molekulare Heterogenität der ursprünglichen Tumore umfänglich und präzise 
widerspiegeln. Die Entwicklung von Primärkulturmodellen, welche die phänotypischen 
und molekularen Eigenschaften von PLC rekapitulieren, ist dringend erforderlich für 
eine erfolgreiche Übertragung der Ergebnisse von Laboruntersuchungen in die 
klinische Praxis. 
In der hier vorliegenden Arbeit wurden sieben neue Patienten-abgeleitete 
Leberkrebszelllinien (patient-derived cell lines; PDCL) erfolgreich generiert und 
umfassend charakterisiert. Die morphologischen und histologischen Eigenschaften der 
Zelllinien sowie der entsprechenden Xenograft-Tumore wurden analysiert und mit den 
ursprünglichen Tumoren verglichen. Tumor-Grading und die genomische Stabilität 
wurden erfasst, um die Voraussetzungen für eine erfolgreiche PDCL-Etablierung zu 
bewerten. Zur Erstellung von molekularen Profilen der neu etablierten PDCL wurden 
Zeitverlaufsanalysen von Genexpression und genomischen Veränderungen wurden 
mittels Next-Generation Sequenzierung (NGS) durchgeführt. Zudem wurde untersucht, 
ob die PDCL Eigenschaften des ursprünglichen Krebsgewebes zuverlässig 
rekapitulieren können. Darüber hinaus wurden potentiell behandelbare Mutationen 
mittels NGS hochauflösend nachgewiesen und in Folge mit spezifischen Inhibitoren 
behandelt. Weiterhin wurde der Effekt einer Langzeitkultivierung auf die 
Behandlungseffektivität klassischer Chemotherapeutika bewertet. 
Die morphologischen Merkmale der primären Krebsarten blieben in PDCL sowohl in 
vitro als auch in vivo über einen längeren Zeitraum in Kultur stabil. Die Ergebnisse 
dieser Studie erbrachten zudem den Nachweis, dass schlecht differenzierte Tumore mit 
höherer genomischer Instabilität eine vermehrte Rate an erfolgreicher Etablierung von 
PDCL aufwiesen. Genomanalysen bestätigten zudem, dass das molekulare Profil der 
Primärtumore während der Langzeitkultivierung in den PDCL konserviert wurde. Mittels 
zielgerichtetem NGS konnte verifiziert werden, dass wichtige onkogene Veränderungen 
wie TP53, KRAS, CTNNB1 sowie behandelbare Mutationen (z. B. MET, KIT, KDR) in 
PDCL nachgewiesen und für individualisierte therapeutische Ansätze genutzt werden 
können. Integrative Analysen zeigten weiterhin, dass PDCL den molekularen und 
prognostischen Merkmalen von PLC stärker ähneln als etablierte Zelllinien und somit 
ein wertvolles Werkzeug für die Bewertung von potenziellen Therapiezielen darstellen. 
Unsere integrative Analyse zeigt, dass PDCL ein geeignetes Modell für die 
Untersuchung relevanter molekularer Untergruppen und die Erforschung von 
präzisionsmedizinischen Ansätzen für die Behandlung von primärem Leberkrebs 
darstellen. 
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1. Introduction 
 General aspects of liver physiology 
 Morphology, histology and liver function 
Liver is the second largest organ and the largest exocrine gland in the human body. 
It accounts for approximately 2,5% of body weight, or about 1,5 kg in average adult 
human.1 The organ is made of soft, reddish-brown tissue, encapsulated by 
connective tissue and divided into two lobes with eight segments of unequal size 
and shapes. The liver is one of the most biochemically and metabolically complex 
and active organs in the body. It receives oxygen-poor and nutrient-rich blood from 
the portal vein, comprising approximately 70-80% of total blood supply in the liver. 
In parallel, liver receives oxygenated blood with low nutrient content from hepatic 
artery, comprising approximately 20-30% of total liver blood supply. Portal vein and 
hepatic artery enter the liver and divide into smaller vessels of the liver lobules. 
Blood further continues through the small blood vessels called sinusoids, 
characterized by high permeability and fewer tight junctions, towards the central vein 
of each lobule. The central veins drain into hepatic vein and next into vena cava 
inferior (Figure 1).2 
 
 
 
Figure 1 Illustration of the microscopic anatomy of the liver.  
Figure shows cross-section of the liver with uniformly organized hexagonal liver lobules. Further in 
the lower part is shown cross-section of the single liver lobule, with details on the blood vessels, bile 
ducts and liver parenchyma mostly composed of the hepatocytes. (Downloaded from: Illustration 
from Anatomy & Physiology, Connexions; Web site: http://cnx.org/content/col11496/1.6/, Sept 2018) 
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 Liver lobule and liver acinus 
The basic structural unit of the liver is the liver lobule, which is a cylindrical structure 
between 0,8 and 2 millimeters in diameter. It forms a hexagonal region within liver 
parenchyma bordered by six portal triads and a central vein in the middle. Portal 
triads consist of branches from the portal vein, hepatic artery as well as bile ductules. 
The lobule is composed of many cellular plates that radiate from the central vein. 
Each hepatic plate is usually two cells thick, where in between the adjacent cells 
lays small bile canaliculi that empties into bile ducts. The basal side of the cells is 
facing perisinusoidal space (space of Disse), an area between liver sinusoidal 
endothelial cells and hepatocytes. This particular region is important for transport of 
lipoproteins, small chylomicron particles and other macromolecules to the 
hepatocytes. Efficient transfer of these compounds from the blood into the space of 
Disse is facilitated by fenestrated sinusoidal epithelium and lack of a basement 
membrane (Figure 2).2-4  
 
 
Figure 2 Illustration of the microscopic anatomy of the single liver lobule.  
Illustration shows anatomical structures within a single liver lobule as well as cellular composition 
(Guyton et al. 20063). 
 
Despite a relatively homogenous composition on histological level, liver lobules 
show an excessive heterogeneity in biochemical and physiological functions.5 This 
is a consequence of specific blood flow from the portal triad to the central vein, 
where oxygen and nutrients are consumed and concentration gradient is formed. 
Therefore, hepatocytes located in close proximity to the central vein receive less 
oxygen and nutrients than hepatocytes surrounding portal triads. As a result, three 
metabolic zones can be distinguished (zone I-III) with a differential distribution of 
key enzymes involved in numerous metabolic pathways.6 Such specific functional 
and zonal organization of the liver can be defined and recognized as a liver acinus. 
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Borders of the acinus are not morphologically clearly delineated, however, it can be 
visualized by connecting two portal triads with a line from which it further extends in 
direction of two adjacent central veins in a triangular shape (Figure 3).7 Zonation 
and acinar organization of the liver provide several advantages. For instance, it 
allows spatial separation between opposing anabolic and catabolic pathways and 
favors more efficient way of xenobiotic metabolism and biotransformation of 
endogenous metabolic byproducts.8 It is important to indicate that many molecules 
and signaling pathways regulate liver zonation, and the most prominent are Wnt/β-
catenin, hepatocyte growth factor (HGF) and Hedgehog (Hh) signaling.4 
 
 
Figure 3 Illustration of structural and functional subunits of liver.  
Figure shows hexagonal liver lobules as a structural and acinus as a functional subunit of the liver. 
Orange rhombus delineates liver acinus, while metabolic zones (I-III) are represented as colored 
ellipses. 
 
 Liver function 
There are several key functions of the liver which can be divided into distinct 
categories: digestive function (bile liquid), metabolic function (carbohydrate, fat and 
protein metabolism), synthesizing function (plasma proteins, hormones and 
nutrients), storage function (glycogen, lipid, cholesterol, vitamins and iron), 
immunological function (production of the circulating innate immunity proteins and 
host for large number of immune cells) and biotransformation (drugs and toxins). 
Substances produced by the liver are secreted to the bloodstream and further 
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distributed through the hepatic vein, or excreted through the bile and biliary system 
(Figure 1).4, 9  
 
 Liver cells 
Liver complexity is also evident on a cellular level, where many different cell types 
are organized in a sophisticated cellular network, which orchestrates metabolic 
processes and keeps the physiological balance of an organism. These cell types 
include: hepatocytes, cholangiocytes, liver sinusoidal endothelial cells (LSECs), 
Kupffer cells (KCs), lymphocytes (e.g. natural killer (NK) cells), hepatic stellate cells 
(HSC), and hepatic progenitor cells (HPC).4 
 
1.1.1.3.1 Hepatic progenitor cells 
HPC are about 10 μm in size and express markers of immature liver cells such as 
alpha-fetoprotein (AFP) as well as markers of biliary epithelium - cytokeratin 19 
(CK19) and hepatocyte lineages (albumin).10 Moreover, there are certain indications 
that epithelial cell adhesion molecule (EpCAM) plays a role in liver cell plasticity and 
liver regeneration, by modulating HPC differentiation status.11 EpCAM is usually 
highly expressed in immature progenitor cells and low in differentiated 
hepatocytes.11 The most important role of HPC is differentiation into mature 
hepatocytes or cholangiocytes. During the course of differentiation, progenitor cells 
that reside in the canals of Hering initially form strands of cells that further expand 
in liver parenchyma and differentiate into hepatocytes, or shape branching ducts 
that move from the canals of Hering to the center of the portal space and form bile 
ducts.10, 12  
 
1.1.1.3.2 Hepatocytes  
Hepatocytes are the most abundant cell type in liver parenchyma and account for 
60% of total cell number and comprise 80% of liver volume.1 During development, 
hepatocytes differentiate from bi-potent hepatoblasts, while in adult liver, during 
intensive regenerative processes, hepatocytes differentiate from bi-potent HPC. 
The bi-potent nature of HPC suggests that they originate from fetal hepatoblasts 
that remain undifferentiated in a stem cell niche.13 Differentiated hepatocytes are 
relatively large polygonal cells between 20–30 µm in diameter with a larger number 
of organelles such as endoplasmic reticulum, golgi apparatuses, large mitochondria, 
as well as lysosomes and peroxisomes.4 Cells are arranged in a specific pattern 
inside hepatic parenchyma, where double-cell thick layers of hepatocytes are 
building up characteristic plate-like architecture.14 As a consequence of a specific 
arrangement, hepatocytes show structural and functional polarity with existence of 
two major domains: 1) basal domain - exposed to sinusoidal endothelial cells and 
space of Disse; 2) apical domain - exposed to a narrow lumen between two 
hepatocytes (site of bile secretion).15 Functional polarity of the hepatocytes can be 
recognized by specific spatial distribution of receptors, pumps, transport channels 
and other proteins across the cell membrane. Consequently, apical part of the cell 
is specialized for bile excretion, while basal segment is functionally adapted for 
extraction of many molecules carried by blood, but also for secretion of final 
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products synthesized or modified by the cells.4, 15 Biochemical machinery of 
hepatocytes has a capability of maintaining homeostasis and physiological balance 
of an organism by synthesizing many essential blood components and by 
biotransformation of xenobiotics and endogenous metabolic byproducts.16, 17 Such 
a complex machinery is mainly involved in amino acid metabolism, protein 
production (e.g. albumin, clotting factors etc.), cholesterol, bile salts, lipoproteins, 
phospholipids and glycoproteins. Other important functions carried by hepatocytes 
include conversion and storage of carbohydrates and proteins, formation and 
secretion of bile and urea, and the detoxification of toxic substances.18 It is important 
to highlight significance of several proteins synthesized in hepatocytes, such as 
albumin and AFP, as level variations can indicate presence of liver injury and 
potential malignant transformation.19-21 Albumin is the most abundant circulating 
protein with diverse roles in metabolism, tissue fluid distribution, transport of 
substrates, antioxidant function etc.22 Studies have shown that level of albumin, as 
well as structural alterations in the protein, correlate with level of liver injury, 
particularly with advanced liver cirrhosis.23, 24 AFP is a fetal plasma protein proposed 
to be the analog of serum albumin during fetal development. Significant amounts of 
this protein are produced by the yolk sac and liver of the fetus, however, total amount 
is significantly reduced after birth.20 In adults, reactivation of AFP production usually 
occurs during liver regeneration and hepatocarcinogenesis.25 Therefore, AFP blood 
concentration has been used to monitor chronic liver disease, onset and progression 
of hepatocellular carcinoma (HCC), effectiveness of curative treatment and 
predicting the outcome.20  
 
1.1.1.3.3 Cholangiocytes 
Cholangiocytes are a heterogeneous population of epithelial cells which line the 
biliary epithelium. They build a complex network of ducts responsible for bile acid 
transport and ductal bicarbonate secretion.26 Cholangiocytes can be found in both, 
intra‐ and extrahepatic ducts of the biliary tree, however, those two cell groups show 
developmental heterogeneity. Cells within intrahepatic biliary tree derive from 
hepatoblast, whereas cholangiocytes lining the extrahepatic biliary tree derive 
directly from endoderm.27 Intrahepatic cholangiocytes comprise relatively small 
volume of the liver, about 3 to 5%, but still play an important role in physiologic 
processes.28 Shape and size of the cells can vary, where in small bile ducts (lumen 
diameter <15 μm), cells are either flattened or cuboidal, while in large bile ducts 
(lumen diameter >15 μm), cholangiocytes are columnar and significantly more 
abundant. Accordingly, the size of cells is also heterogeneous and ranges from 6 - 
15 μm in diameter.26, 29, 30 Along with morphological heterogeneity, cholangiocytes 
demonstrate biochemical and functional diversity with differential expression of 
some key proteins.31 By expressing variety of transporters on both, basolateral and 
apical plasma membrane, they play a role in bile acid modification via processes of 
secretion and absorption. These processes occur as the bile is transported along 
the biliary tree to the intestine. Primary bile is modified predominantly by secretion 
of water, Cl− and HCO3− into the duct, and extraction of glucose, bile acids and 
amino acids. These complex tasks are performed by several transporters, channels 
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and exchangers, which activity depends on the content of the bile and intracellular 
space.26 Important characteristic of cholangiocytes is high expression of CK19 on 
plasma membrane, a common marker expressed in biliary epithelium, which has 
also been shown to be associated with intrahepatic cholangiocarcinoma (iCCA).32, 
33 In iCCA, the expression of CK19, as well as some other members of cytokeratin 
family (CK7, CK20), is much more pronounced than in HCC, allowing distinction of 
these two tumor entities as well as recognition of combined HCC/iCCA type.34  
 
1.1.1.3.4 Non-parenchymal cells 
Non-parenchymal cells of the liver include liver sinusoidal endothelial cells, Kupffer 
cells, lymphocytes, biliary cells and hepatic stellate cells.35 
 
1.1.1.3.4.1 Liver sinusoidal endothelial cells  
Liver sinusoidal endothelial cells constitute a sinusoidal wall, which is also known 
as the liver endothelium, or endothelial lining.36 The liver sinusoids represent a 
unique type of capillaries with the existence of open pores or fenestrae which 
connects them with the space of Disse. This unique property distinguishes them 
from other capillaries in the body.36 Such specific structure of the cells allows free 
access of fluid, solutes, droplets, and particles from the lumen toward the space of 
Disse and hepatocytes, as well as re-circulation in the opposite direction.4 
 
1.1.1.3.4.2 Kupffer cells 
Kupffer cells comprise about 2% of the liver mass and account for about 20% of 
non-parenchymal cells in the liver.4, 37 They derive from circulating monocytes, and 
once localized within the liver, they reside in the lumen of sinusoids.38 Major roles 
of Kupffer cells are to clear endotoxins from  passing blood and to phagocytose 
debris and microorganisms, as well as to pass through the space of Disse and 
phagocytose apoptotic hepatocytes.37 
 
1.1.1.3.4.3 Lymphocytes 
Lymphocytes are dispersed in the liver parenchyma and in the portal tracts.39 
Human liver hosts approximately 1010 lymphocytes, and they can be divided into 
conventional and unconventional lymphocyte subpopulations, namely adaptive 
immune systems (T and B cells) and innate (NKT and NK cells). Lymphocytes play 
an essential role in the first line immune defense against pathogens, modulation of 
liver injury and recruitment of circulating lymphocytes.37 
  
1.1.1.3.4.4 Hepatic stellate cells 
These cells are located in the space of Disse and comprise around 1,5% of the total 
liver mass.4 Stellate cells have many roles, and together with hepatocytes, they take 
part in the metabolism of vitamin A. They also synthetize, secrete, and degrade 
components of the perisinusoidal extracellular matrix.4 Hepatic stellate cells are 
quiescent in normal healthy livers (quiescent HSCs); however, they undergo 
morphological changes during liver injury. They gradually become activated and 
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differentiate into myofibroblastic cells, characterized by a loss of vitamin A and 
increased collagen expression, overall contributing to liver fibrosis.35 
 
 Primary liver cancers 
Primary liver cancers (PLC) are a heterogeneous group of benign and malignant 
solid tumors. Clinically, they are characterized by ethnic, etiological, geographical 
and gender diversity.40-43 There are two major subtypes of primary liver cancers, 
HCC and iCCA. Together, they comprise more than 1 million newly diagnosed cases 
annually. Over the recent years, raising incidence of PLC has been observed 
globally, thus, PLC represent an increasing health care problem worldwide.44 These 
malignancies are the second most common cause of cancer-related death after lung 
cancer and rank among the few solid tumors with increasing mortality rates 
worldwide.45 Due to lack of clinical symptoms and biomarkers for early detection, 
the majority of cancers are identified at late stages when curative treatment options 
are limited. In addition, the majority of the patients present with an underlying liver 
disease and a compromised liver function.40 For HCC, main etiological agents are 
well known and characterized. Specific background, such as viral infections 
(hepatitis B virus (HBV) and hepatitis C virus (HCV)), ethanol abuse, non-alcoholic 
fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and other 
metabolic disorders, contribute to a great extent to the development of HCC.46 
Development of iCCA is associated with parasitic liver flukes infection (Opisthorchis 
viverrini and Clonorchis sinensis) in many parts of the world, conditions resulting in 
chronic biliary tract inflammation. Development of the cancer can also be affected 
by different drugs and toxins, as well as congenital disorders.47 Notably, new 
evidence delineates that inflammatory diseases, such as human immunodeficiency 
virus (HIV), HBV and HCV, are associated with iCCA.47 Overall, disruption of hepatic 
microenvironment and constant remodeling of diseased liver parenchyma, as well 
as activation of immune-cell mediated inflammation, creates an adverse milieu that 
promotes PLC development.48  
Carcinogenesis is a complex process that can be initiated as the consequence of 
genetic and/or epigenetic alterations in different cell types. Therefore, the cellular 
origin of PLC is diverse, and tumors can arise from both stem and progenitor cells 
as well as terminally differentiated cells, such as hepatocytes and cholangiocytes. 
The relative contribution of each cell type to tumorigenesis may depend on diverse 
factors related to inflammation, structural changes in the hepatic microenvironment 
and principal oncogenic events (Figure 4).40  
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Figure 4 Sequential evolution of liver disease leading to PLC.  
Majority of chronic liver diseases develop liver cirrhosis as an end stage, which is one of the most 
important predisposing factors for development of PLC. During the sequential evolution of PLC, from 
chronic liver damage and tumor initiation to tumor progression and metastasis, many of the signaling 
pathways and genes are dysregulated and altered. Evolution of HCC is accompanied with increased 
neovascularization to sufficiently provide nutrient and oxygen supply to the progressing tumor. For 
iCCA, the sequential evolution and underlying phenotypic features are not well known, and yet to be 
precisely defined (Marquardt et al. 201540). 
 
 Hepatocellular carcinoma 
HCC is the most common primary liver cancer, representing approximately 90% of 
all PLC cases. Prevalence of HCC is reported to be highest in Africa and Southeast 
Asia, but with steadily increasing incidence in western countries as well as Japan 
over past several decades.49 In all geographical regions, males have a higher 
incidence of HCC than females.41, 43 As such, HCC has become one of the most 
rapidly developing cancers and the 6th most common malignancy worldwide as well 
as third leading cause of cancer related death.45, 50 High mortality of liver cancer 
partially originates from its resistance to existing anticancer agents, a lack of 
biomarkers that allow detection of surgically resectable tumors, and underlying 
chronic liver disease that limits the application of operative, interventional and 
chemotherapeutic approaches.  
 
 Risk factors 
Development of HCC involves multistep process, where hepatocytes or hepatic 
progenitor cells proliferate in the setting of chronically altered and inflammatory 
microenvironment. Aberrant intracellular signaling and dysregulated genetic and 
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epigenetic events, induced by constant cellular damage and turnover, subsequently 
progress into dysplastic nodules (DN) and ultimately lead to formation of HCC.51  
Liver cirrhosis is the strongest and most common risk factor for development of 
HCC.52 More than 85% of HCC develop on the basis of advanced hepatic fibrosis 
and/or cirrhosis. The cumulative risk of HCC development is significantly influenced 
by the underlying etiological condition.40 Several different risk factors have been 
associated with liver cirrhosis and HCC. The most prominent are chronic HBV and 
HCV infections, alcoholic liver disease, NAFLD/NASH, aflatoxin B1, metabolic 
disorders (e.g. hereditary haemochromatosis, α1 antitrypsin deficiency, hereditary 
tyrosinemia), diabetes mellitus and several others with lower frequency (Figure 5).53  
 
 
Figure 5 Different predisposing risk factors that can lead to the development of HCC.  
In the figure different risk factors (e.g. Aflatoxin B1, viral infections and alcohol), and affected cellular 
processes and genes that could lead to development of HCC are represented (Farazi et al. 200653). 
 
 Cholangiocarcinoma 
Cholangiocarcinoma is the second most common primary liver cancer originating 
from the epithelial lining of the biliary tree.54 It accounts for about 3% of all 
gastrointestinal tumors. The epidemiology of CCA is heterogeneous with the rising 
incidence over the past three decades.55 Gender-related distribution of CCA is more 
homogeneous than for HCC, being very similar for male and female.42 Although  
1-year mortality has improved over time, 5-year survival is still as low as 10%. This 
is a direct consequence of considerably low number of CCA patients diagnosed at 
stages when curative treatments are available.55 Globally, hepatobiliary cancers 
account for 13% of total cancer-related deaths, whereas,  
10–20% of these are attributable to CCA.56 
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 Classification of CCA 
Cholangiocarcinoma is classified based on anatomical location. Intrahepatic 
cholangiocarcinomas are located within hepatic parenchyma, while extrahepatic 
cholangiocarcinomas are separated by the second order bile ducts and categorized 
as perihilar (pCCAs) and distal tumors (dCCAs) (Figure 6). Majority of CCAs,  
60–70%, are perihilar, 20–30% are located distally and intrahepatic CCA accounts 
for 5–10%. The classification of CCA is of clinical relevance for management and 
prognosis of CCA, due to different epidemiological features between pCCA and 
dCCA.55 Incidence rates for CCA show high geographical variation, which is partly 
related to variations in risk factors. However, an increased risk for iCCA 
development has been recently observed in patients with chronic viral hepatitis 
(HBV and HCV) and cirrhosis.40 
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Figure 6 Overview of different parts of the biliary tree in which tumor can develop.  
CCA can be divided into three categories according to its anatomical location in the biliary tree. 
Intrahepatic cholangiocarcinomas (iCCAs) is located in hepatic parenchyma and derived from 
intrahepatic ducts, while perihilar CCA (pCCA) and distal (dCCA) are located outside live 
parenchyma in the second order bile ducts (modified from Marquardt et al. 201540). 
Introduction 
12 
 Risk factors 
Despite most iCCAs arise sporadically, there are several reported risk factors that 
have been assigned to development of iCCA: biliary duct disorders, parasitic 
infections, toxins, as well as chronic liver diseases such as viral infections with HBV 
and HCV. Potential risk factors with less evidence are inflammatory bowel disease, 
diabetes, obesity, gallstone disease, alcohol, smoking and polymorphisms in some 
genes encoding drug metabolizing enzymes and biliary transporter proteins (e.g. 
NAT2, ABCB11, ATP8B1).55, 57, 58 Parasitic infections with the liver flukes 
Opisthorchis viverrini and Clonorchis sinensis are mostly dominant causes of iCCA 
in Southeast Asia, by causing chronic inflammation of biliary epithelial cells further 
increasing the risk of iCCA.55 Inherited biliary disorders can contribute to malignant 
transformation of the cells in the biliary tract. Bile duct cysts are rare congenital 
anomalies characterized by cystic dilatation of the bile ducts, where most patients 
(60%) are diagnosed in their first decade of life but up to 20% are diagnosed in 
adulthood.59 Furthermore, hepatolithiasis or intrahepatic stones are thought to 
predispose to malignancy by causing bile stasis, recurrent cholangitis and chronic 
inflammation.60 In addition, HBV and HCV, as well as liver cirrhosis are associated 
with iCCA. The pathogenesis of iCCA in these conditions is not clear, but 
undoubtedly chronic inflammation and increased cell proliferation could play a role 
in tumorigenesis.55  
 
 Molecular pathogenesis of PLC 
 Molecular pathogenesis of HCC 
Hepatocarcinogenesis is a complex and multistep process that involves 
accumulation of epigenetic and genetic events within chronically altered hepatic 
microenvironment, ultimately driving transformation of normal into malignant cells.61 
Many HCCs develop through a sequential evolution from premalignant nodular 
lesions, i.e. dysplastic nodules (DN), to HCC.62 DNs are divided into two subtypes 
– low-grade dysplastic nodules (LGDN) and high-grade dysplastic nodules (HGDN). 
In general, DNs are defined as dysplastic lesions at least 1 mm in diameter, with 
dysplasia but without histological criteria of malignancy. Furthermore, 
hepatocarcinogenesis is directed from DNs toward development of early carcinoma 
(eHCC) that eventually progresses to HCC (pHCC).63 During early stages of 
hepatocarcinogenesis, changes in DNA methylation patterns are believed to be 
early events preceding allelic imbalances and ultimately leading to cancer 
progression.64 Certain cancer-related genes show global hypomethylation as well 
as promoter hypermethylation, thus, influencing tumor biology and affecting 
prognosis.65 Existing evidence show that hypermethylation of CpG islands occur in 
the premalignant lesions, and tends to accumulate during multistep 
carcinogenesis.66 These data further confirm importance of epigenetic events in the 
initial stages of HCC development. On the genetic level, loss of heterozygosity was 
described in a subset of dysplastic nodules, whereas classical genetic alterations 
(such as β-catenin or TP53 mutations) have not been identified in preneoplastic liver 
lesions.67 Moreover, in the group of patients with chronic HBV infection molecular 
profiles of dysplastic and early lesions are relatively homogeneous, while at the time 
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of advancement into progressed HCC, tumor lesions show a sharp increase in 
heterogeneity at both the genetic and genomic level.68  
As a consequence of epigenetic and genetic alterations, significant number of key 
oncogenes and tumor-suppressor genes have been affected and dysregulated. 
Many of them are key players in maintaining cellular balance, such as cell cycle 
regulators (TP53, CDKN2A), proliferation regulators, immune response, β-catenin, 
ErbB receptor family members, MET and its ligand - HGF, telomerase reverse 
transcriptase (TERT), E-cadherin etc. (Figure 7).53  
As hepatocarcinogenesis is considered to be a complex process dependent and 
influenced by many factors, it should be pointed out that identifying altered signaling 
pathways involved in HCC initiation and progression, rather than individual mutated 
genes, may be a key factor in understanding genetic mechanisms underlying 
hepatocarcinogenesis.69 
 
Figure 7 Oncogenic signaling pathways and genetic landscape in HCC. 
Shown are major signaling pathways in HCC and corresponding frequencies of genetic alterations 
contributing to hepatocarcinogenesis (Marquardt et al. 2015 in DeVita et al. 201547). 
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 Molecular pathogenesis of iCCA 
iCCAs are rare hepatic malignancies with a complex molecular pathobiology.70 
Malignant transformation of iCCA arises from a chronic biliary inflammation and 
biliary damage (cholestasis) triggered by external factors. Obstruction of the bile 
ﬂow can result in aberrant bile acid signaling, further promoting proliferation of 
cholangiocytes.56 Release of cytokines and pro-inflammatory mediators, such as 
interleukin-6 (IL-6) and transforming growth factor beta (TGF-ß) also promotes 
growth of cholangiocytes.56, 70 Such increase in the cell proliferation is usually 
followed by accumulation of molecular aberrations in the cells, leading to the 
malignant transformation. Besides activation and impairment of proliferative and 
pro-inflammatory signaling, key role in carcinogenesis plays impairment of DNA 
damage and repair systems in the tumor suppressor genes as well as activation of 
proto-oncogenes. In addition, similar to HCC many key signaling pathways and 
mediators are dysregulated, such as cyclooxygenase-2 (COX2), 
phosphatidylinositol-3-kinase/Protein Kinase B and the mammalian target of 
rapamycin (PI3K/Akt/mTOR), epidermal growth factor receptor (EGFR), ERBB2, 
Ras/MAPK, HGF/MET, IL-6/JAK/STAT, and vascular endothelial growth factor 
(VEGF). These mechanisms, alongside with interaction between the epithelial and 
stromal compartments, contribute to uncontrolled proliferation, survival, 
angiogenesis, invasion and metastasis in iCCA.70  
In iCCA several major activating mutations in KRAS (19%), low frequency mutations 
in BRAF (5%), FGF (10-15%), EGFR (3%), as well as loss of function mutations in 
the tumor suppressor TP53 (approximately 16%) have been described.71 Moreover, 
epigenetic alterations are also known to play important role in the development of 
iCCA. Frequent events that can lead to malignant transformation can occur through 
promoter hypermethylation in some genes (e.g. p16INK4A/CDKN2, p14ARF, 
RASSF1A, APC, GSTP and SOCS-3), but also through the impaired activity of 
different epigenetic modulators, like DNA methyl-transferases (DNMT). 
Inflammation-related signaling pathways, such as JAK/STAT3, and proliferation-
related pathways, like EGFR and HGF/MET signaling, show profound dysregulation 
in iCCA. In addition, recent findings imply that Notch and Wnt signaling might play 
role in iCCA pathogenesis.70, 71 
 
 Signaling pathways and regulators in molecular pathogenesis of PLC 
 Cell cycle regulation - P53 
P53 is a key cell-cycle regulator at the G1/S regulation checkpoint, also involved in 
control of DNA repair and apoptosis. The signaling pathway is activated in response 
to a variety of stress signals and coordinates transcriptional programs that ultimately 
guide tumor suppression. Loss of p53 function is a common feature in the majority 
of human cancers including HCC.72, 73 Frequency of TP53 mutations in HCC vary in 
the different regions of the world.67 Asian and African countries show higher 
frequency of TP53 mutations due to exposure to aflatoxin B1 and HBV infections. 
In western countries, aflatoxin B1 exposure is very low and HCC-related to HBV 
infection is rare. The rate of TP53 mutations in HCC is therefore lower (10–20%) 
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than in Asian countries (40–60%).67 Hot spot mutations at codon 249 (Arg249Ser 
G:C to T:A transversion) are associated with exposure to aflatoxin B1 and could be 
identified in more than 50% of HCC in African and Asian patient. Therefore, it was 
suggested that codon Arg249Ser mutation in TP53 of HCC may be utilized as a 
biomarker for exposure to aflatoxin B1 and for detection of early HCC.74 
Furthermore, HBV infection can affect the activity of p53 by inducing DNA damage. 
Prognostically, TP53 alterations are generally associated with larger, less 
differentiated tumors and poor survival.75 
Frequency of TP53 mutations in iCCA varies greatly between investigated cohorts 
of iCCA patients, ranging from 9–38%.76 Higher frequency of TP53 mutation is 
typically observed in the patients with Opisthorchis viverrini infection, whereas 
patient without fluke infection show significantly lower mutations in TP53 gene.77 
Moreover, there is a positive association between iCCA patients positive for 
hepatitis B surface antigen (HBsAg) and the presence of mutations in TP53, which 
might further imply that those patients share a common p53-mediated pathway 
with HBsAg positive HCC.76 
 
 Wnt/β-Catenin signaling 
CTNNB1 gene encodes β-catenin, a protein involved in multiple processes including 
organ formation, stem cell renewal and cell survival. β-catenin is found in the 
adherens junctions and plays a key role in intercellular adhesion and 
communication. Within the liver, Wnt/β-catenin pathway is highly active in liver 
development, zonation, amino acid metabolism, regeneration and oxidative stress.78 
It is a well-known oncogene mutated in many types of cancer, such as 
medulloblastoma, colon, thyroid and breast cancer.67 Further, impaired activity of 
Wnt/β-catenin signaling has been described in many HCC studies.79-83 Deletions or 
missense mutations in exon 3 of CTNNB1 gene in the liver are the most common 
activating mutations associated with the development of HCC.79, 84 Besides 
mutations in CTNNB1 gene, dysregulation of Wnt/β-catenin pathway could be 
driven by different mechanisms, such as mutations in the genes coding components 
of this signaling pathway (e.g. Axin-1, GSK3-β) as well as epigenetic changes.85 
Many findings suggest that Wnt/β-catenin mutation and overexpression have an 
important role in early-stages of tumorigenesis and in transformation of benign liver 
tumors to HCC.53, 67 
Only very limited data demonstrated implication of Wnt signaling pathway in 
development of iCCA.86 It is known that progressive activation of Wnt pathway 
mediated by Wnt7B ligand, frequently overexpressed in tumor stroma, promotes 
cholangiocarcinogenesis and directly correlates with the tumor growth.86  
 
 PI3K/Akt/mTOR signaling 
The PI3K/Akt/mTOR signaling pathway is essential for cell growth and survival.87, 88 
Somatic mutations and/or gains and losses of key genes in this pathway are 
detected in a number of different solid and hematological tumors.89, 90 Activation of 
the PI3K/Akt/mTOR pathway results in an impaired cell growth and survival, which 
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leads to competitive growth advantage, metastatic dissemination, angiogenesis, 
and therapy resistance.87 PI3K/Akt/mTOR signaling pathway can be induced by 
binding of variety of different growth factors (e.g. insulin-like growth factor (IGF), 
epidermal growth factor (EGF)) to corresponding receptors. PI3K subsequently 
produces the second messenger PIP3 (phosphoinositoltriphosphate), which in turn 
activates the serine/threonine kinase Akt. In normal tissue, this pathway is 
negatively regulated by the phosphatase and tumor suppressor on chromosome 10 
(phosphatase and tensin homolog (PTEN)), which targets the lipid products of PI3K 
for dephosphorylation (Figure 8).91 In HCC, activity of the PI3K/Akt/mTOR pathway 
has close association with tumor cell survival and early recurrence.92 Impaired 
activity of mTOR signaling pathway is more frequently induced by activation of either 
the IGF and/or EGF cascade, than direct activation by somatic mutations of the 
different components.93 Emerging evidences also suggest that PI3K/Akt/mTOR 
signaling may be activated by somatic mutations in the PI3K catalytic A gene 
(PIK3CA), which encodes the p110a catalytic subunit of PI3K.91 Further, decreased 
expression of PTEN gene due to mutation or methylation, as well as changes in 
PTEN function, can also lead to increased activity of the PI3K/Akt/mTOR pathway 
in HCC.94 Reduced activity or expression of the PTEN phosphatase can result in 
constitutive activation of the PI3K/Akt/mTOR pathway. In addition, PTEN expression 
can be downregulated directly by the hepatitis B virus protein (HBx) protein in HBV-
infected patients, or by HCV core protein at transcriptional level.93, 95 
This signaling pathway also plays a critical role in iCCA and it is involved in drug 
resistance, autophagy, as well as in programmed cell death regulation.96 
Constitutive activation of PI3K/Akt/mTOR pathway is predominantly caused by 
PTEN inactivation, or by increased expression in its pathway components, such as 
EGF and HER-2 growth factors, as well as by IL-6 pathway activation in chronically 
inflamed biliary epithelium.97 Activation of the pathway can also be achieved through 
bile acid intake by apical sodium bile acid cotransporter (ASBT), or by induction of 
EGFR phosphorylation.98, 99 Overall, above mentioned factors contribute to the 
tumor progression and poor prognosis in iCCA patients.96  
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Figure 8 Schematic overview of the PI3K/Akt/mTOR signaling pathway.  
PI3K is activated through growth factors (GF) or cytokines (CY) binding to a receptor resulting in the 
conversion of PIP2 into PIP3 by phosphorylation. PKB/Akt further binds to PIP3 at the plasma 
membrane and latter undergoes conformational changes leading to its phosphorylation and 
activation by PDK1 and mTORC2. Akt finally participates in the regulation of cellular processes. 
Termination of the signaling cascade occurs through the dephosphorylation of PIP3 by the 
phosphatase PTEN or SHIP, or further downstream through the dephosphorylation of Akt by PHLPP 
or PP2A (modified from Diehl et al. 2013100) 
 
 IL-6/JAK/STAT signaling 
JAK/STAT (Janus kinase/signal transducers and activators of transcription) 
pathway is activated by more than 40 cytokines and regulates many processes in 
the cells, mainly immune response, development, proliferation, differentiation and 
apoptosis.101, 102 Herein, the signaling pathway is involved in transmitting information 
from extracellular signal molecules to target gens. Analyses have shown that many 
solid tumors exhibit activation of the JAK/STAT signaling pathway, including 
HCC.103 Mutations in JAK1 gene are found in about 1% of the HCCs. This pathway 
is related to chronic inflammation that could be triggered by pro-inflammatory 
cytokines such as IL-6. A constitutive activation of JAK/STAT pathway can also 
result from aberrant hypermethylation of SSI-1 gene (stress survival islet-1), which 
has been identified in 53% of HCC patients, according to the study of Nagai et al.104, 
105 Furthermore, silencing of suppressor of cytokine signaling 1 (SOCS1) due to 
promoter methylation has been described in 61% of HCC. In addition, between 30-
38% of HCC exhibit epigenetic inactivation of SOCS3 due to promoter methylation.67 
Thus, JAK/STAT signaling pathway is crucial for liver homeostasis and cancer. 
In iCCA inflammatory cytokine IL-6 can promote tumor growth in autocrine manner 
by epigenetic modulation of the genes involved in growth-regulatory signaling 
pathways, such as those involved EGFR.106 IL-6 can also act as Akt pathway 
activator, leading to high expression of antiapoptotic protein myeloid cell leukemia-
1 (Mcl-1) and consequently promoting apoptosis resistance.107 
 
 Ras/MAPK signaling 
The Ras/MAPK pathway plays a fundamental role in the control of major cellular 
processes, such as cell survival and proliferation. Dysregulation of the pathway is 
implicated in malignant transformation and progression of many cancers including 
liver cancer.108 Although the frequency of mutations in RAS gene is low (>1%) in 
HCC, several studies have shown that aberrant activation and overexpression of 
the RAS gene is associated with shorter overall survival in HCC patients.108, 109 
Additionally, overexpression of downstream member of Ras/MAPK pathway, Raf-1 
was proven to carry prognostic value, and it can be used as a biomarker for 
predicting the early tumors recurrence and poor prognosis in HCC.109 Also, 
increased MEK1/2 and ERK phosphorylation and expression was frequently 
observed in HCC when compared to adjacent normal liver tissue.110 Finally, 
Ras/MAPK pathway activation is observed in HBV-mediated HCC, where chronic 
infection with HBV induces expression of two transcriptional activators, hepatitis B 
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virus X protein (HBx) and the PreS2-activator large surface protein (LHBs), that can 
trigger the activity of the pathway.91  
In iCCA several commonly activating mutations in Ras/MAPK signaling were 
identified. Activating mutations in kristen rat sarcoma (KRAS) gene are frequent, in 
average 19% iCCAs, particularly in codon 12.111 Moreover, BRAF gene, encoding 
a downstream component of signaling pathway, is mutated in 7% cases. Activating 
mutations in the epidermal growth factor receptor (EGFR) gene is rare event (2%), 
however, deregulation of Ras/MAPK pathway downstream of EGFR is one of the 
hallmarks of iCCA.70 
 
 Notch signaling 
The Notch signaling pathway is evolutionary conserved and present in most 
multicellular organisms. It is important for many cellular processes including 
maintenance of stem cells, specification of cell fate, differentiation, proliferation 
and apoptosis.112 Activation and regulation of the pathway is finely tuned on multiple 
levels and highly dependent on the cellular context in which it is activated. In the 
liver, Notch signaling pathway is activated after injury and mediates interactions 
between different cell types involved in the repair process. It is important factor in 
the regulation of liver metabolism, inflammation and cancer.113 Another important 
aspect of the pathway is temporal- and dose-dependent coordination of biliary fate 
and morphogenesis.114 Earlier studies have shown that overexpression of NOTCH1 
inhibits HCC cell growth by promoting cell cycle arrest and apoptosis.115, 116 
However, in the more recent studies, new evidence demonstrated pro-oncogenic 
role of Notch during hepatocarcinogenesis. In a study by Villanueva et al. authors 
demonstrated that Notch signaling promotes liver carcinogenesis in a genetically 
engineered mouse model.117 This finding was further confirmed in a cohort of HCC 
patients where activation of the pathway was detected in 30-35% cases. Moreover, 
they showed that pro-oncogenic function of NOTCH1 depends on molecular 
context, particularly, upregulation of IGF2 and SOX9.117 Another study 
demonstrated that NOTCH3 may function as an important factor contributing to 
therapy resistance in HCC and that elevated expression of NOTCH3 protein could 
represent a selective advantage for HCC development, whereas after depletion of 
NOTCH3 by specific shRNAs, they observed increased TP53 expression and 
improved doxorubicin sensitivity by promoting apoptosis.118 Accordingly, Notch 
represents a novel candidate in targeted approach and a starting point for new drug 
development to fight HCC.   
As the Notch pathway appears to be a key regulator in normal cholangiocytes for 
differentiation and bile duct ontogenesis, it is rationale to expect that in a chronically 
diseased liver this pathway becomes dysregulated and further implicated in 
malignant processes.119 Recent studies have demonstrated that dysregulation of 
Notch pathway can have implications in development and progression of iCCA.120, 
121 Significant number of patients with iCCA demonstrated upregulation in Notch 
receptors, namely Notch1 in 83%, Notch2 in 56%, Notch3 in 39% and Notch4 in 
34% cases. Further, in this study it was revealed that aberrant expression of Notch 
Introduction 
19 
receptors 1 and 4 play more important role during iCCA progression than other 
receptors.122 In another study exploring differentially expressed genes in HCC and 
iCCA, Notch pathway was identified as one of the top pathways based on the 
overexpressed genes, when compared to HCC.123 Overall, considering the 
importance of Notch pathway activation in the pathogenesis of iCCA, it is important 
to target these pathways by using available inhibitors as well as to proceed with 
development of novel treatments.71  
 
 Growth factor signaling and other regulators 
Several growth factors and their receptors mediate tumorigenic activity through a 
variety of signaling pathways.124 After liver injury or damage, when activation of 
regenerative processes is required, adult hepatocytes as well as other non-
parenchymal cells are able to produce different growth factors, such as EGF, 
transforming growth factor alpha (TGF-α), IGF and VEGF. In chronically injured liver 
production of these growth factors as well as activation of corresponding receptors 
and downstream signaling is dysregulated. Such impaired growth factor production 
and signaling can lead in the direction of hepatocarcinogenesis.124 
 
1.2.4.7.1 HGF/MET signaling 
c‐Met is a receptor tyrosine kinase activated by binding of only one known ligand, 
i.e. HGF. After binding to MET receptor, HGF can induce cytoprotective role in the 
liver, by providing protection from damage and suppression of FAS-induced 
apoptosis in hepatocytes.125 Accordingly, expression of HGF is increased in 
response to liver injuries, while depletion of HGF enhances liver damage.126 Despite 
having beneficial role in liver regeneration and different liver diseases, increased c‐
Met activity plays an important role in initiation and progression of HCC.127 
Dysregulation of c-Met has been noted in approximately 50% HCC patients. Further, 
aberrant c‐Met activation is in close connection with enhanced tumor growth, 
aggressive behavior and poor prognosis.128 Mechanisms of aberrant activity are 
heterogeneous and range from gene mutation, gene amplification, receptor 
overexpression to increased mRNA expression.126 Tumors with overexpressed c-
Met can show reduced dependence on HGF due to constant receptor dimerization 
and activation. In this context, c‐Met inhibition represents an active area of research 
in HCC, and several selective c‐Met inhibitors are under clinical evaluation in 
patients with advanced HCC.126  
It has been reported that c-Met overexpression is present in more than half of iCCA 
cases and that it correlates with degree of tumor differentiation, being highest in 
well-differentiated and low in poorly differentiated tumors.129 Moreover, 
overexpression of the MET gene in cholangiocarcinoma can lead to increased cell 
migration and invasion, angiogenesis and tumor differentiation/proliferation.130-132  
 
1.2.4.7.2 Angiogenesis 
Angiogenesis significantly contributes to the growth of many cancers, including 
PLC.91, 133 VEGF is a main regulator of angiogenesis in cancerous tissue known to 
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be upregulated in both PLCs. Several other angiogenic growth factors, including 
angiopoietin-2 and platelet-derived growth factor (PDGF) were also shown to be 
upregulated in HCC.134 In iCCA several other factors that influence angiogenesis 
are found to be upregulated, such as angiopoietin 1 and 2, thrombospondin, EGF, 
EGFR and fibroblast growth factor (FGF).133 These factors play important roles in 
proliferation of endothelial cells, which activates neovascularization around and 
within the tumor tissues leading to tumor expansion and progression. Angiogenic 
signaling is further mediated through a variety of mechanisms, including activation 
of the Ras/MAPK, PI3K/Akt/mTOR and Janus kinase.91, 134 
 
1.2.4.7.3 TGF-β signaling 
Transforming growth factor beta TGF-β is an important signaling pathway in the liver 
affecting and regulating many important processes and cell types.135 During cancer 
initiation, TGF-β signaling exerts tumor suppressor effects at pre-neoplastic and 
early tumor stages, while cytostatic effects of TGF-β are often disrupted in 
progressed stages due to genetic dysregulation of different members of the 
signaling pathway.136 This progressed stage is characterized by a late TGF-β 
signature which promotes the phenotypic switch from tumor suppressor to tumor 
promoter. In advanced stage, cancer cells undergo an epithelial-mesenchymal-
transition (EMT) where they acquire invasive and pro-metastatic properties.137 Thus, 
targeting TGF-β pathway could be a promising therapeutic tool in advanced stages 
of PLC. 
 
1.2.4.7.4 c-MYC regulation 
c-MYC is a transcription factor involved in many diverse cellular processes, such as 
control of cell cycle progression, proliferation, growth, adhesion, differentiation, 
apoptosis and metabolism.138 In the context of the liver, it has been strongly 
associated with hepatocyte proliferation occurring during liver damage and 
regeneration.139 Emerging data suggests that dysregulation of c-MYC function might 
be associated with chronic liver disease and hepatocarcinogenesis.139 Studies have 
reported that dysregulation of MYC expression is a very early event in liver 
carcinogenesis, and that MYC oncogene amplification is an indicator of malignant 
potential and poor prognosis in HCC patients.140, 141 According to Kawate et al. 
dysregulation of c-MYC is closely associated with proliferative activity and TP53 
overexpression, and it has close association to progression of HCC.140 
Studies have also revealed important roles of c-MYC in different stages of liver 
disease, including iCCA.142 It is shown that c-MYC induction promotes cholestatic 
liver injury and iCCA progression.142 Moreover, c-MYC is capable of abolishing 
contact inhibition in human iCCA that is mediated by mTOR pathway and Yes-
associated protein (YAP). Loss of contact inhibition is a hallmark of a wide range of 
human cancer cells, and therefore it represents an important aspect of 
cholangiocarcinogenesis.143  
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1.2.4.7.5 Telomere maintenance 
Telomerases are nucleoprotein complexes with the main function to maintain 
chromosomal integrity and genome stability during cell division, primarily by 
lengthening terminal regions of telomeric DNA.144 Human telomerase is composed 
of two main core subunits, TERT that forms the catalytic subunit and RNA 
component (TERC) that provides a template for telomerase elongation. A positive 
correlation between TERT mRNA expression and telomerase activity has been 
observed, thus implying that telomerase is regulated by TERT gene expression.145 
Accordingly, reactivation or re-expression of telomerase is frequently observed in 
many human cancers, including HCC.146 Molecular alterations in TERT are the 
most frequent somatic genetic alterations in human HCC detected in 20-60% of all 
cases. They are also observed in cirrhosis as well as in the normal liver tissue.147 
TERT promotor mutations are early major events in carcinogenesis occurring first 
at preneoplastic stages in cirrhosis and further in malignant transformation, often in 
association with Wnt/β-catenin pathway activation.148 Mutations in TERT promotor 
are rare events in iCCA, contrary to high frequency observed in HCC.111 
 
 Epigenetic changes in PLC 
Epigenetic changes can be defined as heritable changes in a cellular phenotype 
that were independent of alterations of the DNA sequence, such as methylation, 
acetylation, histone modification etc. The information carried by epigenetic 
modifications play a critical role in the regulation of all DNA-based processes, such 
as transcription, DNA repair and replication.149 As a consequence, impaired 
expression or genomic alterations in chromatin regulators can have critical 
implication in the induction and maintenance of various cancers including HCC and 
iCCA.70, 150 Epigenetic changes such as DNA hypermethylation or hypomethylation, 
dysregulation of histone modification patterns, chromatin remodeling and aberrant 
expression of micro-RNAs (miRNAs) and long noncoding RNAs (lncRNAs) are 
associated with PLC.70, 151 
 
 Systemic therapies for advanced HCC and iCCA 
Both primary liver cancers, HCC and iCCA, are asymptomatic at early stage and 
lack biomarkers of early detection.152 As a consequence, only one-third of HCC and 
small number of iCCA patients are diagnosed at early stages, when potentially 
curative treatments, such as resection, transplantation or local ablation are still 
available. Majority of primary liver cancers are still diagnosed at late stages when 
curative treatment options are limited and mortality rates are very high.153 For 
patients with advanced stage disease, systemic chemotherapy is the most widely 
used treatment approach.154 
 
 First-line therapy in HCC 
Sorafenib was the first systemic therapy to show a significant survival benefit, and 
consequently, it has become a standard of care for patients with advanced HCC.154 
It is a multikinase inhibitor that affects tumor cell proliferation and tumor 
angiogenesis. Sorafenib actively affects key signaling pathways by targeting 
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numerous serine/threonine and tyrosine kinases, such as RAF1, BRAF, vascular 
endothelial growth factor receptor (VEGFR)1,2,3, platelet-derived growth factor 
receptor (PDGFR), KIT, FLT3, fibroblast growth factor receptor one (FGFR1) and 
RET.155 Treatment with sorafenib in Western patients demonstrated improved 
median overall survival in comparison with placebo (10,7 vs. 7,9 months) and longer 
median time to progression (5,5 vs. 2,8 months).156 Lenvatinib is a multiple-receptor 
tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of VEGFR1,2,3, 
FGFR1,2,3,4, PDGFRα, KIT and RET.157 Lenvatinib was approved by FDA (US 
Food and Drug Administration) for the first-line HCC treatment in 2018 based on the 
data from a phase III clinical trial comparing with sorafenib in the patients with 
unresectable HCC in a non-inferior setting. The median overall survival in the 
treatment group was increased in comparison with placebo (13,6 vs 12,3 months), 
as well as progression-free survival (7,4 vs. 3,7 months) and median time to 
progression (8,9 vs. 3,7 months).158 In addition, lenvatinib is used in other solid 
cancers as an antineoplastic agent (in treatment of advanced, metastatic medullary 
thyroid cancer and refractory renal cell carcinoma).159 
 
 Second-line therapy in HCC 
One phase III clinical trial demonstrated that regorafenib can result in survival 
benefit for HCC patients who show progression but tolerated sorafenib. This 
particular finding led to FDA approval of regorafenib as a second-line treatment for 
HCC after sorafenib administration.160 Similar to sorafenib, it inhibits multiple 
protein kinases, including those involved in tumor angiogenesis (VEGFR1,2,3, 
TIE2, PDGFR-β, FGFR1) and oncogenesis (KIT, RET, c-RAF/RAF-1, BRAF). It 
also affects proteins involved in MAPK signaling pathway (P-ERK1/2, P-JNK, P-c-
Jun), apoptosis (Bax, Bcl-2, Bcl-X, survivin, cleaved caspase 3,7,8 and 9) and 
autophagy (Beclin-1, LC3-II).161 
Additionally, new treatment possibilities are emerging from clinical trials using 
antibodies targeting the immune checkpoint inhibitors - programmed cell death 1 
(PD-1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4).162 For instance, FDA has approved the use of 
nivolumab for advanced HCC patients who failed to respond to first-line treatment 
with sorafenib. In general, nivolumab is a fully human immunoglobulin G4 (IgG4) 
PD-1 immune checkpoint inhibitor antibody that disturbs interaction between PD-1 
and its ligands (PD-L1/2). Positive effects occur due to the restoration of T-cell 
antitumor immunity directed against tumor cells.163 Several other inhibitors are 
showing positive results in phase III clinical trials for sorafenib treated patients with 
advanced HCC. Treatment with cabozantinib, a tyrosine kinase inhibitor that inhibits 
VEGFR 1,2,3, MET, and AXL, demonstrated longer overall survival and 
progression-free survival than placebo. Furthermore, ramucirumab, a fully 
humanized monoclonal antibody targeting VEGFR2, improved overall survival as 
well as progression-free survival of the patients in a phase III clinical study.156  
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 Systemic chemotherapy in iCCA 
For the patients with advanced stage iCCA, standard treatment options include 
combination of gemcitabine and cisplatin.162 Gemcitabine is a nucleoside analog 
and it has been used as a chemotherapeutic agent for almost two decades. 
Gemcitabine has several modes of action, and the most important is inhibition of 
DNA synthesis. Additionally, it can act through self-potentiation by inhibition of 
enzymes related to deoxynucleotide metabolism, and by induction of apoptosis 
through caspase signaling.164 Moreover, cisplatin is capable to crosslink with the 
purine bases on the DNA. It interferes with DNA repair mechanisms, causing DNA 
damage, and subsequently induces apoptosis in cancer cells.165 For the patients 
who show progression on gemcitabine and platinum based therapy, there is no 
standard 2nd line option. Several trials that are evaluating regimens for iCCA in the 
second-line setting show promising activity.166 
 
 Models to study PLC 
Recent developments in precision medicine approaches have produced effective 
molecularly targeted therapies in many solid cancers, however, outcome in PLC 
remains low due to a pronounced phenotypic and molecular diversity. Development 
of representative models is urgently needed as a necessity to provide effective 
translation from descriptive genomic studies into clinical practice.61, 153 In the liver 
cancer field, there is a lack of models that accurately represent morphological and 
molecular heterogeneity of the original tumors. Ideally, models to be used in cancer 
research should reflect human disease on several levels, from anatomical and 
physiological to (epi-)genetic and transcriptomic. Importantly, tumor models should 
reflect the background setting of the disease that it is arising from (etiology), since 
it can influence molecular basis of the disease evolution and progression.167 
 
 Animal models 
Animal models play an important role in cancer research, particularly for studying 
and better understanding mechanisms of human (hepato-)carcinogenesis. The goal 
of animal research is to mediate a transition from in vitro studies to clinical practice 
and ultimately bring the benefits to patients.168 Since rodents entered into laboratory 
studies, particularly mice, a variety of different models have been developed to study 
liver diseases including hepatocarcinogenesis.169 In general, they can be divided 
into distinct categories based on the mechanism of inducing desired phenotype: 1) 
chemically induced models, 2) transplantation models (syngeneic and xenograft 
models), 3) viral models, and 4) genetically engineered mouse models. Availability 
and reproducibility of mice made them one of the most exploited organisms in 
human cancer research. They carry very important features for liver research, such 
as small size, short life span, high breeding capabilities, genetic engineering options 
and similarities to human hepatic diseases.167 Apart from rodents, many other 
animal models have been developed over the years, e.g. rabbit, swine, primate 
etc. Nevertheless, these models show only limited overlap to human liver cancers 
in terms of physiology, etiology and clinical setting.170 
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1.2.6.1.1 PDX models 
A novel model potentially closely reflecting and preserving human PLC features is 
generated by xenotransplantations. Xenograft mouse model (patient-derived 
xenograft – PDX) is created by transplanting small pieces of primary tumors directly 
into immunocompromised mice.171 Propagation of the PDX models includes direct 
passaging of the cells from a mouse to a mouse, as the tumor burden increases in 
an animal. There are two main methods to create PDX models - orthotopic and 
heterotopic. Orthotopic model includes direct implantation to the mouse organ of 
choice, while heterotopic PDX model includes implantation into the subcutaneous 
flank of a mouse.171, 172 PDX models have shown some advantages over classical 
commercially available cell lines. Examination of PDX indicated that histology and 
gene expression profiles as well as genomic alterations were retained when 
compared to their original tumors. In several studies, authors have further shown 
that PDXs were able to predict patient’s response to chemotherapy.173, 174 
Nevertheless, wider application of this model in the medical studies is limited due to 
existing disadvantages. PDX lack to show tumor progression or metastasis and do 
not reproduce all the stages of the disease usually observed in the patients. Lack of 
representative tumor microenvironment, as well as severely compromised immune 
system limits exploitation of PDXs to the full scale. Additionally, low success rate of 
implantation hampers global application of the model. Large scale drug testing to 
identify potential new therapeutics still remains challenging as high amount of 
resource, time, and animals are required.175, 176 
 
 Organoids 
In the last years, new 3D models of human cancers emerged as an alternative to 
classic 2D cell line and PDX models.177, 178 High expansion rate of 3D organoid 
models for variety of different cancers has been demonstrated. Establishment and 
extensive morphological and molecular characterization of early 3D models in 
prostate, pancreatic, colorectal, bladder etc. cancers had served as a basis for 
development of equivalent models for liver cancer.179-183 Organoids are generated 
from the primary cancerous tissue by enzymatic/mechanic dissociation or from 
single cells and propagated by using a matrix and a media that promotes cell 
proliferation. New cultivation system that allows multidimensional growth of the 
tumor cells is largely comprised of a matrigel as growth matrix and a cocktail of 
different growth factors that promote expansion of cancer cells.184 Several studies 
have reported successful establishment of organoids derived from primary liver 
cancers, HCC, iCCA and combined hepatocellular cholangiocarcinoma (CHC).177, 
178 Authors of the studies showed that derived organoid models recapitulated 
histological, transcriptomic and genomic traits of original tumors, and demonstrated 
that potential drug screening applications are feasible with organoids. 177, 178 
Yet, organoids appear to be very reliable and easy to establish in vitro models, but 
there are several limitations to this. Firstly, success rate of derived organoids 
remains low and it is highly dependent on properties of each individual tumor (e.g. 
tumor grading).177 Furthermore, when compared with cancer cell lines, organoid 
cultures require significantly higher amount of resources, making them more difficult 
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to produce for large-scale applications. Intrinsic limitations of organoid culture are 
the lack of stroma, blood vessels and immune cells. The requirement for 
extracellular matrix substitutes, such as matrigel, and need for the fetal bovine 
serum, leaves the possibility that undefined extrinsic factors influence the outcome 
of the experiments, such as drug sensitivity.177 Some organoids derived from 
advanced cancers often display lower proliferation rate than organoids derived from 
normal epithelial cells. This leaves a space for epithelial-derived organoids to 
overgrow and become dominant entity in the culture.177, 178, 185  
 
 Cell lines 
Cancer cell lines have been used for several decades to study biology and 
molecular processes of the cancers, and they are widely used model in 
pharmacogenomics studies.186 Overall, great potential of the cell lines was exploited 
to dissect general mechanisms of human carcinogenesis, to identify novel molecular 
targets for therapy, and to discover novel biomarkers for drug sensitivity.187 Cell lines 
derived from human tumors provide an unlimited, self-replicating and easily 
propagating source of cancerous cells. Since cancer cells in the culture harbor high 
proliferative capacity, they are widely used for mechanistic and high-throughput 
analyses in many laboratories across the world.188 Through the history, cell lines 
have played a significant role in the development of anti-cancer drugs. New idea of 
large-scale screens of cancer cell line panels, such as NCI-60, is being further 
explored in order to characterize genomic profiles to mimic genetic heterogeneity 
of the original tumors and predict sensitivity to many compounds.189 This approach 
is already influencing standardized pipelines of drug development, and, thus, 
cancer cell lines are an important tool for pharmaceutical industries with the main 
focus on development of molecularly targeted cancer therapies.189 These 
investigations clearly demonstrated that cell lines can be used to identify drugs that 
are active in the specific genetic contexts.  
However, due to clonal origin and possible selection during long-term cultivation, 
several important questions have been raised among the scientific community, 
questioning whether the cell lines closely represent, both on genomic and 
transcriptomic level, original tumors which they were derived from.190 Several 
decades of propagation under artificial culture conditions, exchange among different 
laboratories, might have further induced phenotypic, functional and molecular 
changes that make the cells no longer suitable to accurately represent the primary 
tumor characteristics. Therefore, detailed comparison of the original tumors and 
their cell lines is essential, but since many of the cell lines were established several 
decades ago, a direct comparison to the original tumors cannot be performed 
anymore.191 Thus, the establishment of well-characterized novel patient-derived cell 
lines (PDCL) for PLC that closely resemble phenotypic and molecular features of 
the original tumor is highly desirable.  
In vitro PDCL can be derived from the cancer tissue by mechanical and enzymatic 
dissociation, followed by cultivation in various conditions and, dependent on cell 
requirements, medium containing combination of specific growth factors and/or 
Introduction 
26 
serum. Limitation to this system is lower success rate to establish stabile growth, of 
about 10–15% of samples, and the fact that cultures can take weeks to several 
months to reach significant growth.192 Several studies successfully established and 
propagate PDCL in culture, and compare them with their original tumor. One study 
showed that isolated glioblastoma cells retained mutation in a specific tumor 
suppressor gene that was originally detected in a corresponding tumor tissue.193 
Furthermore, it was found that human non-small cell lung carcinoma (NSCLC) cell 
line after long cultivation period in great extent preserved properties of their parental 
tumors and could be used as a suitable model system for biomedical studies.188 
Recently, a study generated several PDCL from the same tumors, where they tried 
to dissected intrahepatic tumor heterogeneity in HCC.194 They demonstrated that 
PDCL model derived from multiregional cancer samples in early passage could be 
useful platform to determine how intratumoral heterogeneity affects sensitivity to 
different therapeutic agents. Additionally, one study successfully utilized lung cancer 
PDCL to predict therapy response and to select effective drug combinations for a 
potential patient application.195 
Overall, results of these studies confirm the similarity in key morphological and 
molecular features in PDCL and matched primary cancers and support their 
usefulness as a patient-specific model for treatment evaluation and drug response 
testing. However, to date the usefulness of PDCL from different cellular origins of 
human liver cancer has not been fully explored. 
Short comparison between different preclinical models can be seen in the Table 1 
below. All important aspects of models utilized in cancer research are briefly 
summarized. 
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Table 1 Comparison between different cancer models. 
In the table are summarized and compared important aspects of preclinical cancer research models. 
Number of stars represents the importance of a given feature, where three stars stand for the best 
feature, while one star stands for the modest feature. 
 
 Cell lines Organoids Animal models 
Established Patient-derived PDX Chemical/Genetic 
Success rate of 
establishment * * ** ** *** 
Time to establish * * ** ** * 
Handling *** *** * * ** 
Long term 
propagation *** *** ** ** *** 
3D growth - - ** *** *** 
Representation of 
cancer spectrum * ** ** ** ** 
Matched tumor 
controls - ** ** ** *** 
Phenotypic 
stability * ** ** *** *** 
Genetic stability * *** *** *** *** 
Microenvironment 
(tumor-stroma) - - - ** *** 
Immune context - - - - ** 
Genetic 
modification *** *** ** - * 
High-throughput 
drug screening *** *** * - - 
Costs of 
maintenance *** *** * * ** 
 
*** best  ** very good * modest - N/A 
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2. Aim  
Primary liver cancers rank among the deadliest cancers world-wide with high 
mortality and poor life expectancy. Lack of clinical symptoms and biomarkers for 
early detection are the main causes of late diagnosis, when curative options are 
limited. Despite identification of several potentially drugable targets and subsequent 
development of next-generation targeted therapies, translation of these findings into 
clinical practice remains challenging in liver cancer due to a pronounced phenotypic 
and molecular diversity. Therefore, it is essential to develop representative models 
of the primary liver cancers that would lead transition from laboratory research into 
clinical practice. To overcome the existing obstacle in the translational cancer 
research, it is necessary to establish well-characterized novel PDCL for liver 
cancers that closely resemble phenotypic and molecular features of the original 
tumor. While the usefulness of PDCL for individualized, patient-specific modeling of 
treatment effects and drug response has been shown in different solid tumors, their 
potential in human liver cancer is largely unknown. Based on these observations, 
the research project presented in this thesis has aimed to address following aspects 
of PDCL biology: 
 To establish long-term cultures of patient-derived cancer cell lines from 
major primary liver cancers – hepatocellular carcinoma and intrahepatic 
cholangiocarcinoma 
With the implementation of standard cell isolation procedure, our goal was to 
establish stable long-term culture of PLC-PDCL and propagate in in vitro 2D 
conditions to subsequently perform phenotypic, molecular and translational 
analyses. 
 
 To test whether PDCL recapitulate phenotypic and molecular diversity of 
the primary cancers, and the effects of long-term cultivation on 
phenotypic and molecular profiles 
By using state-of-the-art technologies, such as next generation sequencing, we 
were aiming to deeply characterize and generate molecular profiles of newly 
derived PDCL and investigate how accurately they represent original cancer 
tissue. Further, we wanted to test how long-term cultivation conditions affect 
morphologic, transcriptomic and genomic profiles in newly established PDCL 
models. 
 
 To investigate whether PDCL reflect genomic and prognostic features of 
authentic primary liver cancers 
We wanted to implement obtained genomic and transcriptomic results together 
with authentic human HCC and CCA data to confirm molecular similarities and 
to test if the PDCL can be used as a representative model for different 
established prognostic subgroups of PLC patients. 
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 To evaluate if PDCLs could be used as a useful model for personalized 
treatment approaches 
We wanted to detect key oncogenic alterations that are potentially amenable to 
specific inhibition and to predict a response to the therapy. Overall, goal was to 
determine potential utility of PDCL for individualized treatments strategies. 
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3. Materials and methods 
 Materials 
 Electronic devices and laboratory equipment 
Table 2 Applied instruments. 
Name   Manufacturer  
Agilent 2100 Bioanalyzer  Agilent, Santa Clara, California, USA 
Autoclave Systec V150 Systec, Osnabrück, Germany 
Balance Adventurer Pro OHAUS OHAUS, Greifensee, Switzerland 
Biofuge fresco Heraeus, Hanau, Germany 
Cell Counter Biorad TC20 Biorad, Hercules, California, USA 
Centrifuge Hettich Universal 320R Andreas Hettich GmbH & Co.KG, Tuttlingen, 
Germany 
CO2 Incubator Steri-Cycle i160 Thermo Fischer Scientific, Braunschweig, 
Germany 
Eppendorf centrifuge 5415R Eppendorf, Hamburg, Germany 
Eppendorf Research Plus Pipette 1000 
µl 
Eppendorf, Hamburg, Germany 
Eppendorf Research Plus Pipette 200 µl Eppendorf, Hamburg, Germany 
Eppendorf Research Plus Pipette 20 µl Eppendorf, Hamburg, Germany 
Eppendorf Research Plus Pipette 10 µl Eppendorf, Hamburg, Germany 
Eppendorf Research Plus 12 channel 
Pipette 100 µl 
Eppendorf, Hamburg, Germany 
Hera Freeze deep freezer Thermo Fischer Scientific, Braunschweig, 
Germany 
Herasafe Biological Safety Cabinet Thermo Fischer Scientific, Braunschweig, 
Germany 
HiSeq 4000 System Illumina, San Diego, California, USA 
Hot plate Leica HI1220 Leica, Wetzlar, Germany 
Illumina HiSeq 4000 Illumina, San Diego, California, USA 
IKA MS3 Vortexer  IKA, Staufen, Germany 
IKA Vortex MS1 Minishaker IKA, Staufen, Germany 
iScan System Illumina, San Diego, California, USA 
Leica CM1850 UV Cryostat Leica, Wetzlar, Germany 
Leica EG1150 C Leica, Wetzlar, Germany 
Leica HI1210 Leica, Wetzlar, Germany 
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Name   Manufacturer  
Leica TP1020 Leica, Wetzlar, Germany 
Liebherr Premium Freezer Liebherr, Bulle, Switzerland 
Liebherr MediLine Refrigerator  Liebherr, Bulle, Switzerland 
LSM 710 NLO Confocal microscope  Carl Zeiss AG, Oberkochen, Germany 
Microtome blade MX 35 premier  
34/80 mm 
Thermo Fischer Scientific, Braunschweig, 
Germany 
Microtome Leica RM2255 Leica, Wetzlar, Germany 
Microscope Axio Zeiss Vert.A1 Carl Zeiss AG, Oberkochen, Germany 
Ministar Silverline Minicentrifuge VWR International, Darmstadt, Germany 
MiSeq System Illumina, San Diego, California, USA 
MultiGourment Steamer Braun, Frankfurt, Germany 
NanoDrop 1000 Spectrophotometer Peqlab, VWR International, Darmstadt, 
Germany 
pH meter inoLab Ph7110 WTW, Weilheim, Germany 
Pipetboy Acu 2 Pipette Controller INTEGRA Biosciences AG, Zizers, Switzerland 
Qubit 4 Fluorometer Invitrogen, San Diego, USA 
TECAN infinite M 200Pro Tecan, Männedorf, Germany 
Vacuubrand BVC Control Vacuum pump Vacuubrand, Wertheim, Germany 
Water Bath GFL 1083 GFL Gesellschaft für Labortechnik, Burgwedel, 
Germany 
 Consumables 
Table 3 Applied consumables. 
Name Manufacturer  
1000 l Tips  Starlab GmbH, Ahrensburg, Germany 
200 l Tips Starlab GmbH, Ahrensburg, Germany 
0,1-20 l Graduated Tips Starlab GmbH, Ahrensburg, Germany 
96 well-plates flat bottomed  Greiner Bio-One, Frickenhausen, Germany 
Cell culture flasks (75 cm2) Thermo Fischer Scientific, Braunschweig, 
Germany 
Cell culture TC Dish 100 SARSTEDT AG & Co. KG, Nümbrecht, 
Germany 
Counting slides for cell counter Biorad, Hercules, California, USA 
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Name Manufacturer  
Conical centrifuge tubes (15 ml and 50 
ml) 
SARSTEDT AG & Co. KG, Nümbrecht, 
Germany 
Cell strainer (30 µm and 70 µm) Miltenyi Biotec, Bergisch Gladbach, Germany 
Cryo tubes Greiner Bio-One, Frickenhausen, Germany 
DAKO Pen Dako Deutschland GmbH, Hamburg, Germany 
Inject-F (single use injection) 1 ml B.Braun, Melsungen, Germany 
Knittel glass cover slips 24*50 mm Iss, Bradford, United Kingdom 
Microscope coverslips  LifeTechnologies GmbH, Darmstadt, Germany 
One-time reagent reservoir Carl Roth GmbH, Karlsruhe, Germany 
Parafilm M Bemis Company, Neenah, Wisconsin, USA 
Pasteur Pipettes Carl Roth GmbH, Karlsruhe, Germany 
Poly-L-lysine slides Thermo Fischer Scientific, Braunschweig, 
Germany 
Rotilabo syringe filters Carl Roth GmbH, Karlsruhe, Germany 
Superfrost ultra plus slides Thermo Fischer Scientific, Braunschweig, 
Germany 
Safe-lock tubes 2,0 ml Eppendorf, Hamburg, Germany 
Safe-lock tubes 1,5 ml Eppendorf, Hamburg, Germany 
Serological pipette, sterile (5, 10, 25 ml) Greiner Bio-One, Frickenhausen, Germany 
 Chemicals and kits 
Table 4 Applied reagents and kits. 
Name Manufacturer  
-mercapthoethanol  Sigma Aldrich, Steinheim, Germany 
4′,6-diamidino-2-phenylindole (DAPI) Carl Roth GmbH, Karlsruhe, Germany 
Acetone AppliChem GmbH, Darmstadt, Germany 
Bovine Serum Albumin (BSA) Carl Roth GmbH, Karlsruhe, Germany 
Collagenase type IV Gibco Life Technologies, Karlsruhe, 
Germany 
Dimethyl sulfoxide (DMSO) Carl Roth GmbH, Karlsruhe, Germany 
DEPC treated water Life technologies GmbH, Darmstadt, 
Germany 
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Name Manufacturer  
Dulbecco’s modified eagle medium 
(DMEM) 
Gibco Life Technologies, Karlsruhe, 
Germany 
DNase I Sigma Aldrich, Steinheim, Germany 
Eosin Thermo Fischer Scientific, Braunschweig, 
Germany 
Ethanol Technical grade Thermo Fischer Scientific, Braunschweig, 
Germany 
Ethylendiamintetraacetat (EDTA) Merck KGaA, Darmstadt, Germany 
Eukitt O. Kindler GmbH & Co, Freiburg, Germany 
Fetal bovine serum (FBS) Pan-Biotech, Aidenbach, Germany 
FluorSave Reagent Merck KGaA, Darmstadt, Germany 
Hematoxylin Merck KGaA, Darmstadt, Germany 
Hydrogen peroxide 30% Carl Roth GmbH, Karlsruhe, Germany 
Isoflurane AbbVie Inc. North Chicago, Illinois, United 
States 
Isopropyl alcohol Aug. Hedinger GmbH & Co. KG, Stuttgart, 
Germany 
Matrigel BD Becton Dickinson, Franklin Lakes, New 
Jersey, USA 
Methanol Technical grade Thermo Fischer Scientific, Braunschweig, 
Germany 
Paraffin  Carl Roth GmbH, Karlsruhe, Germany 
Paraformaldehyde (PFA) Carl Roth GmbH, Karlsruhe, Germany 
Penicillin/Streptomycin      Sigma Aldrich, Steinheim, Germany 
peqGOLD Tissue DNA Mini Kit  Qiagen GMBH, Hilden, Germany 
Phosphat-buffered saline solution (PBS) Gibco Life Technologies, Karlsruhe, 
Germany 
Proteinase K Qiagen GMBH, Hilden, Germany 
Qiagen RNEasy mini Kit Qiagen GMBH, Hilden, Germany 
Sodium chloride (NaCl) Carl Roth GmbH, Karlsruhe, Germany 
Sodium chloride 0,9% solution B. Braun Melsungen, Melsungen, Germany 
Tissue Tek OCT Sakura, Torrance, USA 
Triton X – 100 Carl Roth GmbH, Karlsruhe, Germany 
Trypan Blue Sigma Aldrich, Steinheim, Germany 
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Name Manufacturer  
Trypsin/EDTA Pan-Biotech, Aidenbach, Germany  
Tween 20 Carl Roth GmbH, Karlsruhe, Germany 
WST-1 Roche Holding AG, Basel, Switzerland 
Xylene Applichem, Darmstadt, Germany 
 Antibodies 
Table 5 Applied primary and secondary antibodies. 
Name Manufacturer 
Primary antibody (dilution and host)  
α-Fetoprotein (1:400, rabbit) Dako Deutschland GmbH, Hamburg, Germany 
Albumin (1:100, mouse) Dako Deutschland GmbH, Hamburg, Germany 
Cytokeratin 19 (1:80, mouse) Dako Deutschland GmbH, Hamburg, Germany 
Epithelial cell adhesion molecule (1:80, 
mouse) 
Cell Signaling Technology, Danvers, 
Massachusetts, United States 
Secondary antibody (dilution)   
anti-mouse Alexa 488 (1:500) Cell Signaling Technology, Danvers, 
Massachusetts, United States 
anti-rabbit Alexa 555 (1:500)  Cell Signaling Technology, Danvers, 
Massachusetts, United States 
 Inhibitors 
Table 6 Applied inhibitors. 
Name Manufacturer (location, country) 
BGJ398 Selleckchem, Huston, Texas, USA 
Doxorubicin Selleckchem, Huston, Texas, USA 
Gemcitabine Selleckchem, Huston, Texas, USA 
Imatinib Selleckchem, Huston, Texas, USA 
KU-55933 Selleckchem, Huston, Texas, USA 
Refametinib Selleckchem, Huston, Texas, USA 
Sorafenib Selleckchem, Huston, Texas, USA 
Tivantinib Selleckchem, Huston, Texas, USA 
Tofacitinib Selleckchem, Huston, Texas, USA 
Vandetanib Selleckchem, Huston, Texas, USA 
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 Establishment of patient-derived cell lines 
 Patient data and sample processing 
Tissues from patients that underwent resection between 2013 and 2015 at the 
Department of Surgery, University of Mainz, Germany were included in the study 
following patient informed consent and approval of local ethics committee. Isolation 
and establishment of PDCL was performed in a total of 38 HCC, 28 iCCA. Clinico-
pathological details for successful PDCL are provided in Table 7 and Table 8. 
 
 Primary cancer cell isolation 
Tissue samples from patients with histologically or radiologically confirmed HCC or 
iCCA undergoing resection at the Department of Surgery, University of Mainz, 
Germany were collected. Tumor samples infected with HIV, hepatitis B or C virus 
were excluded from the experiments in accordance with local requirements. 
Collected tumor samples were immediately cut into smaller pieces. Tumor cells 
were isolated by using mechanic and enzymatic dissection: tissue sample was first 
cut to small pieces (~1 mm3) and incubated for 30 min. in 8 ml of 1 mg/ml 
collagenase type IV (Gibco) in Dulbecco’s modified eagle medium (DMEM) (Gibco) 
without Fetal bovine serum (FBS) (Pan-Biotech) at 37°C with gently shaking. After 
30 min 4 ml of 1 mg/ml fresh collagenase was added and further incubated for 
another 30 min at 37°C. After incubation, solution containing cells and undigested 
pieces was filtered through 70 µm Nylon strainer (Miltenyi Biotec). Undigested 
pieces from the top of the strainer were collected and plated in 10 cm dish and grown 
in complete DMEM medium supplemented with 5% FBS. Flow through was 
centrifuged at 300-400x g, for 5 min at room temperature (RT) and pellet was re-
suspended in complete DMEM medium supplemented with 5% FBS and plated in 
separate 10 cm dish. Isolated tumor cells and the remaining undigested pieces were 
kept in CO2 incubator at 37°C and 5% CO2 atmosphere.  
 
 Cell culture 
Patient-derived cancer cell lines were cultured in DMEM supplemented with 5% 
FBS, 1% penicillin and 1% streptomycin (Sigma Aldrich) in humidified 5% CO2 
incubator at 37°C (Thermo Fischer). The medium was routinely changed every 2-3 
days and the cells were split after reaching 80% confluence, approximately once in 
one to two weeks, depending on cell proliferation ratio. For passaging, cells were 
dissociated by adding 1,5 ml 1x Trypsin/EDTA (Pan-Biotech) and shortly incubated 
at room temperature. After cells were detached, reaction was inhibited by adding 
cold DMEM containing 10% FBS. Cells were further centrifuged at 400x g for 5 min 
at RT and re-suspended in 2 ml of fresh DMEM. Cell number was determined by 
BioRad cell counter (Biorad TC20), using Trypan Blue vital dye (Sigma Aldrich) 
staining. In total, 1x106 cells were transferred into new 10 cm petri dish and 
incubated under conditions mentioned above. At defined passage (P5, P10, P15, 
P20, P30, P50 and P100), part of the cells was collected in 1,5 ml Eppendorf tubes, 
centrifuged at 400x g for 5 min at RT, and obtained pellets were stored at -80°C for 
further analyses. One portion of the cells was frozen in 10% DMSO (Carl Roth), 40% 
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FBS, 50% DMEM and stored, first in deep freezer at -80°C, then transferred into 
liquid nitrogen at -196°C. For re-cultivation of the frozen cell lines, they were thawed 
in water bath at 37°C, transferred into cold medium and centrifuged (400x g, 5 min,  
4°C). Cell pellet was re-suspended in a complete medium and transferred into a  
10 cm cell culture dish. Next day medium was changed and when cells were 
reaching confluence, they were passaged. 
 
 Paraffin fixation and hematoxylin-eosin staining 
Besides establishing primary tumor cell lines, a part of tissue samples obtained from 
surgery were either fixed in 4% paraformaldehyde (PFA) (Carl Roth) or preserved 
for cryosections at -80°C. PFA fixed tissue was further embedded in paraffin by 
Leica TP 1020 automated embedder, following standard protocol. Briefly, tissue was 
dehydrated through series of alcohol (70-100%) and xylene (Applichem), and then 
incubated two times 2 hours in paraffin wax (Roth) at 60°C. Next, tissue samples 
were embedded in paraffin blocks and cut into 3,5 µm sections on LEICA RM2255 
microtome. Hematoxylin-eosin (HE) staining was performed by standard techniques 
using Mayer’s Hemalum Solution (Merck) and Eosin-y Alcoholic solution (Thermo 
Fisher). Before staining, tissue slides were placed in xylene and decreasing alcohol 
series for rehydration (100-70%). After staining, samples were dehydrated through 
increasing alcohol series (70-100%) and xylene, and then closed with cover slips 
and mounting medium (Sigma Aldrich). 
  
 Immunoflourescence staining of primary tumor cells and frozen tumor 
tissue 
Staining of isolated primary tumor cells was performed by the following procedure: 
cells were grown in ibidi 8 well chamber slides (Ibidi) or on standard microscope 
slides placed in a 10 cm dish (Sarstedt) and cultivated in complete DMEM containing 
10% FBS. After reaching confluency of approximately 80%, cells were fixed in 4% 
PFA or Aceton/MetOH at -20°C. Cells were rehydrated in distilled water and washed 
with phosphate buffered saline supplemented with 0.1% Tween20 (PBS-T) (Gibco), 
and permeabilized with triton-x (0,1% in PBS) (Carl Roth). Next, cells were washed 
with PBS-T and incubated one hour with 10% bovine serum albumin (BSA) (Carl 
Roth) to inhibit unspecific binding. The primary antibodies against Albumin (1:100), 
EpCAM (1:80), AFP (1:400) and CK19 (1:80) were added and the slides were 
placed in a humidified chamber overnight. Antibodies were diluted in PBS-T 
containing 0,1% BSA. On the following day, slides were washed with PBS-T and the 
fluorophore-coupled corresponding secondary antibodies were added (anti-mouse 
alexa488 and anti-rabbit alexa555, 1:500, in PBS-T) for one hour in darkness. 
Counter staining was performed with DAPI for 20 min (1:1000) (Carl Roth). Lastly, 
slides were closed with cover slips and FluoroSave embedding medium (Merck). 
Frozen tissue samples were embedded in OCT gel (Sakura) and cut into 5 µm slices 
on Leica CM1850 UV Cryostat at -24°C. After fixation with 4% PFA, samples were 
stained using same procedure as described for primary tumor cells. 
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 Microscopy 
Hematoxylin-eosin samples were visualized by a Zeiss Axioskop microscope with 
10x magnification objective and further processed in cellSens Dimension software 
(Olympus). Living primary tumor cells were viewed by Zeiss Axioplan microscope 
with phase-contrast setup. All images were obtained with 10x magnification 
objective and analyzed in AxioVision 3.1 software.  
All immunofluorescent stainings were visualized and recorded by Laser Scanning 
Microscope LSM-710 Zeiss with 25x magnification oil objective. During scanning 
“tile” option was enabled, where images were organized together in 4x4 format. 
Obtained images were further processed in Zen 2.3 software. 
 
 Functional assays 
 Dose-response analyses 
Stock solutions of inhibitors were prepared by dissolving in dimethyl sulfoxide 
(DMSO) (Carl Roth) according to manufacturer’s recommendations. For the 
following inhibitors 100 mM stock solutions were prepared: tofacitinib, KU55933, 
refametinib, imatinib, tepotinib, sorafenib, gemcitabine and doxorubicin. Due to 
lower solubility in DMSO, vandetanib was prepared as 10 mM and BGJ398 as 1 mM 
stock solution (inhibitors are listed in the Table 6). Working concentrations were 
further prepared by diluting stock solution in complete DMEM (10% FBS). Dilutions 
of specific inhibitors, except tepotinib, were prepared as follows: 0,016; 0,08; 0,4; 2; 
10; 20; 30; 40; 80 and 160 µM; Concentrations of tepotinib, sorafenib and 
gemcitabine were prepared as 2; 4; 8; 12; 16; 32; 64 µM; doxorubicin was prepared 
as: 0,016; 0,08; 0,4; 2; 4; 10 µM. Totally, 5×103 cells were plated in 96 well-plates. 
After overnight incubation in complete DMEM medium (10% FBS), medium was 
replaced with fresh medium containing respective inhibitors for 72 hours. Selection 
of inhibitors was based on predicted specificity to the target alterations determined 
by panel NGS. HCC derived primary cell lines were treated with imatinib, tepotinib, 
BGJ398, KU55933, sorafenib and doxorubicin while iCCA derived primary cell lines 
were treated with tofacitinib, refametinib, vandetanib, sorafenib, gemcitabine and 
doxorubicine. Results were calculated as viability of treated cells compared to non-
treated controls. Viability was measured by WST-1 assay (Sigma Aldrich) according 
to the manufacturer's protocol and as described in the section 3.3.2. Cell viability 
defined as the absorbance in the treatment group compared to controls expressed 
as viability percent ± SD (n = 3). DMSO was used as vehicle control whenever 
suitable. IC50 values were calculated by non-linear regression using GraphPad 
Prism 6 software (GraphPad Software, La Jolla, CA).  
 
 Viability assay 
Viability was measured by WST-1 assay according to the manufacturer's protocol 
(Roche Applied Sciences). This spectrophotometric assay is designed to assess cell 
proliferation and viability in 96 well-plate format. Moreover, high sensitivity of the 
assay allows cytotoxic and cytostatic effects of anti-cancer drugs to be investigated. 
Assay is based on the cleavage of tetrazolium salts to formazan by enzymes present 
Materials and methods 
38 
in viable cells, particularly by mitochondrial dehydrogenases. Accumulation of 
formazan and accompanying color change directly correlates with number of living 
cells. Maximum absorption is at 440 nm wavelength, while absorbance could be 
measured in the range from 420–480 nm. To assess cell viability, WST-1 reagent 
was first mixed with DMEM (10% FBS) in ratio 1:10. Next, medium was removed 
from the wells with seeded cells, and then 100 µl of WST-1 working reagent was 
applied in each well of 96 well-plates. Absorbance at 450 nm was measured every 
30 min for next two hours on a microplate spectrophotometer (TECAN infinite M 
200Pro). Wells containing only WST-1 working reagent were used as a blank. 
Reference wavelength was measured at 660 nm.  
 
 Next generation sequencing 
 RNA isolation 
Total RNA from the tissue and cells was extracted using the Qiagen RNEasy mini 
Kit (Qiagen) following the manufacturer’s instructions. In brief, approximately 20-40 
mg of tissue or 5x105–1x106 of cells were mechanically dissociated, lysed and 
homogenized in 600 µl lysis buffer. Lysate was filtered with Shredder-filter columns 
to ensure homogenization of the starting material. To provide ideal binding 
conditions, lysate was mixed with 600 µl ethanol and loaded on a RNeasy Mini spin 
column allowing RNA to bind to the membrane. Remaining DNA was removed by 
adding DNase (Qiagen). Column was further washed three times with washing 
buffer, and total RNA was eluted in 50 µl of RNase-free water. RNA quantity and 
purity were estimated using a Nanodrop ND-1000 Spectrophotometer (NanoDrop 
Technologies), and integrity was assessed by Agilent 2100 Bioanalyzer (Agilent). 
For RNA sequencing only samples reaching integrity number equal or higher than 
6 (RIN≥7) was used. 
 
 DNA isolation 
DNA was extracted using peqGOLD Tissue DNA Mini Kit (Qiagen) following the 
manufacturer’s instructions. Approximately 20-40 mg of tissue or 5x105–1x106 of the 
cells was used for genomic DNA isolation. Samples were first homogenized, lysed 
under denaturing conditions with Proteinase K and RNase A (Qiagen) at 50°C for at 
least 1 hour and then applied to the PerfectBind DNA columns, where the DNA was 
effectively bound to the silica membrane. Cellular debris, proteins and other 
contaminants were washed away by specific buffers. The high-quality DNA was 
finally eluted in 200 µl of elution buffer. DNA quantity and purity were estimated by 
using a Nanodrop ND-1000 Spectrophotometer or Qubit Fluorometer (Thermo 
Fisher). Fluorescence-based method, such as Qubit, employs a double-stranded 
DNA (dsDNA) specific dye, allowing accurate quantification of dsDNA even in the 
presence of many common contaminants, which is required for high precision 
analyses such as DNA sequencing. 
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 RNA Sequencing 
RNA sequencing (RNA-seq) services were provided by BGI TECH SOLUTIONS 
(HONGKONG) CO. In total, 27 human RNA samples, obtained from the tissue and 
cell pellets, were provided for sequencing. Total RNA was extracted from 
surrounding liver, primary tumor, early passage (P5) and late passage (P30) of 
corresponding PDCL. All the samples fulfilled quality requirements requested by 
service provider: (i) RNA samples were treated by DNase and provided without 
protein contamination; (ii) sample quantity of total RNA was ≥ 200 ng; (iii) sample 
concentration was ≥ 20 ng/µl; (iv) Sample purity: RNA 28S:18S ≥ 1.0, RIN ≥ 7.0. 
Before sequencing, library preparation was performed according to manufacturer’s 
instructions (Illumina® TruSeq® RNA Sample Preparation Kit v2). By this process, 
mRNA was converted into a library of template molecules suitable for subsequent 
cluster generation and DNA sequencing. The first step of library preparation was 
purifying the poly-A containing mRNA molecules using oligo-dT attached magnetic 
beads. After purification, the mRNA was fragmented into small pieces using divalent 
cations under elevated temperature. The cleaved RNA fragments were copied into 
first strand cDNA using reverse transcriptase and random primers, followed by 
second strand cDNA. The cDNA fragments then went through an end repair 
process, the addition of a single ‘A’ base, and ligation of the adapters. The products 
were in the end purified and enriched with PCR to create the final cDNA library. 
Samples were further sequenced in 3 lanes with 100PE reads by Illumina’s 
HiSeq4000 technology. At the end, 3 lanes of clean data were generated (data after 
removing adaptor pollution and low quality sequence) and transferred clean data 
(*.fq files). Raw reads were filtered by removing adapter sequences, contamination 
and low-quality reads. The reads were then mapped with human genome reference 
sequence (GRCh37.82) using HISAT2 (hisat2-2.0.2-beta) followed by read 
summarization with featureCounts (subread-1.5.0-p1). Data analysis was 
performed using R programming language and related packages. The output matrix 
from featureCounts was input into the Bioconductor package DESeq2 for differential 
expression analysis. Significance testing was performed using Wald Test statistics. 
To visualize the data Principal Components Analysis (PCA) and clustering was 
performed. All plots were generated using the MADE4 package. Gene Set 
Enrichment analysis (GSEA) was performed using GSEA software provided by 
Broad Institutes (http://www.broad.mit.edu/gsea/). Human gene sets from the 
MSigDB database were tested and gene sets with a NOM P-value <0.05 and FDR 
<0.25 were considered significantly enriched in a priori defined set of genes.  
 
 Target DNA Sequencing and data analysis 
DNA sequencing services were provided by Institute of Pathology, University 
Medical Center Mainz. Targeted sequencing was performed using Illumina TruSeq 
Amplicon - Cancer Panel including 48 important cancer-related genes according to 
manufacturer’s instructions (Figure 9 and Figure 10). Genomic DNA was extracted 
from surrounding liver, primary tumor and different passages (P3, P5, P8, P10 and 
P30) of corresponding PDCL. Total amount of genomic DNA provided for the 
analysis was 250 ng. TruSeq Amplicon cancer panel is a highly multiplexed targeted 
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resequencing assay for detecting somatic mutations within important cancer-related 
genes. In the panel, predesigned and optimized oligonucleotide probes for 
sequencing mutational hotspots in > 35 kilobases (kb) of target genomic sequence 
were provided. 48 genes were targeted with 212 amplicons in a highly multiplexed, 
single-tube reaction. One pair of oligos was designed for each amplicon. 
Hybridization of oligos to unfragmented genomic DNA occurred in a 96well-plate, 
followed by extension and ligation to form DNA templates consisting of the regions 
of interest flanked by universal primer sequences. Using index adapters, libraries 
were indexed, PCR amplified, and then pooled into a single tube before sequencing. 
After sequencing, further analyses were performed using automated variant calling 
integrated in the Illumina analyses pipeline. 
 
  
 
Figure 9 TruSeq Amplicon - Cancer Panel Workflow.  
The following diagram illustrates the workflow using the TruSeq Amplicon - Cancer Panel Kit 
(modified from Ilumina TruSeq® Amplicon - Cancer Panel Reference Guide). 
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Figure 10 TruSeq Amplicon – Cancer-Related Genes.  
Figure displays cancer-related genes represented in TruSeq Amplicon - Cancer Panel Kit (modified 
from Ilumina TruSeq® Amplicon - Cancer Panel Reference Guide). 
 
  Single nucleotide variations and copy number analysis 
Single nucleotide variations (SNV) and Copy number analyses were provided by 
Institute of Human Genetics, Department of Genomics, Life & Brain Center, 
University of Bonn. The Infinium Omni2.5Exome-8 v1.3 BeadChip was used to 
deliver comprehensive coverage of common, rare and exonic SNP content from the 
1000 Genomes Project (1 kGP) and provided maximum genomic information. These 
8-sample BeadChips allowed high throughput, optimized tag single nucleotide 
polymorphisms (SNPs) and copy-number variation (CNV) analysis. Genomic DNA 
was extracted from surrounding liver, primary tumor, and different passages (P5 and 
P30) of corresponding PDCL. Total amount of genomic DNA provided for the 
analysis was 200 ng. Calling of genotypes was performed using the Illumina SNP 
assay software GenomeStudio version 2011.1. All SNVs with call Frequencies>0.95 
and Gen TrainScore>0.7 were included. The log R ratio (LRR) and B allele 
frequency (BAF) were then exported from the normalized Illumina data. 
Segmentation analyses were performed using CBS algorithm (DNAcopy) and 
significant copy number changes were determined by GISTIC2.0.  
 
 In vivo experiments (xenograft studies) 
All procedures were performed in accordance with the guidelines of the National 
Institutes of Health animal care committee following approval from local authorities. 
All xenograft experiments were performed in non-obese diabetic/severe combined 
immunodeficient (NOD/SCID) mice. To investigate tumorigenicity of freshly isolated 
primary cell lines, in total 1-5x106 viable cells were harvested from the 10 cm dishes 
when reached 80% confluency, re-suspended in 100 µl DMEM and 100 µl matrigel 
(BD Bioscience) and injected into both flanks of NOD/SCID mice. Tumor formation 
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was monitored weekly by palpation for 8-10 weeks. After reaching tumor volume of 
approximately 500 mm3, mice were sacrificed, and tumors were collected. Part of 
the obtained xenograft tumors was used for tumor cell isolation (2nd generation), 
while remaining tissue was either fixed in 4% PFA or preserved at  
-80°C. In vivo experiments addressing the effects of specific inhibitor targeting 
detected oncogenic mutation were conducted in the following manner: first, 
inhibitors were dissolved in DMSO in the concentrations of 100 mM as a stock 
solution. Prior the treatments, inhibitors were further diluted to respective IC50 
concentrations in complete DMEM supplemented with 10% FBS. Primary 
cholangiocarcinoma cells (CCA16) were plated in 10 cm dishes with 1x106 cell 
density. After 24h medium was removed and replaced by fresh medium containing 
IC50 concentrations of inhibitors. After 72h of treatment cells were harvested and 
counted. Prior the injection, animals were divided into three groups (control, 
refametinib and tofacitinib). In total, three animals per each group were injected in 
both flanks with 1x106 viable cells mixed with 100 µl DMEM and 100 µl matrigel. 
Untreated cells were used as a control. Tumor formation was monitored weekly by 
palpation for 10 weeks, and tumor incidence was reported. After reaching 10 weeks, 
animals were sacrificed, tumors were collected and either frozen at -80°C or fixed 
in 4% PFA. 
 
 Statistics, databases and patient integration 
Statistical analysis was performed using Student's t-test or Mann–Whitney U test as 
indicated. P-values ≤0.05 were considered statistically significant. Results are 
presented as means ± SD from 3 independent experiments. Survival analyses were 
performed using log rank (Mantel-Cox) tests. For integration of patients, expression 
data from HCC and iCCA tumor specimens generated by Illumina beadchips was 
used.196, 197 
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4. Results 
 Generation of PDCL from primary human liver cancer 
 Clinicopathological information of the patients 
We collected fresh tumor tissues from 38 patients with HCC and 28 patients with 
iCCA (Table 7 and Table 8). The majority of HCC patients were male (79%).43 In 
our iCCA cohort, gender distribution was equal (50% male, 50% female), similarly 
to distribution that was reported in a study of 11296 iCCA cases, where 53% of the 
patients were male and 47% female.42 Majority of the HCC patients developed 
NASH as a dominant etiological factor (32%) followed by alcoholic liver disease 
(16%). Liver cirrhosis as only predisposing factor without presence of other factors 
was reported in 8% patients. Etiological factors were not available for 40% of the 
patients. Importantly, majority of iCCA patients in our cohort showed liver 
inflammation (75%) (Table 8). Moreover, most of HCC tumors were well to 
moderately differentiated and it accounted 64% of all cases (well – 8%; well to 
moderate – 11%; moderate – 45%), while 33% were moderately to poorly 
differentiated (moderate to poor – 11%; poor – 22%). Differentiation was not 
determined for 3% HCCs. Similar to HCC, our iCCA samples were mostly well to 
moderately differentiated with total percentage of 71% (well to moderate – 3%; 
moderate – 68%), while small number showed poor differentiation (21%). 
Remaining 8% was not determined. Tumor grading showed that 65% of HCC were 
low graded (G1, G1-2, G2), while the rest (35%) showed higher grading (G2-3, G3). 
For iCCA, tendency was even higher for low grading tumors with 71% cases (G1, 
G1-2, G2), while 21% were high graded (G2-3, G3). Tumor sizes were very 
heterogeneous, from 0,5 cm to 14,5 cm in diameter (Table 7, Table 8). After surgical 
resection, tissue samples were processed by mechanical and enzymatic digestion 
to establish the PDCL. A total of 7 PDCL from PLC (4 HCC and 3 iCCA) were 
successfully established and cultured over 30 passages (Figure 13). Overall, tumors 
with derived PDCL were poorly differentiated, mainly with high grading of G2-G3 
and G3, whereas only one tumor showed low grading of G1 and higher 
differentiation status. Pathological reports revealed different tumor sizes, from 
relatively small (2,6 cm for HCC31) to big in size (13 cm for HCC9) (Table 7, Table 
8). Efficacy of establishing the PDCL was 11% for both tumor types, HCC-PDCL 
and CCA-PDCL. Rapid overgrowth by tumor-associated spindle cells and 
fibroblasts was the predominant reason for failure of culturing in unsuccessful 
attempts. 
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Table 7 Clinicopathological information of HCC tumors. 
Tumorigenicity of the primary cell lines and serial transplantation were assessed in NOD/SCID mice. 
A total of 5 mio cells were transplanted subcutaneously in both flanks of the mice. Green color 
indicates tumors that PDCLs were successfully derived from.  
 
Tumor 
sample Gender 
Size 
(cm) TNM Grading Differentiation Etiology 
In vivo 
tumorigenicity / 
serial 
transplantation 
HCC2 F 8 pT2, pNx, M0, R0 G3 Poor NASH N/A 
HCC3 M 11 pT3b, pNx, M1, R2 G3 Poor NASH N/A 
HCC4 F 3 pT1, pNx, M0, R0 G2 Moderate N/A N/A 
HCC6 F 12 pT1, pN0, M0, RX G3 Poor N/A N/A 
HCC9 F 13 pT2, pNx, M0, R0 G2-G3 
Moderate to 
poor 
NASH Yes / No 
HCC10 M 4,5 pT1, pNx, M0, R0 G2 Moderate NASH N/A 
HCC11 M 9 pT1, pNx, M0; R0 G1-G2 Moderate NASH N/A 
HCC12 M 10,9 pT1, pNx, M0, pR0 G2 Moderate NASH N/A 
HCC13 M 11 pT3b, pNx, M0 G2 Moderate EtOH N/A 
HCC14 M 2 pT1, N0, M0, R0 G2 Moderate N/A N/A 
HCC15 M 4,7 pT1, pNx, M0, R0 G1 Well No cirrhosis N/A 
HCC16 M 5,2 pT3b, pNx, M0, R1 G2-G3 
Moderate to 
poor 
NASH No / N/A 
HCC17 M 14 pT1, pN0, M0, R0 G1 Well NASH N/A 
HCC18 F 10 pT0, pNx, M0, R0 N/A N/A NASH N/A 
HCC26 M 3,5 pT3a, pN0, M0, R0 G2 Moderate NASH N/A 
HCC27 M 5 pT1, pNx, M0, R0 G2 Moderate EtOH N/A 
HCC28 F 4 pT1, pNx, M0, R0 G3 Poor N/A N/A 
HCC31 M 2,6 pT2, pN0, M0,R0 G1 Well EtOH Yes / Yes 
HCC33 M 6,3 pT3, pNx, M0, R0 G2 Moderate NASH N/A 
HCC36 M 3,6 pT1, pNx, M0, R0 G2 Moderate Cirrhosis N/A 
HCC37 M 11,5 pT1, pNX, M0, R0 G1-G2 
Well to 
moderate 
N/A N/A 
HCC39 F 5,8 pT1, pNx, M0, R0 G1-G2 
Well to 
moderate 
N/A N/A 
HCC46 M 9 pT3b, pN1, M0, R0 G3 Poor N/A N/A 
HCC48 M 4,7 pT1, Nx, Mx, R0 G2 Moderate N/A N/A 
HCC52 M 7 pT1, pN0, M0, R0 G3 Poor N/A N/A 
HCC53 M 1,7 pT1, rNx, Mx, R0 G2 Moderate NASH N/A 
HCC54 M 1,3 pT3, Nx, Mx, R1 G2 Moderate N/A N/A 
HCC55 M 5,5 pT1, Nx, M0, R0 G2-G3 
Moderate to 
poor 
EtOH N/A 
HCC57 M 10 pT1, pN0, M0, R0 G1-G2 Moderate N/A N/A 
HCC58 M 4,8 pT1, pNx, M0, R0 G2-G3 N/A EtOH N/A 
HCC59 M 6,6 pT1, pN0, M0, R0 G2 Moderate N/A N/A 
HCC60 M 3,5 pT3b, pN0, M0, R0 G1-G2 
Well to 
moderate 
EtOH N/A 
HCC61 M 9 pT1, pN0, Mx, R0 G2-G3 
Moderate to 
poor 
No cirrhosis N/A 
HCC62 F 3,5 pT3, pN0, R0 G1-G2 
Well to 
moderate 
N/A N/A 
HCC63 M 14,5 pT3a, pN0, M0, R0 G2 Moderate N/A N/A 
HCC64 M 8,5 pT3b, pN0, M0, R1 G3 Poor N/A N/A 
HCC65 M 1,8 pT1, Nx, M0; R0 G2 Moderate Cirrhosis N/A 
HCC68 M 11 pT2, pNx, M0, R0 G3 Poor No disease Yes / Yes 
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Table 8 Clinicopathological information of iCCA tumors. 
Tumorigenicity of the primary cell lines and serial transplantation were assessed in NOD/SCID mice. 
A total of 1 mio cells were transplanted subcutaneously in both flanks of the mice. Green color 
indicates tumors that PDCLs were successfully derived from. 
 
Tumor 
sample Gender 
Size 
(cm) TNM Grading Differentiation Inflammation 
In vivo 
tumorigenicity 
/ serial 
transplantation 
CCA1 M 1,4 N/A G2 Moderate Yes N/A 
CCA2 F 13 pT1, pN0, M0, R0 G2 Moderate Yes N/A 
CCA3 F 6 pT2b, pN0, M0, R0 G1-G2 Well to moderate Yes N/A 
CCA4 F 6,5 pT2b, pN0, M0, R1 G2 Moderate No N/A 
CCA5 F 10,3 pT1, pN0, M0, R0 G2 Moderate Yes N/A 
CCA6 M 3,5 pT1, pN0, M0, R0 G2 Moderate Yes N/A 
CCA7 M 12 pT2a, pN0, M0, R0 G2 Moderate No N/A 
CCA8 F 5 pT1, pN0, M0, R0 G2 Moderate No N/A 
CCA9 F 6,4 pT3, pN0, R0 G2 Moderate Yes N/A 
CCA10 F 5,9 pT3, pN1, M0, R0 G2 Moderate Yes Yes / Yes 
CCA13 M 4,3 pT3, pN1, M0, R0 G2 Moderate Yes N/A 
CCA14 M 3,5 N/A G2 Moderate Yes N/A 
CCA15 F 12 pT2b, pN0, M0, R0 G2 Moderate Yes N/A 
CCA16 M 10 pT3, pN1, M0, R0 G3 Poor No Yes / Yes 
CCA17 M 14,5 pT3, pN1, M0, R1 G2-G3 Poor Yes N/A 
CCA18 F 10,2 pT2a, pN1, M0, R0 G3 Poor Yes N/A 
CCA19 M 7,3 pT3, pN1, M0, R0 G2 Moderate No N/A 
CCA22 M 9 pT2a, pN0, M0, R0 G3 Poor Yes N/A 
CCA23 F N/A pT1, Nx, M0, R0 G2 Moderate Yes N/A 
CCA24 M 3 pT1, pNX, M0, R0 G2 Moderate Yes N/A 
CCA25 M 0,5 ypT1, pN0, Mx, R0 N/A N/A Yes N/A 
CCA26 F 6,2 pT3, pN0, pM1, R0 G2 Moderate No N/A 
CCA27 F 5,5 pT1, pNx, M0, R0 G2 Moderate Yes N/A 
CCA28 M 2,6 N/A N/A N/A No N/A 
CCA29 F 0,6 pT2b, pN0, Mx, R0 G2 Moderate Yes N/A 
CCA30 F 14 pT2b, pN0, M0, R0 G2 Moderate Yes N/A 
CCA31 M 7,5 pT2a, N0, M0, R0 G3 Poor Yes N/A 
CCA33 M 8,5 pT2a, pN1, M0, R0 G3 Poor Yes Yes / Yes 
 
 
 Examining tumor grading and genomic alterations as a background 
setting for successful PDCL generation 
As the success rate of establishing new PDCL was relatively low, we wanted to 
assess basic characteristics that might contribute to successful cell isolation and 
PDCL propagation. After analyzing tumor grading for both tumor entities, HCC and 
iCCA, we observed a trend for a higher tumor grading in tumors with successful 
generation of PDCL. In HCC group almost 80% of the successful tumors were G2-
G3 and G3, and about 80% iCCA tumors were comprised of G3 (Figure 11a). To 
further investigate underlying mechanisms of successful PDCL generation, we 
performed genomic analyses and compared the spectrum of genetic alterations in 
tumor specimens of HCC and iCCA patients with and without successful 
establishment of PDCL. We observed a significant number of increased genomic 
gains and losses in the tumors with successful PDCL establishment (Figure 11b,c). 
Furthermore, recurrent copy number alterations (CNAs) were observed in several 
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chromosomal locations, including 4q, 5q, 8p, 9p and 13q. These CNAs affected 
amplifications in 4q13.1 (LPHN3), 5q22.1 (TSLP), 8p21.1 (CCDC25, PBK, ESCO2), 
9p22.2 (CNTLN) and 13q14.3 (MIR1297) previously associated with the proliferative 
capacity and cancer (Figure 11b).198-200 201, 202 Additionally, by using Ingenuity 
Pathway Analysis (IPA), we identified molecular and cellular functions of significant 
genomic alterations present in HCC and iCCA with successful PDCL establishment. 
Overall, major molecular and cellular functions centered on pro-oncogenic 
properties such as cellular growth and proliferation, movement as well as cell death 
and survival (Figure 11d). These investigations indicate that a poor differentiation 
status, as well as increased genomic alterations, favor successful PDCL 
establishment.      
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Figure 11 Tumor grading and genomic alterations underlying successful and non-
successful PDCL establishment.  
A) Percentage of differently graded tumors in successful and unsuccessful PDCL establishment. Left 
is shown grading of HCCs, middle iCCAs and right combined both entities B) Significant genomic 
alterations for primary tumors with successful vs non-successful PDCL establishment. Lower rows 
show CNAs analyses for each entity as well as the corresponding GISTIC analyses. Red and blue 
colors represent level of gain and loss, respectively C) Number of significant copy number alterations. 
D) Molecular and cellular functions of significant genomic alterations present in HCC and iCCA with 
successful PDCL establishment.  
 
 Morphological and molecular characterization of the PDCL 
 Morphology of the PDCL during long-term cultivation 
Using slightly modified, established culture conditions (see “3.2.3 Cell culture”), 
clean epithelial cultures, free of fibroblast and macrophages, were progressively 
established and confirmed within 1-3 passages in the newly derived PDCL (Figure 
13). Initial culturing of the cells (passage 0) was continued until sufficient number of 
epithelial cells were detected (>100000 cells). Cells were then split into a new 
passage (passage P1), and further propagated until fibroblasts and macrophages 
were exhausted and clean cultures could be obtained. Time from isolation to stable 
growth and clean cultures ranged between four and eight weeks. For each newly 
established PDCL average doubling time across different passages was calculated 
(Figure 12). The fastest growth was observed in CCA10 with an average doubling 
time of 31 hours, while other PDCL showed slower doubling, in average between 
50 and 54 hours. Proliferation rate influenced time necessary to reach passage 30, 
and it was between 34 and 52 weeks. Once stable growth of PDCLs was achieved, 
morphological characteristics of the cells over the course of time were assessed by 
phase-contrast microscopy. Cells were analyzed after defined number of passages, 
at P3, P5, P8, P10, P15 and P30. We observed that morphology of established 
cultures remained relatively stable over the complete observation time and 
comparable to early passages (e.g. P3, P5). However, one of the PDCL (HCC16) 
acquired additional morphological changes reflected in increased cellular size and 
appearance of vacuole-like structures. They further showed a decline in proliferation 
rate, which led to complete cessation of cell growth after 10 passages. Inability to 
further proliferate and no vital cultures could be re-established for this cell line after 
initial freezing which prevented us from further characterization of this PDCL. 
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Figure 12 Population doubling time of PDCL. 
Doubling time for each PDCL (except HCC16) was calculated as an average value across different 
passages. Bars represent number of hours required for each cell lines to double cell population. n=3 
 
 
 
Figure 13 Morphology of PDCLs at different passages and the second generation 
obtained from xenograft tumors.  
Bright field images demonstrating morphology of newly-derived PDCL over 30 passages. Last 
pictures on the right side represent cells isolated from patient-derived xenograft tumors. 
Representative PDCLs for HCC and iCCA are shown. Scale bars indicating 100 µm. 
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 Examining malignant status of the PDCL by xenotransplantation 
To confirm malignant potential of PDCL, we performed subcutaneous 
xenotransplantations as well as serial transplantations into immune-compromised 
NOD/SCID mice (Table 7, Table 8, Figure 13, Figure 14). For HCC-PDCL we 
transplanted 5 million cells in each flank of the animals, while for CCA-PDCL a total 
of 1 million cells were used. Successful tumor growth was achieved for all 6 PDCL, 
confirming their tumorigenic properties. As mentioned before, one cell line (HCC16) 
stopped to proliferate, and its malignant status could not be confirmed thereafter by 
this method. After the first generation of xenograft tumors had grown, we isolated 
second generation of PDCL and successfully performed serial transplantation of 1 
million cells (Table 7, Table 8). Importantly, tumor cells that were re-isolated from 
xenograft tumors, except from HCC9 (did not grow second generation of tumors), 
showed similar morphological features to the parental cells that were initially 
transplanted into immune-compromised NOD/SCID mice (Figure 13). Next, we 
compared histological features of the xenograft tumors to the matched primary 
tumor tissues (Figure 14). Overall, PDCL closely recapitulated morphological 
patterns of the original tumor. Both HCC primaries and HCC-PDLC showed 
trabecular growth with large hepatocytic tumor cells with minimal stromal 
desmoplasia, whereas iCCA as well as corresponding PDCL showed glandular 
differentiation with stromal desmoplasia indicating that the newly derived PDCL 
could serve as a valid patient-specific in vitro model.  
 
 
Figure 14 Histology of the xenograft and matched primary tumors.  
Hematoxylin and eosin staining of primary tumors and xenograft transplantations. Scale bars 
indicating 100 µm.  
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 Expression of specific markers to validate cellular origin of PDCL 
Immunofluorescence staining and confocal microscopy analyses of the classic 
hepatocellular (AFP, Albumin), biliary (CK19) and epithelial progenitor (EpCAM) 
markers gave us more insight into cellular origin of our freshly derived cell lines. We 
compared our PDCL with corresponding primary cancers. Expression of albumin 
was observed in all HCC-derived cell lines as well as the original tumors, while 
EpCAM and AFP were only stained in HCC68. High expression of CK19 and 
EpCAM was noticed in iCCA tumors and corresponding PDCL, while albumin 
staining remained completely negative. Overall, expression patterns between 
original tumor tissue and PDCL were similar which confirmed the cellular origin of 
the newly established HCC and iCCA cell lines (Figure 15). 
 
 
Figure 15 Expression of selected markers in tumors and PDCL by 
immunofluorescence. 
Immunofluorescence staining of selected hepatocellular (Albumin, AFP), biliary (CK19) and epithelial 
progenitor (EpCAM) markers by confocal microscopy. Shown are representative images from 
matched tumors and PDCL. Scale bars indicating 100 µm.     
 
 Transcriptome profiling of PDCL and original tumor 
As we observed that morphological and molecular features of PDCL remained 
similar to primary tumors, we further assessed the landscape of molecular 
alterations in order to confirm the utility of the PDCL as patient-specific models. 
First, RNA sequencing was performed to assess the transcriptomic profile of the 
tumor surrounding liver tissue, PDCL and the original tumor. By performing multiple 
comparison analysis between different groups (tumor (T), passage 5 and passage 
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30), we identified a total of 5014 differentially expressed genes. Unsupervised 
hierarchical cluster analyses based on these significantly differentially expressed 
genes demonstrated that both early stage (passage 5) and later stage (passage 30) 
PDCL formed dense sub-clusters with the corresponding primary tumor, confirming 
that the gene expression profiles are similar between the newly derived PDCL and 
the tumors and remain stable during transient expansion of the cells. Analysis 
further revealed clear separation between HCC and iCCA entities, with exception of 
HCC31. Interestingly, this PDCL and original tumor formed a cluster together with 
iCCA indicating presence of similar expressional profile between those entities, 
particularly with CCA10. Similar transcriptional profile between HCC31 and other 
CCAs could also be observed in a PCA (principal component analyses) plot (Figure 
16a,b). A similar observation was noted in several studies examining expressional 
profiles of PLCs.203-205 For instance, Woo et al. defined a novel HCC subtype that 
expressed CCA-like traits and defined it as CCA-like HCC.204 Transcriptome 
correlation further confirmed that the molecular characteristics of the tumors are 
retained in the PDCL. As expected, tumor-surrounding liver tissue (SL) from all 
different primary tumors formed a distinct sub-cluster overall validating that PDCL 
resemble malignant tumor properties (Figure 16c). 
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Figure 16 Concordance in transcriptome profiles of PDCLs and matched primary 
tumors and separation of surrounding liver tissue.  
Whole RNA-seq was performed on surrounding liver (SL), primary tumors (T) and PDCLs at passage 
5 and 30. A total of 5014 genes significantly differed across the different PDCLs. A) Unsupervised 
clustering analyses and B) principal component analyses (PCA) of the PDCLs and matched tumors 
(T). C) Transcriptome correlation confirms a clear separation of tumor-surrounding livers from 
transformed tumors and PDCL. Result shows that different PDCL form tight sub-clusters with the 
primary tumors. 
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Comparative functional network and pathway analyses for commonly disrupted 
genes in each PDCL were performed. Several key oncogenic pathways associated 
with the different primary cancers could be revealed (Figure 17). For HCC-PDCL 
this included activation of MYC, p14/p19ARF, Sirtuin, p53 as well as Notch 
signaling.53, 206 Genes centering on MAPK, ubiquitination, autophagy and 
pluripotency were also enriched. In CCA-PDCL we observed activation and 
enrichment of Wnt/β-Catenin, Pi3K, insulin receptor, VEGF signaling as well as 
pathways mediating p53 and pro-inflammatory related pathways.207 Interestingly, 
some of the affected pathways were only detected in a single PDCL, such as cyclin 
dependent cell cycle regulation and mitotic regulation through polo-like kinase in 
HCC68, also reported to be dysregulated in some HCC.208, 209 Moreover, our CCA-
PDCL showed a higher number of uniquely activated pathways in each primary cell 
line than observed in HCC-PDCL (Figure 17). Accordingly, CCA10 showed the 
highest diversity of unique pathways, predominantly involved in different aspects of 
immunity, such as modulation of immune response, induction of inflammation, as 
well as role in cell proliferation and apoptosis.210, 211 These pathways include CD40, 
TLR, Lymphotoxin β receptor, B-cell activating factor, TWEAK and TNFR2 
signaling. Other CCA-PDCL showed lower number of unique pathways, where 
CCA16 was characterized by activation of VEGF and MAPK signaling through Erk5, 
and CCA33 by PI3/Akt/mTOR.212 However, several signaling pathways were 
commonly activated in two or more of the respective PDCL from the same cellular 
origin (Figure 17). For instance, majority of HCC-PDCL exhibit frequently enriched 
pathways that are related to p53 signaling, pluripotency and stemness features 
(Nanog and Human embryonic stem cell pluripotency signaling), cell cycle 
regulation (p53 and cell cycle G2/M damage checkpoint regulation).213 Furthermore, 
number of commonly overlapping signaling pathways was highest in HCC9, HCC16 
and HCC68, while HCC31 had the most distinct profile. In addition, CCA-PDCL 
overlapped in the signaling pathways commonly found in this tumor entity, such as 
MYC, cyclin and cell cycle regulation, p53 and Wnt/β-catenin signaling.76, 86, 142 
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Figure 17 Activated signaling pathways in the different PDCLs.  
Comparative ingenuity pathway analyses (IPA) were performed based on the specific transcriptome 
profiles of the different PDCLs. Each color represents different PDCLs/primary tumors. Pathways 
were selected based on log p-values for each PDCL and divided according to the cellular origin, i.e. 
HCC, CCA. 
Gene Set Enrichment Analysis (GSEA) further confirmed that distinct gene sets 
associated with the corresponding tissue of origin are commonly enriched in 
different PDCL. While MYC and EpCAM signaling could be revealed in the HCC-
PDCL, CCA-PDCL were characterized by enrichment of KRAS signaling (Figure 
18a). We next explored activated signaling pathways and gene sets in individual 
HCC- and CCA-PDCL (Figure 18b). Interestingly, the spectrum of the activated 
gene sets resembled major signaling pathways of PLC, e.g. MYC, IL-6/JAK/STAT3, 
HGF as well as KRAS. However, activation of the selected pathways was quite 
heterogeneous and unique for the corresponding PDCL (e.g. E2F targets, 
cholesterol homeostasis, EGFR). These investigations confirm that the PDCL retain 
common and individual transcriptomic features and key signaling pathways as well 
as oncogenic molecules of the primary cancers. 
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Figure 18 Activated gene sets in HCC- and CCA-PDCLs. 
A) Figure B shows GSEA of combined HCC-PDCLs vs CCA-PDCLs. B) Gene set enrichment 
analysis (GSEA) of each individual HCC- and CCA-PDCL was performed. Normalized enrichment 
score (NES) reflects degree of overrepresentation for each group at the peak of the entire set. 
Statistical significance calculated by nominal P value of the ES by using an empirical phenotype-
based permutation test.   
 
 Genomic landscape of PDCL and original tumors 
Genome-wide genetic alterations including SNVs and CNAs were assessed using 
genotyping arrays. Clustering by PCA was based on 44.329 significant SNVs within 
the transcriptome signature, where SNVs confirmed that different stage PDCL and 
matched tumor group together in the same cluster (Figure 19a). Moreover, both 
PDCL and tumors displayed a similar spectrum of recurrent CNAs (Figure 19b). 
Among those, typical CNAs associated with the primary cancers could be 
detected.214, 215 For example, amplifications of 6p, 8q, 9p and 12p including well 
known oncogenes MYC and KRAS as well as losses of 1p, 4q, 8p, 13q, 16q and 
17p associated with PLC could be recognized in different PLC-PDCL.40 
Interestingly, the overall genomic alterations were highly similar among PDCL and 
Results 
56 
matched tumors and, generally, concordance in detected changes from the normal 
counterpart generally exceeded 70% (Figure 19c). Several of the PDCL (e.g. HCC9, 
CCA16, CCA33) showed an increasing frequency of alterations from tumor to late 
passage PDCL. Collectively, these observations confirm that the PDCL closely 
recapitulate the original tumor and could be a valuable patient-specific tumor model.   
 
 
 
Figure 19 Landscape of genomic alterations in PDCLs and matched primary tumors.  
A) Principal component analyses (PCA) of the primary tumors and PDCLs at different passages are 
shown. Analyses were based on genome-wide SNVs assessed by genotyping arrays. Analyses were 
based on 44.329 significant SNVs within the transcriptome signature. B) Upper rows show the 
combined significant genomic alterations for the seven PDCL. Lower rows show CNAs analyses for 
each sample as well as the corresponding GISTIC analyses. Red and blue colors represent level of 
gain and loss, respectively. C) Paired analyses of genetic alterations in PDCLs from different 
passages and matched primary cancers in comparison to surrounding liver were performed. Samples 
were grouped according to the corresponding cellular origins of the tumors, i.e. HCC, iCCA. 
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 PDCL reflect genomic and prognostic features of primary liver cancer 
To test whether PDCL can be used as a representative model for different 
established prognostic subgroups of PLC patients, we integrated our transcriptome 
data with pre-existing data from authentic human HCC and iCCA (53 and 45 
patients) representing well defined prognostic subgroups of PLC patients (i.e. good 
and poor outcome).196, 197 While HCC9 and HCC16 grouped together with poor 
prognostic HCC patients, HCC31 and HCC68 recapitulated transcriptome features 
of good prognostic HCC (Figure 20). Similar, CCA10 and CCA33 formed a cluster 
with good prognostic iCCA patients. KRAS-mutated CCA16 shared adverse gene 
expression profiles of poor prognostic iCCA patients with enrichment for KRAS 
mutations (Figure 20). Overall, these results indicate that PDCL resemble a broad 
spectrum of different prognostic subclasses of PLC patients. 
 
Figure 20 Integration of PLC-PDCLs with prognostic subgroups of the patients. 
Upper graph shows integration of HCC-PDCLs with our previously published dataset of 53 HCC 
patients. In the poor prognostic group (left) are clustered HCC9 and HCC16 PDCL. In the good 
prognostic group (right) are clustered HCC31 and HCC68 PDCL. Lower graphs show integration of 
CCA-PDCLs with a previously published dataset of 45 iCCA patients. iCCA patients with KRAS 
mutations are depicted and labeled with pink color. In the poor prognostic group (left) is clustered 
CCA16 PDCL. In the good prognostic group (right) are clustered CCA10 and CCA33 PDCL. 
 
We further evaluated the genomic similarity between PDCL and established cell 
lines by integrating SNV data from both PLC-PDCL with 7 established HCC and 8 
CCA cell lines. PCA showed that the spectrum of alteration is quite distinct, and a 
higher concordance within the established cell line than across different PDCLs 
(Figure 21a,b). Furthermore, we integrated both PLC-PDCL and established cell 
lines with the cohorts of 48 HCC and 28 iCCA patients based on corresponding SNV 
profiles.48 PDCL reliably formed sub-clusters within a broad spectrum of primary 
HCC and CCA, whereas established lines showed a distinct genomic alterations, 
reflecting genetic profiles of only few primary cancers (Figure 21c,d, Supplementary 
Table 1 and 2).  
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Figure 21 Integration of PLC-PDCLs with established cell lines and human HCC and 
iCCA based on genomic alterations.  
A) PCA of HCC-PDCLs and B) CCA-PDCLs with established cell lines based on corresponding SNVs 
determined by array-based genotyping. Colors indicate the PDCLs and corresponding cell lines. For 
CCA, cell lines from extrahepatic and intrahepatic CCA origin were distinguished. C) PCA of HCC-
PDCLs, established HCC cell lines and 48 authentic human HCC based on corresponding SNV 
profiles. D) PCA of CCA-PDCLs, established iCCA cell lines and 28 authentic human iCCA based 
on corresponding SNV profiles.  
 
In line with this, while genetic losses were quite similar across authentic tumors, 
PDCL and established cell lines, the number of genetic gains was highly comparable 
in primary tumors (13% HCC; 17% iCCA) and PDCL at early passages (passage 5 
– 17% HCC; 16% iCCA). In addition, number of genetic gains slightly increased over 
time in culture (passage 30 – 26% HCC; 28% iCCA) and further remained stable 
during long period of cultivation (passage 50 – 27% HCC; 24% iCCA and passage 
100 – 21% HCC; 25% iCCA). Amount of genetic alterations were markedly higher 
in established cell lines in comparison with PDCL and primary tumors (31% HCC; 
41% iCCA) (Figure 22). Together, these results suggest that there is an acquisition 
of genetic alterations at earlier stages of cell culture propagation, while during further 
extended in vitro culturing level of genetic alterations remains equal without 
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significant changes. These results clearly demonstrate that PDCL model more 
closely mimic the genomic landscape of authentic HCC than established cell lines. 
 
 
 
Figure 22 Compared genetic alteration of PLC-PDCLs, established cell lines and 
authentic human HCCs and iCCAs.  
Left are shown paired analyses of genetic alterations in 48 authentic human HCC, HCC-PDCLs and 
established HCC cell lines and right 28 authentic human iCCA, CCA-PDCLs, established HCC cell 
lines. 
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 PDCL for targeted therapy and personalized medicine 
approach 
 Mutational profiles of key oncogenes and tumor suppressor genes in 
PDCL, matched primary tumor and surrounding liver tissue 
To explore the potential of the PDCLs as a model for therapeutic approaches and 
subsequent target evaluation we assessed changes in several key oncogenes or 
tumor suppressor genes in PDCL, primary tumors and surrounding liver tissue (N) 
(Figure 10, Figure 23). As expected, DNA sequencing unveiled high frequency of 
mutations in TP53, a hallmark feature of PLC.40 Several oncogenic mutations and 
variants were detected in HCC-PDCL, such as FGFR3, CTNNB1, KIT, MET, ATM, 
frequently reported in HCC patients.40, 215, 216 Similarly, CCA-PDCL mutational 
profile displayed several alterations distinctive for iCCA, namely JAK3, KRAS, KDR 
and ABL1. JAK3 mutation and dysregulation of IL-6/JAK/STAT3 signaling pathway 
is typically observed in more than 50% iCCA cases, while activating KRAS 
Gly12Asp mutation is detected in 19% iCCA cases and associated with 
invasiveness and poor outcome.40, 111, 217 Additionally, presence of several 
alterations was observed in the surrounding liver tissue, and could be a 
consequence of tumor cell infiltration, germline or a passenger mutation. 
Nevertheless, once alteration was detected in the tissue (tumor or N), frequency 
remained stable in PDCL over continued period of cultivation. These results showed 
that all the cell lines, except CCA33, poses distinct genetic alterations in known key 
oncogenes.218 
 
 
Figure 23 Targeted DNA sequencing of key oncogenes. 
DNA sequencing of 48 key genes associated with cancer using Illumina TruSeq Amplicon - Cancer 
Panel. Results for individual PDCLs including matched primary cancers (T) and tumor surrounding 
liver (N; dark grey) are shown. Red color indicates mutated samples. 
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 Targeting key oncogenic alterations as an individualized therapeutic 
approach 
After obtaining information about mutational profiles of our cell lines, we interrogated 
different publicly available resources as well as TARGET database 
(http://archive.broadinstitute.org/cancer/cga/target) to identify whether detected 
molecular alterations could be used for specific drug targeting. As a result, we 
identified several commercially available inhibitors that potentially target, with high 
specificity, the detected genetic alterations or corresponding downstream targets 
(Table 9). We used specific inhibitors to perform dose-response analyses and to 
determine IC50 values conforming to detected alterations in a PDCL. Several 
alterations showed significantly higher sensitivity to corresponding targeted 
treatment approaches than non-altered counterpart, such as KIT Met541Leu 
(HCC31), KRAS Gly12Asp (CCA16) and MET Arg1022Leu (HCC68). Altered and 
non-altered cells demonstrated completely different dynamics of dose-response 
(Figure 24a-d) as well as IC50 values (imatinib: KIT-altered cell line HCC31 =  
15,59 µM vs 29,06 µM in non-altered cell line HCC9; tepotinib: MET-altered cell line 
HCC68 = 5,9 µM vs non-altered cell lines HCC9 = 16,5 µM and HCC31 = 15,3 µM; 
refametinib: KRAS-altered cell line CCA16 = 1,30 µM vs 72,26 µM in non-altered 
CCA10). Interestingly, some of the cell lines did not show treatment benefit or 
showed more resistant phenotype than non-altered cells. Lack of significant 
response between specific inhibition and a control was observed in ATM and JAK3 
altered cell lines with the alterations in ATM Arg748Ser and JAK3 Val722Ile (KU-
55933: ATM altered cell line HCC31 = 90,90 µM vs 104,50 µM in non-altered cell 
line HCC9; tofacitinib: not assessable) (Figure 24e-f). In the cell lines containing 
FGFR3 Phe386Leu and KDR Gln472His was observed more resistant phenotype 
when treated with the specific inhibitors BGJ398 and vandetanib (BGJ398:FGFR3-
altered cell line HCC9 = 10,02 µM vs 5,14 µM in non-altered cell line HCC31; 
vandetanib: KDR-altered cell line CCA10 = 5,30 µM vs  
2,33 µM in non-altered cell line CCA16) (Figure 24g-h).  
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Table 9 List of specific inhibitors used in targeted and long term approach. 
In the table are listed single and multi-target inhibitors, target/drug function and manufacturer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 Sensitivity to targeted treatment based on individual oncogenic alterations.  
PDCLs containing potential targetable mutations and non-altered controls from the same cellular 
origin were treated with specific inhibitors to target individual molecular alterations. Dose-response 
curves for specific inhibitors are shown. Growth was measured in triplicates and viability was 
assessed 3 days after treatment at the indicated drug concentrations (mean ± SD). * indicating p-
value <0.05. A-D) Shows alterations in KIT, MET and KRAS potentially conferring to higher sensitivity 
to corresponding inhibitors. E-H) Cell lines with alterations in ATM and JAK3 showed a similar viability 
after administration of the specific inhibitor. Cell lines with alterations in the corresponding genes are 
plotted in red lines. G-H) Cell lines carrying alterations in FGFR and KDR displaying a higher 
resistance to the corresponding inhibitor.  
 
Inhibitors 
Target / Drug 
function 
Manufacturer 
BGJ398 FGFR3 Selleckchem 
Doxorubicin 
DNA topoisomerase 
II inhibitor 
Selleckchem 
Gemcitabine 
Inhibits DNA 
synthesis 
Selleckchem 
Imatinib KIT Selleckchem 
KU-55933 ATM Selleckchem 
Refametinib MEK Selleckchem 
Sorafenib 
VEGFR2, VEGFR3, 
PDGFRβ, Flt3, c-Kit 
Selleckchem 
Tepotinib MET Selleckchem 
Tofacitinib JAK3 Selleckchem 
Vandetanib KDR Selleckchem 
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To validate our in vitro findings, we tried to recapitulate selective sensitivity to 
specific inhibitors in in vivo setting (Figure 25). Consistent with our in vitro findings, 
results demonstrated that KRAS- and JAK3-cell line CCA16 had beneficial response 
to refametinib treatment, reflected in a considerable reduction in both frequency and 
latency of tumor growth. In addition, treatment with tofacitinib did not show a 
significant tumor incidence reduction when compared with non-treated control cells 
(Figure 25). These investigations confirm that individual genetic alterations could be 
potentially explored for individualized treatment approaches.  
 
 
Figure 25 Validation of sensitivity for targeted treatment in vivo.  
CCA16 cells harboring known KRAS- and JAK3-alterations showed a predicted high sensitivity to 
refametinib in vivo while remained without mentionable effects after treatment with tofacitinib. 1 mio. 
cells treated with specific inhibitors for 72h or control cells were transplanted into both flanks of 
NOD/SCID animals. Tumor growth was monitored for a total of 10 weeks. 
 
 Effects of established chemotherapies on PDCL after extended in vitro 
cultivation 
To test the utility of the established PDCL for drug evaluation in long term cultures, 
different passages of PDCLs up to passage 100 (1-2 years in culture) were treated 
with established chemotherapeutic and targeted compounds for the respective 
entity. HCC-PDCL were exposed to increasing concentrations of doxorubicin, 
sorafenib and tepotinib, while CCA-PDCL were exposed to doxorubicin, sorafenib 
and gemcitabine. Cell viability was reported (Figure 26). Overall, response to the 
treatment was highly consistent across the different cell lines and passages, 
confirming the utility of the PDCL for translational approaches during long-term 
culturing. 
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Figure 26 Response to established therapies during extended time in culture.   
Different passages of the PDCLs were treated with established chemotherapeutic compounds (i.e. 
doxorubicin for HCC; doxorubicin and gemcitabine for iCCA) as well as the tyrosine-kinase inhibitor 
sorafenib. Dose-response curves for the corresponding compounds and cell lines are shown. Growth 
was measured in triplicates and viability was assessed 3 days after treatment at the indicated drug 
concentrations (mean ± SD). * indicating p-value <0.05. A) Shown are treatments of HCC-PDCLs 
and B) CCA-PDCLs 
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5. Discussion 
Over the past two decades, rapid technological advancement and growing expertise 
led to a tremendous progress in cancer research. Today, changes towards cutting-
edge technologies, for instance, from array-based gene profiling to next generation 
(DNA, RNA) sequencing are emerging by the minute. While DNA sequencing was 
costly and time-consuming almost two decades ago, when the human genome 
project was initiated,219 nowadays next-generation sequencing technologies are 
rapid, standardized and accessible to the larger scientific community.220 The 
relatively low costs of sequencing and fast data acquisition accompanied by 
advancement in bioinformatics and machine learning algorithms,221 allow more 
individualized approach to target specific diseases, such as primary liver cancers.220 
Therefore, it seems promising to utilize these technologies for the benefit of each 
individual patient, i.e. by implementing them into representative models. Currently, 
existing models to study primary liver cancers are lacking to accurately represent 
individual aspects of the diseases, thus, hampering further therapeutic progress.167, 
190 Since dissection of the diseases with much higher resolution than ever before is 
possible, it is of great importance to generate novel models that would ideally 
represent patients. This includes the full range of etiological background of the 
diseases, to the phenotypical and molecular complexity. New models should 
consider heterogeneity from different perspectives - genetic, epigenetic, 
transcriptomic, as well as morphologic, and explore potential consequences on the 
treatment options as well as survival benefits.  
Developing a new liver cancer model, which would fulfill these important criteria, 
could help to better understand complex processes that occur during disease 
initiation and progression, but most importantly, to help finding adequate treatment 
strategy for each patient. We successfully generated seven PDCL from a Western 
cohort of patients as a representative model to study hepatocellular and 
cholangiocarcinoma. In our study, we comprehensively analyzed the newly 
generated PDCL and matched primary cancers on several different levels. We 
perform transcriptomic and genomic analyses to confirm the utility of the newly-
derived PDCL as a patient-specific in vitro model. A key goal of our study was to 
explore whether PDCL closely resemble the molecular and phenotypic features as 
well as key oncogenic alterations present in matched primary tumors. Therefore, we 
performed long-term cultivation of PDCL and propagated them continuously for 
more than 30 passages in vitro. Finally, we tried to identify potentially actionable 
genetic and transcriptomic targets for individual PDCL and predict a treatment 
response in order to determine potential utility of PDCL for individualized treatments 
strategies. 
Except the PDCL model that we are investigating in this study, there are several 
alternative models that have been developed over the past several years. Two 
promising and novel, but still very distinct approaches, involve 3D organoid cultures 
and patient-derived xenografts.222, 223 Two recent studies exploited the potential of 
organoids to be utilized as a model of PLC.177, 178 Authors of the studies derived the 
organoids directly from resected HCC, CCA and mixed HCC/CCA, or from the tumor 
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needle biopsies. They were able to show that derived organoids could faithfully 
recapitulate the molecular profile of the original tumors.177, 178 Similarly to the 
organoids, only a few studies exploited the potential of PDX as a model for PLC and 
demonstrated similar histopathologic and genomic characteristics with the original 
HCC tumors.224, 225 Nevertheless, all the available patient-derived models have 
important common as well as specific limitations. While selective growth expansion 
in immunocompromised animals is utilized in PDX models, three dimensional 
growth might be problematic for drug evaluation in organoid cultures.226 Also, all 
approaches require significant amount of resources, making it difficult to be used for 
large-scale applications. Most importantly, all the models including the current PDCL 
2D approach lack the tissue context of the hepatic microenvironment. Therefore, 
detailed comparative analyses are needed to estimate the impact and utility of each 
approach for translational research. 
 
 Higher tumor grading and increased genomic alterations favor 
successful PDCL generation 
Despite usefulness of PDCL as a reliable model, there are certain limitations that 
should be considered and further addressed: major obstacles in PDCL, as well as 
other patient-derived models, are low efficacy of successful generation. In addition, 
it is unclear whether these models can cover a representative spectrum of human 
liver cancers. In our study, success rate of generating PLC-PDCL reached 11%, a 
similar range as observed in other solid malignancies.227 Success rate of 
established PDCL reported in our study is in concordance with other approaches 
such as PDX and organoid cultures derived from tumor needle biopsies (usually 
ranging from 10-33%).178, 179, 224, 225 Interestingly, a recent study of Broutier et al. 
reported successful establishment of tumor organoid cultures from PLC (HCC, CCA 
and mixed HCC/CCA phenotype) with success rate of 100% from tumor samples 
with high cellular proliferation rate and moderate to poor differentiation.177 However, 
it is interesting to observe that well-differentiated tumors completely failed to 
establish primary culture, remaining at 0% of success rate. Taken together, results 
in this study show that successful establishment of organoid cultures does not 
exceed 47% and that is favored in poorly differentiated tumors.177 Therefore, further 
validation and identification of factors contributing to successful establishment of 
PDCL and subsequent optimization of the culture conditions is urgently needed to 
establish large and representative repositories required for extensive studies in 
PLC. This should also include establishment of PDCL from more advanced stages 
of PLC, such as biopsies, and comparative analyses of PDCL from primary and 
metastatic sites. 177 Of note, Nuciforo et al. also reported that successful 
establishment of organoid cultures from the needle biopsies had strong correlation 
with the histopathological grading of the HCC. In that study, all the organoids were 
derived from poorly differentiated tumors (grading III and IV), with cells showing high 
proliferation rate. Authors were able to establish 26% organoid cultures from a total 
number of needle biopsies (10 out of 38), while a complete number of established 
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organoids, based on the number of patients (from some patients multiple biopsies 
were taken), was 33%. 178  
In our study we can observe similar trend, where 50% of all successful PLCs are 
graded as G3 and more than 25% as G2-G3, indicating higher grade and low 
differentiation status. Overall, these analyses confirm the observation that 
successful establishment of PDCL is favored by less differentiated tumors and high 
grading (Figure 11). Furthermore, we demonstrate that genetic heterogeneity, as 
well as pro-tumorigenic genomic amplifications, might be additional factors 
contributing to a success rate. Our findings show significant number of increased 
genomic gains and losses in the tumors with successful PDCL establishment 
(Figure 11), notably in the chromosome regions associated with high proliferation 
and cancer, such as 4q, 5q, 8p, 9p and 13q (Figure 11). Expression of LPHN3 and 
TSLP genes, located on 4q and 5q, has been associated with poor prognosis and 
metastases in several solid tumors.198, 199 For instance, TSLP expression was the 
most frequently observed in advanced gastric cancer (T2, T3 and T4) as well as in 
liver metastases from this tumor.198, 199 Additionally, CCDC25 (8p) was identified to 
modulate EGFR signaling and reported that overexpression can significantly 
enhance cell migration in iCCA.228 Furthermore, importance of miRNAs (miRs) in 
tumorigenesis has been shown over the past decade and it is emerging as a 
potential therapeutic target in many cancers, including PLC.229 Chengyoung et al. 
showed potential impact of miR-1297, encoded by MIR1297 gene (13q), on cell 
death and cell cycle regulation in liver cancer cells. They noticed that tumor cell 
proliferation was significantly induced by miR-1297 overexpression and proposed a 
mechanism of carcinogenesis via miR-1297 induced downregulation of the tumor-
suppressor gene RB1.200 Overall, our findings support the evidence that miRNAs, 
particularly miR-1297, might contribute to higher tumor proliferation and 
consequently to successful establishment of primary cancer cell lines. Additionally, 
molecular and cellular functions of a significant number of genomic alterations 
present in PLC with the successful PDCL establishment centered on pro-oncogenic 
properties, favoring cellular growth and proliferation, as well as cell death and 
survival (Figure 11c). 
 
 Morphology of the PDCL remains stable during long-term 
cultivation 
Until now, very limited number of investigators tried to characterize and utilize PDCL 
as a reliable liver cancer model in personalized medicine.230 Only a few studies 
reported successful establishment of few HCC primary cell lines, with a limited data 
output and very narrow translational implications. In one study, authors used an 
early-stage and moderately differentiated HCC to derive primary cell lines.231 
Despite a fairly high number of primary cancer tissues that were processed, cell line 
authentication and characterization was conducted in one specimen, thus making 
further translational implications of this study challenging.231 Similarly, in another 
study authors derived nine cell lines from primary HCC tissue and compared early 
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stage passages with corresponding tumor tissue. Transcriptomic and genomic data 
of the early passages showed similarities with cancerous tissue and unveiled 
possible protein-altering mutations. In spite of early-stage characterization, long-
term effects of cultivation and functional validation were missing.230 Overall, limited 
number of representative cell lines as well as characterization only at the early 
stage, together with lack of functional validation and translational implications, 
hinder further utilization of proposed models. 
The here presented study is one of the first to demonstrate preserved phenotypic 
stability of PDCL over an extended period of propagation in 2D culture conditions 
for the entire spectrum of primary liver cancers. Our results clearly show that cells 
at early stage of cell propagation are highly comparable with cells in the late stage 
as well as with xenograft-derived second generation (Figure 13). Serial 
transplantation and rapid tumor expansion in immunocompromised mice emphasize 
the ability of PDCL to maintain tumorigenic properties. However, necessity of higher 
cell number in HCC-PDCL to initiate tumor growth was observed in our study. 
Difference in tumor-initiating capacity between HCC-PDCL and CCA-PDCL could 
be a consequence of distinct biology of these tumor entities, where iCCA mainly 
show more aggressive phenotype than HCC, which is also reflected in shorter long-
term survival of iCCA patients.232-234 In addition, difference in tumor initiating 
capacity can be explained by differential expression of EpCAM in our cell lines. 
Studies have shown that EpCAM and genes regulated by this protein are involved 
in cellular growth, proliferation, cell cycle and cell death.235 Consequently, 
overexpression of EpCAM in many solid tumors has been associated with poor 
prognosis.235-237 Recently Sulpice et al. demonstrated a new potential role of 
EpCAM on iCCA progression and indicated that EpCAM might represent a 
promising candidate in personalized medicine.237 Interestingly, in our study, all CCA-
PDCL and matching primary tumors showed strong expression of EpCAM, unlike 
HCC-PDCL, where only HCC68 exhibited very weak EpCAM expression (Figure 
15). Strong expression of EpCAM in CCA-PDCL could potentially confer higher 
tumorigenicity than HCC-PDCL and, therefore, demonstrate more aggressive 
phenotype. Histological analyses further provide better insight into xenograft 
tumors, where morphological and cellular patterns are highly preserved and 
resemble matched primary tumors (Figure 14). Homology with the original tumor is 
further confirmed by the expression of well-established hepatocellular, biliary and 
epithelial progenitor markers (Figure 15).238-240 Cellular origin of HCC-PDCL is 
characterized by the strong expression of albumin and AFP, and weak expression 
of EpCAM in one PDCL, while CCA-PDCL display substantial expression of biliary 
marker CK19 as well as EpCAM. 
 
 Transcriptome profiles of PDCL closely recapitulate original 
tumor characteristics 
High-throughput technologies, such as RNA-seq, have been decisively instrumental 
to explore diversity and complexity of the gene expression profiles in PLC over the 
last two decades. These types of analyses have produced a large amount of 
Discussion 
69 
information, utilized to better understand the oncogenic process in PLC.241 It is 
generally accepted that altered gene expression patterns in cancer tissues are 
observed during malignant processes, such as tumor initiation and progression.242 
Many studies have demonstrated the importance of characterizing HCC- and CCA-
specific gene expression patterns and crosstalk between different signaling 
pathways, to provide useful insights for potential drug development and 
prognosis.243, 244 Taking this into consideration, it is important to develop a PDCL 
model which preserves transcriptional profile of the original cancerous tissue and 
remains stable during the course of time. 
Our transcriptome analyses indicate that early and late stages of PDCL retain very 
similar transcriptional profiles with the primary cancers and remain stable during 
extended expansion (Figure 16). Importantly, our PDCL and tumor tissue show 
completely distinct profile from surrounding liver demonstrating malignant tumor 
properties (Figure 16c). Notably, our detailed molecular characterization confirmed 
that PDCL recapitulate hallmark features of the primary cancers.40, 215, 245, 246 
Commonly for HCC, our HCC-PDCL demonstrated activation of MYC, p53 and 
Notch signaling, as well as genes centering on MAPK, pluripotency and several 
others relevant genes (Figure 17). Similarly, CCA-PDCL clearly showed activation 
of Wnt/β-Catenin, Pi3K, VEGF signaling as well as pathways mediating p53. We 
observed enrichment of key cancer-associated common, as well as individual, 
transcriptomic changes resembling proliferative and invasive properties observed in 
most of the PDCL. Our HCC-PDCL were enriched for gene sets centering around 
MYC or mTOR, while CCA-PDCL were characterized by activation of networks 
involved in KRAS, Notch and Hedgehog signaling (Figure 18).9, 247 Overall, our 
transcriptome analyses confirm that the PDCL retain common and individual 
transcriptomic features and key signaling pathways as well as oncogenic molecules 
of the primary cancers. 
 
 Stabile genomic landscape of PDCL faithfully reflects genomic 
and prognostic features of primary liver cancer 
As our findings demonstrate that expressional profiles of PDCL remain stable and 
that PDCL faithfully recapitulate hallmark features of the primary cancers, we 
additionally provide evidence that spectrum of genomic alterations remain 
consistent with profiles of primary tumors, thus, confirming the utility of the newly-
derived PDCL as a patient-specific and reliable in vitro model. By analyzing the 
spectrum of recurrent CNAs, we can observe that PLC-PDCL, both in the early and 
late stage, display similar profiles to the corresponding primary tumors (Figure 19). 
In addition, chromosomal amplifications/losses detected in our model are commonly 
reported in PLC together with amplification of known oncogenes (MYC and KRAS) 
(Figure 19).40 Despite of relatively stable and representative genomic profile, an 
interesting aspect of our results is increasing number of genetic alterations over time 
observed for several PDCL. A similar observation was recently revealed for PDX 
and organoid cultures during serial passaging. Ben-David et al. observed increasing 
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accumulation of CNAs during PDX propagation in an earlier stage, followed by 
gradual reduction and reaching stabile level in the late stage of passaging. Authors 
also observed that pre-existing alterations play a major role in acquiring CNAs in 
PDXs, especially at early stages, but point out that de novo events can severely 
influence genomic instability. They emphasize that specific selection pressure 
between physiological conditions in patients and cultivation in animal hosts can 
cause different evolution paths of PDXs and, consequently, have an impact on 
therapy response. Overall, such implications should be considered when using PDX 
as a model for personalized medicine approach.248 To test whether our PDCL would 
continue gaining additional alterations, we extended cultivation time up to two years 
in the culture (up to P100), and in parallel we monitored CNV changes. Similarly, to 
the findings of Ben-David et al., our PDCL stopped accumulating additional 
alterations after passage 30 and remained stable during extended time period (P50 
and P100) (Figure 22). In concordance with that, response to the commonly used 
chemotherapeutic agents, including standard therapy for HCC (Sorafenib) and iCCA 
(Gemcitabine), remained stable over extended time in culture for our PDCLs (P30, 
P50 and P100) (Figure 26). 
Early categorization of the patients into specific prognostic subgroups, based on 
their molecular profile, could further define course of a therapy and potentially bring 
survival benefit. Our PLC-PDCL model shows similar molecular profile with the 
authentic HCC and iCCA patients and integrates into different established 
prognostic subgroups of PLC (poor and good prognosis).196, 197 It is known that 
activating mutations in KRAS, particularly mutation in codon 12, has close 
association with reduced overall survival in comparison with non-mutated iCCA and 
represents a poor prognostic marker for the patients.249, 250 Our CCA16 cell line, that 
carries activating KRAS mutation (Gly12Asp), clustered with other KRAS mutated 
tumors into poor-survival subgroup, reflecting adverse characteristics typical for 
those patients. Overall, our results imply that both PLC-HCC groups resemble a 
broad spectrum of different prognostic subclasses of PLC patients, and could be 
used to predict the outcome and course of a treatment (Figure 20). 
 
 PDCL more closely reflect PLC than established cell lines 
Since commercial cell lines are widely used as a model for PLC, we wanted to test 
how closely cell lines can recapitulate molecular features of authentic patients and 
compare the molecular profiles with our PDCL model. A significant limitation of 
established cell lines is the fact that direct comparison to the earlier stages of 
culturing and, most importantly, corresponding original tumors is not feasible due to 
long time span between culture establishment and today’s applications. This further 
raises concerns to which extent existing functional and molecular properties of cell 
lines can accurately represent primary tumors. Nevertheless, usefulness of 
established cell lines should not be undermined, since many important findings in 
translational cancer research are based on comprehensive investigations on cell 
lines. However, here presented data confirms results from several reports 
suggesting that newly-derived cell line might share the highest degree of molecular 
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similarities with primary cancers regarding key genetic alterations at early stages 
after isolation.251  
Our Integrative analyses of SNV in PDCL and established cell lines further show 
that the spectrum of alterations in established cells is more homogenous and quite 
distinct from our PDCL (Figure 21a,b). Additionally, we integrated both PLC-PDCL 
and established cell lines with our HCC and iCCA patient cohorts based on 
corresponding SNV profiles.48 Results show that PDCL reliably form sub-clusters 
within a primary HCCs and iCCAs, while established lines show more distinct 
genomic profile, similar only to few primary cancers (Figure 21c,d). Overall, 
integration of PLC-PDCL with authentic human PLC patients demonstrated that 
newly-derived cell lines faithfully recapitulate both the genomic profile as well 
different prognostic subclasses of liver cancer. 
 
 Targeting key oncogenic alterations as an individualized 
therapeutic approach 
Development of next-generation sequencing technology has allowed us to evaluate 
and describe in great details genes and molecular pathways altered in PLC and to 
effectively distinguish driver from passenger mutations.252 The most prominent 
alteration in PLC have been well characterized and include somatic mutations in 
CTNNB1, TP53, MYC, MET, TERT promoter, KRAS as well as dysregulation in 
Notch, PI3K/Akt/mTOR, IL-6/JAK/STAT, Ras/MAPK signaling pathways. Detection 
and characterization of mutated driver genes and affected pathways in HCC, opens 
an interesting and testable avenue for development of novel targeted therapies.252 
Application of molecular targeted treatments could more effectively prevent disease 
progression and bring survival benefit to the patients.253 However, characterization 
of genomic landscape in HCC to identify potential targets has not been fully 
explored.147 Comprehensive whole exome sequencing studies showed that around 
one third of HCC patients and up to 70% of iCCA patients might harbor genetic 
alterations potentially targetable by US Food and Drug Administration (FDA)-
approved drugs.215, 254 Therefore, identification and prospective evaluation of 
potentially drugable targets is a main objective of patient-specific models. PDCL, as 
a model of PLC, could be exploited for predicting drug sensitivity to both existing 
therapeutics as well as for identification of new drugable targets. Implementation of 
PDCL in drug screening could make a crucial link between laboratory and patients, 
thus, become a mandatory constituent of translational cancer research. 
In this study we demonstrate the potential of the PDCL as a representative model 
for therapeutic target evaluation. Our comprehensive NGS analysis shows that the 
majority of our PDCL harbor potentially actionable mutations (Figure 23). Although 
many oncogenes have been identified in HCC and associated with tumor 
development and progression, such as TERT, TP53 and CTNNB1,252 suitable 
targeted treatments exploring this genetic diversity have not been developed yet. 
Although we were able to detect the presence of TP53 and CTNNB1 in several 
PDCL, absence of specific inhibitors currently prevents targeted approaches for 
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affected patients. In addition, we detected several well-described germline variants 
such as KDR, KIT and FGFR3. Interestingly, several studies described that these 
variants have an impact on either the clinical course or response to specific 
inhibitors in different tumor entities.255-257 Masago et al. reported that KIT Met541Leu 
variant plays a role in recurrence and drug resistance of NSCLC, and points out that 
suppression of KIT with drugs like imatinib may be a useful therapeutic choice in 
patients with KIT variant tumors.255 Similarly, one of our PDCL with detected KIT 
Met541Leu variant shows beneficial response to the imatinib treatment (Figure 24a) 
It is also known that Gly12Asp KRAS mutation leads to constitutive activation of this 
oncogene and such tumors usually harbor more adverse and invasive properties.258 
This potent oncogene is mutated in 10-19% of iCCA, therefore significant number 
of patients could benefit from a targeted therapy.71 Notably, inhibition of 
constitutively active KRAS (Gly12Asp mutation) in one of ours CCA-PDCL by MEK 
inhibition demonstrates favorable treatment effect. Furthermore, as a result of 
detailed mutational profiling, we revealed two MET variations in our PDCL with 
apparently differential effect on the kinase activity of the receptor. In accordance 
with the study of Krishnaswamy et al., identified MET Asn375Ser alteration in our 
HCC31 cell line might lead to suboptimal kinase activity after ligand binding,259 while 
the detected MET Arg1022Leu in HCC68 is a potentially activating and damaging 
mutation. So far, the alteration was only identified in biliary tract cancers in the 
context of PLC, but with limited functional information and number of studies have 
reported functional consequences of the variant.260 Importantly, our data provide the 
first evidence for the relevance of this alteration in HCC. Here, we also demonstrate 
benefit of specific MET inhibition in the cell line carrying MET Arg1022Leu mutation. 
HCC68 displays significantly higher sensitivity to tepotinib than MET Asn375Ser 
mutated HCC31 and non-mutated HCC9 (Figure 24b,c). Finally, selective sensitivity 
to specific targeted inhibition is further recapitulated in in vivo xenograft setting 
(Figure 25). Together, our observations clearly underline the potential of individual 
PDCL for mechanistic studies, therapeutic validation of specific genetic alterations 
as well as prospective drug screenings as an important tool to improve precision 
medicine approaches. 
Similar to our PDCL, other PLC models could also have significant implications for 
potential translational therapeutic approaches. It is important to note that in the 
recent study Broutier et al. tested sensitivity of generated PDOs to general anti-
cancer compounds. Several of the tested drugs significantly impaired expansion and 
viability of organoids, allowing authors to identify potential drug-candidates that 
might results in a benefit for the patients.177 Moreover, this study showed that some 
PDOs possess several potentially actionable genetic alterations. However, authors 
did not perform further validation against respective inhibitors, and despite 
complexity of the study, potential application in targeted therapy and, consequently, 
in personalized medicine have not been explored. Lack of critical standardization in 
the experimental setting, where “cell clumps” and organoids of uncertain and diverse 
sizes were utilized rather than single cells, despite overall complexity as well as 
costs of the conditions necessary for organoid propagation, keeps this approach 
further away from large-scale drug screenings and limits its translational impact.177 
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Nuciforo et al. went one step further with development of PDO model, where they 
were able to create more standardized testing conditions and provide, to the certain 
extent, insight into intratumoral heterogeneity and its implications in PDOs.178 In 
parallel with individually established PDOs, multiple organoid lines from two patients 
were derived (e.g. HCC5A and HCC5B; HCC12I and HCC12II) and 
comprehensively analyzed. As anticipated, majority of detected mutations remained 
stable in PDOs, reflecting mutational profile of the original tissue. However, several 
mutations were detected only in one of two PDOs (and corresponding tumor tissue) 
established from the same patient, indicating existence of genetic heterogeneity and 
clonal expansion within the same tumor. Moreover, investigation of sorafenib 
response in those PDOs showed shift in treatment sensitivity.178 As existence of 
intratumoral heterogeneity has already been documented in HCC, these results 
imply that heterogeneity within the tumors could have important role in organoid 
propagation as well as significant implications in treatment response.261  
Overall, development and optimizations of all in vitro models should be vigorously 
supported, as at the moment, there is no ideal model to cover all the spectrums of 
the disease, from etiological background and (intra-)tumoral heterogeneity to 
translational implications and drug screening. Mutual complementation of the 
models, together with continuous advancements in this challenging field, could bring 
a bright future to the translational cancer research, and more importantly, to the 
patients. 
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6. Summary 
Cancer is a complex genetic disease. Despite of many models that were developed 
to mimic the human, all of them harbor obstacles that limit their applicability for 
authentic human patients and, thus, translational value. Therefore, development of 
new more representative models is essential. Established cell lines have been 
present in the cancer studies for several decades and they have made key 
contributions to many important discoveries in the cancer field. However, since the 
lines are conserved for many years in culture, the main concern is how accurately 
they represent the tumors that they were derived from, and consequently the 
patients per se. Patient-derived xenograft models and organoids were recently 
introduced as a novel model, but due to specific conditions that are required for 
isolation, propagation and large-scale analyses, such as drug screening, their 
advancements for translational applications as well as large scale screenings are 
questionable. 
To address the issue of limited patient-specific models of primary liver cancers, we 
have successfully generated and comprehensively characterized seven novel 
PDCL from hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Firstly, 
we were able to identify potential cellular and molecular characteristics for 
successful establishment of PDCL. Results of this study provide evidence that less 
differentiated tumors with higher genomic instability are more prone to successfully 
establish PDCL. Nevertheless, since there are a significant number of the patients 
with highly differentiated and low graded tumors, it is important to optimize isolation 
and cultivation conditions to promote growth of PDCL from these tumor entities. 
Our results further confirmed phenotypical stability of the PDCL over an extended 
period in culture. Preserved cellular morphology and long-term stability of key 
lineage markers are additionally complemented with results of transcriptomic and 
genomic profiling. We performed detailed transcriptome analyses of the original 
tissue and compared with early and late stage of PDCL. Notably, our detailed 
characterization confirms that PDCL recapitulate hallmark features of the primary 
cancers and that the PDCL retain common as well as individual transcriptomic 
characteristics of the primary cancers. Importantly, expression and activation of key 
signaling pathways and oncogenic molecules remains stable over the long-term 
cultivation. 
Genomic analyses additionally confirm that our cells maintain similar profile to the 
corresponding primary tumors, both in the early and later stages of cultivation. 
Integration of PDCL with authentic human PLC patients implies that both PDCL 
groups resemble a broad spectrum of different prognostic subclasses of PLC 
patients. 
By utilizing next-generation sequencing approach, we are able to shows that key 
oncogenic alterations such as TP53, KRAS, CTNNB1 as well as actionable 
alterations (e.g. MET, KIT, KDR) are highly conserved in the PDCL. Detailed 
analyses of detected alterations and drug evaluation are essential steps in 
translational approach, since distinct alterations within one particular gene can 
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cause differential response to a therapy. Respectively, we show here that two MET 
variants harbor different sensitivity to specific inhibition, which could potentially have 
clinical implications in the patients carrying the same alterations. Also, we could 
demonstrate that some alterations display beneficial response to the targeted 
treatment, while a few show no benefit or reverse effect. Overall, our study indicates 
importance of precise drug testing for the purpose of personalized treatment 
approach.  
Altogether, our results for the first time provide solid evidence that PDCL can 
faithfully recapitulate the full spectrum of human liver cancer over extended time in 
culture. The PDCL represent a sophisticated model for both genomic sub-
classification as well as direct exploring of precision medicine approaches for the 
treatment of this deadly disease.      
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8. Appendix 
Supplementary Table 1 List of authentic HCC patients used for genomic analyses. 
Cohort of 48 authentic human HCC that were on used in the genomic studies of PDCL are listed in the 
table below. Given are clinicopathological information of HCC tumors. 
HCC patients Gender Size (cm) TNM Grading Differentiation Etiology 
HCC2 F 8 pT2, pNx, M0, R0 G3 Poor NASH 
HCC3 M 11 pT3b, pNx, M1, R2 G3 Poor NASH 
HCC4 F 3 pT1, pNx, M0, R0 G2 Moderate N/A 
HCC5 M 9 pT2, pnX, M0, R0 G3 Poor N/A 
HCC8 M 9 pT2, pNx, M0, Rx G2 Moderate HBV 
HCC9 F 13 pT2, pNx, M0, R0 G2-G3 Moderate to poor NASH 
HCC10 M 4,5 pT1, pNx, M0, R0 G2 Moderate NASH 
HCC11 M 9 pT1, pNx, M0; R0 G1-G2 Moderate NASH 
HCC17 M 14 pT1, pN0, M0, R0 G1 Well NASH 
HCC20 M 1,2 ypT1, pNX, M0, R0 N/A N/A HCV 
HCC21 M 2,8 ypT1, pNX, M0, R0 G2 Moderate HCV 
HCC23 F 3 pT2, pNx, M0, R0 G2 Moderate HCV 
HCC24 F 14 pT3b, pNx, M0, R1 G2 Moderate HCV 
HCC26 M 3,5 pT3a, pN0, M0, R0 G2 Moderate NASH 
HCC27 M 5 pT1, pNx, M0, R0 G2 Moderate EtOH 
HCC31 M 2,6 pT2, pN0, M0,R0 G1 Well EtOH 
HCC32 M 6 pT2, pNx, M0, R0 G2 Moderate Cirrhosis 
HCC33 M 6,3 pT3, pNx, M0, R0 G2 Moderate NASH 
HCC34 M 7 pT4, pNX, M0, R0 G2 Moderate HCV 
HCC36 M 3,6 pT1, pNx, M0, R0 G2 Moderate Cirrhosis 
HCC37 M 11,5 pT1, pNX, M0, R0 G1-G2 Well to moderate N/A 
HCC38 M 4,5 pT1, pNx, M0, R0 G1 Well HCV 
HCC39 F 5,8 pT1, pNx, M0, R0 G1-G2 Well to moderate N/A 
HCC41 M 12,3 pT2, pN0, R0 G1 Well HBV 
HCC45 M 1,5 rpT2, rpNx, M0, R0 G2 Moderate Cirrhosis 
HCC46 M 9 pT3b, pN1, M0, R0 G3 Poor N/A 
HCC48 M 4,7 pT1, Nx, Mx, R0 G2 Moderate N/A 
HCC49 M 16 pT3b, pN0, MX, R1 G2-G3 Moderate to poor HCV 
HCC52 M 7 pT1, pN0, M0, R0 G3 Poor N/A 
HCC55 M 5,5 pT1, Nx, M0, R0 G2-G3 Moderate to poor EtOH 
HCC56 M 7 pT1, pNx, M0, R0 G1-G2 Well to moderate HBV 
HCC57 M 10 pT1, pN0, M0, R0 G1-G2 Moderate N/A 
HCC59 M 6,6 pT1, pN0, M0, R0 G2 Moderate N/A 
HCC60 M 3,5 pT3b, pN0, M0, R0 G1-G2 Well to moderate EtOH 
HCC61 M 9 pT1, pN0, Mx, R0 G2-G3 Moderate to poor No cirrhosis 
HCC62 F 3,5 pT3, pN0, R0 G1-G2 Well to moderate N/A 
HCC63 M 14,5 pT3a, pN0, M0, R0 G2 Moderate N/A 
HCC64 M 8,5 pT3b, pN0, M0, R1 G3 Poor N/A 
HCC65 M 1,8 pT1, Nx, M0; R0 G2 Moderate Cirrhosis 
HCC69 F 13,5 pT2, pN0, M0, R0 G3 Poor N/A 
HCC70 F 14 pT1, pNx, M0, R0 G2 Moderate Cirrhosis 
HCC71 M N/A N/A G2-G3 Moderate to poor N/A 
HCC72 M 10 pT3a, pN0, M0, R0 G3 Poor HCV 
HCC73 M 5,8 pT3a, pNx, M0, R0 G3 Poor N/A 
HCC74 M 3,2 pT2a, pNx, M0, R0 G2 Moderate Cirrhosis 
HCC76 M 7 pT2, pNx, M0, R0 G2-G3 Moderate to poor EtOH 
HCC77 M 9 pT3a, PNx, M0, R1 G3 Poor N/A 
HCC80 M 9 N/A N/A N/A N/A 
Appendix 
 
 
Supplementary Table 2 List of authentic iCCA patients used for genomic analyses. 
Cohort of 28 authentic human iCCA that were on used in the genomic studies of PDCL are listed in the 
table below. Given are clinicopathological information of iCCA tumors. 
CCA patients Gender Size (cm) TNM Grading Differentiation Inflammation 
CCA1 M 1,4 N/A G2 Moderate Yes 
CCA2 F 13 pT1, pN0, M0, R0 G2 Moderate Yes 
CCA3 F 6 pT2b, pN0, M0, R0 G1-G2 Well to moderate Yes 
CCA4 F 6,5 pT2b, pN0, M0, R1 G2 Moderate No 
CCA5 F 10,3 pT1, pN0, M0, R0 G2 Moderate Yes 
CCA6 M 3,5 pT1, pN0, M0, R0 G2 Moderate Yes 
CCA7 M 12 pT2a, pN0, M0, R0 G2 Moderate No 
CCA8 F 5 pT1, pN0, M0, R0 G2 Moderate No 
CCA10 F 5,9 pT3, pN1, M0, R0 G2 Moderate Yes 
CCA11 M 8,3 R0 G2 Moderate No 
CCA12 F 0,5 pT2, R1 G3 Poor No 
CCA13 M 4,3 pT3, pN1, M0, R0 G2 Moderate Yes 
CCA14 M 3,5 N/A G2 Moderate Yes 
CCA15 F 12 pT2b, pN0, M0, R0 G2 Moderate Yes 
CCA16 M 10 pT3, pN1, M0, R0 G3 Poor No 
CCA17 M 14,5 pT3, pN1, M0, R1 G2-G3 Poor Yes 
CCA18 F 10,2 pT2a, pN1, M0, R0 G3 Poor Yes 
CCA19 M 7,3 pT3, pN1, M0, R0 G2 Moderate No 
CCA21 M 3,5 rpT3, pN0 (0/1), R0 G2 Moderate Yes 
CCA22 M 9 pT2a, pN0, M0, R0 G3 Poor Yes 
CCA23 F N/A pT1, Nx, M0, R0 G2 Moderate Yes 
CCA24 M 3 pT1, pNX, M0, R0 G2 Moderate Yes 
CCA25 M 0,5 ypT1, pN0, Mx, R0 N/A N/A Yes 
CCA28 M 9,5 N/A N/A N/A No 
CCA29 F 0,6 pT2b, pN0, Mx, R0 G2 Moderate Yes 
CCA30 F 14 pT2b, pN0, M0, R0 G2 Moderate Yes 
CCA31 M 7,5 pT2a, N0, M0, R0 G3 Poor Yes 
CCA33 M 8,5 pT2a, pN1, M0, R0 G3 Poor Yes 
 
Supplementary Table 3 cell lines. 
Listed are commercial cell lines of HCC and CCA used for genomic analyses. 
 
Hepatoma cell 
lines 
CCA cell lines 
Hep3B EGI-1 
HepG2 HuCCT-1 
Huh7 RBE 
KMCH SNU-478 
LECHCC SNU-1079 
PLC/PRF/5 SNU-1196 
WRL68 SSP-25 
 WITT 
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Supplementary Table 4 Commonly dysregulated genes.   
Shown are the numbers of significant genes between different PDCL determined by Wald test as well 
as the unique genes commonly dysregulated in each PDCL 
 
Wald-Test 
pvalue<0.01 
ALL CCA16 CCA33 HCC9 HCC16 HCC31 HCC68 
CCA10 54 3054 2540 3055 2954 2223 2095 
CCA16 205  2866 3456 3471 3490 3402 
CCA33 61   2800 2721 2367 3428 
HCC9 108    2545 2284 2995 
HCC16 190     1964 2468 
HCC31 30      2714 
HCC68 77       
 
Unique GenesCCA10(log2FC) 
No. Ensembl GeneID Symbol T P5 P30 
1 ENSG00000238098 ABCA17P 2.41432 2.45439 2.80946 
2 ENSG00000224063 AC007319.1 4.7015 2.98897 4.3294 
3 ENSG00000143429 AC027612.6 -1.2305 -2.10696 -1.15119 
4 ENSG00000233006 AC034220.3 4.33508 2.39928 1.07882 
5 ENSG00000267270 AC139100.2 3.92004 1.24991 0.284368 
6 ENSG00000184160 ADRA2C 2.97333 5.07193 3.82671 
7 ENSG00000196581 AJAP1 1.9089 5.56852 5.9915 
8 ENSG00000215033 AL603965.1 4.35847 5.82004 4.83971 
9 ENSG00000088448 ANKRD10 1.22394 1.31887 1.71618 
10 ENSG00000162813 BPNT1 -1.18319 -1.26368 -0.874488 
11 ENSG00000074410 CA12 0.0174293 -3.36153 -2.75126 
12 ENSG00000147889 CDKN2A 2.64105 3.36639 3.94857 
13 ENSG00000136425 CIB2 -1.17897 -3.236 -2.94765 
14 ENSG00000164778 EN2 6.23294 7.83049 6.87128 
15 ENSG00000119782 FKBP1B -2.16248 -3.99712 -3.93116 
16 ENSG00000174500 GCSAM 2.14029 2.30775 1.73417 
17 ENSG00000104381 GDAP1 -1.54551 -4.64693 -4.77362 
18 ENSG00000164949 GEM 0.790971 3.42223 1.04834 
19 ENSG00000110422 HIPK3 0.531431 0.771268 0.0613949 
20 ENSG00000231908 IDH1-AS1 -4.21139 -5.26842 -3.81015 
21 ENSG00000105655 ISYNA1 1.47942 3.54065 4.20287 
22 ENSG00000233237 LINC00472 6.22254 6.33968 4.97121 
23 ENSG00000006062 MAP3K14 0.457768 1.98261 2.13432 
24 ENSG00000112139 MDGA1 3.2457 6.5543 6.33459 
25 ENSG00000247516 MIR4458HG -4.11653 -7.63299 -7.75968 
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26 ENSG00000075975 MKRN2 -0.90971 -0.49853 -0.283895 
27 ENSG00000133030 MPRIP 2.2042 3.79337 3.49739 
28 ENSG00000144959 NCEH1 1.88787 2.8615 3.0803 
29 ENSG00000163121 NEURL3 1.55835 5.78088 2.81771 
30 ENSG00000147862 NFIB 1.51351 1.29263 1.46305 
31 ENSG00000253873 PCDHGA11 6.21383 1.75395 1.09674 
32 ENSG00000071994 PDCD2 -1.38338 -0.955786 -0.82456 
33 ENSG00000184203 PPP1R2 -0.877538 -0.670792 -0.504274 
34 ENSG00000121481 RNF2 -0.978119 -1.32691 -0.566755 
35 ENSG00000258285 RP11-103B5.2 0.432467 4.16899 -0.570684 
36 ENSG00000254634 RP11-231C14.3 3.78296 2.71172 0.570672 
37 ENSG00000225265 RP11-378J18.3 -4.88946 -3.48706 -3.07318 
38 ENSG00000231365 RP11-418J17.1 3.44205 3.51075 0.871675 
39 ENSG00000235902 RP11-626E13.1 5.11054 3.18279 -2.07318 
40 ENSG00000215548 RP11-764K9.4 -0.609353 -0.79965 -2.29558 
41 ENSG00000239218 RPS20P22 3.96852 3.78143 2.45038 
42 ENSG00000139218 SCAF11 1.36497 2.42021 2.58178 
43 ENSG00000164023 SGMS2 -0.161462 0.88755 0.25432 
44 ENSG00000197375 SLC22A5 1.82692 1.95344 1.28671 
45 ENSG00000137968 SLC44A5 -1.75196 -2.80899 -4.81015 
46 ENSG00000205571 SMN2 -0.474424 1.71647 0.589781 
47 ENSG00000171148 TADA3 -1.88681 -1.33178 -1.42087 
48 ENSG00000028839 TBPL1 -1.62329 -1.10059 -0.683113 
49 ENSG00000029639 TFB1M -1.19556 -2.30603 -1.82973 
50 ENSG00000231770 TMEM44-AS1 -1.3947 -2.31846 -1.83218 
51 ENSG00000056558 TRAF1 1.92324 1.1384 2.32951 
52 ENSG00000132549 VPS13B 3.28168 2.81381 2.97896 
53 ENSG00000105875 WDR91 3.09982 4.02384 3.27057 
54 ENSG00000171307 ZDHHC16 -1.26694 -1.77772 -1.34038 
      
Unique Genes CCA16 (log2FC) 
No. Ensembl GeneID Symbol T P5 P30 
1 ENSG00000109576 AADAT -10.1804 -10.3797 -11.1208 
2 ENSG00000023839 ABCC2 -8.92619 -10.4151 -8.49317 
3 ENSG00000136379 ABHD17C 3.62504 3.99509 2.04631 
4 ENSG00000127220 ABHD8 -2.76785 -1.76141 -1.889 
5 ENSG00000226363 AC009336.24 4.29426 6.06769 5.32544 
6 ENSG00000224769 AC069213.1 8.03921 5.45943 0.693694 
7 ENSG00000078124 ACER3 1.11588 2.18276 1.75493 
8 ENSG00000112304 ACOT13 -4.1074 -3.79279 -3.38792 
9 ENSG00000100591 AHSA1 1.4527 0.893817 1.97109 
10 ENSG00000189366 ALG1L 5.97194 5.29161 5.8673 
11 ENSG00000148677 ANKRD1 -3.088 -2.28739 -1.44348 
12 ENSG00000166825 ANPEP -7.55656 -8.17907 -9.05008 
13 ENSG00000164144 ARFIP1 1.28543 1.62753 0.399497 
14 ENSG00000137962 ARHGAP29 -4.13963 -6.06339 -5.44264 
15 ENSG00000157399 ARSE -7.79057 -9.405 -11.316 
16 ENSG00000148219 ASTN2 -0.820521 -2.34183 -2.96741 
17 ENSG00000181652 ATG9B 8.59067 8.39391 2.64162 
18 ENSG00000095739 BAMBI -2.06539 -3.42705 -3.30303 
19 ENSG00000132840 BHMT2 -11.3697 -11.1767 -12.7251 
20 ENSG00000166619 BLCAP 0.323342 1.00109 1.36582 
21 ENSG00000125999 BPIFB1 11.8529 7.89989 4.43576 
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22 ENSG00000177627 C12orf54 1.3494 6.95802 4.73089 
23 ENSG00000169609 C15orf40 0.847876 1.30261 0.842232 
24 ENSG00000171984 C20orf196 4.60037 2.62251 2.55301 
25 ENSG00000183287 CCBE1 -5.76694 -4.57401 -7.70738 
26 ENSG00000170558 CDH2 -7.32156 -6.30211 -9.41954 
27 ENSG00000147889 CDKN2A 2.3069 1.83823 1.57992 
28 ENSG00000105388 CEACAM5 9.97037 8.86185 7.14377 
29 ENSG00000086548 CEACAM6 9.2549 7.8354 3.88558 
30 ENSG00000170835 CEL 5.62951 8.2748 4.24835 
31 ENSG00000064886 CHI3L2 -1.97252 -2.58695 -4.91296 
32 ENSG00000117971 CHRNB4 3.78236 7.5294 5.40896 
33 ENSG00000137975 CLCA2 5.49508 9.95778 7.41683 
34 ENSG00000070371 CLTCL1 -2.0324 -2.50709 -1.11401 
35 ENSG00000117519 CNN3 -3.02554 -4.07312 -2.77732 
36 ENSG00000230183 CNOT6LP1 1.61244 4.05953 2.41551 
37 ENSG00000065618 COL17A1 4.26482 7.91373 7.60525 
38 ENSG00000093010 COMT -3.866 -3.8618 -4.18782 
39 ENSG00000196353 CPNE4 4.66651 5.77646 3.13143 
40 ENSG00000143320 CRABP2 10.4276 9.30484 5.75059 
41 ENSG00000108342 CSF3 -3.97252 8.77678 5.39822 
42 ENSG00000121552 CSTA 1.31582 2.95399 2.06978 
43 ENSG00000134030 CTIF -2.06053 -0.572787 -1.70345 
44 ENSG00000112514 CUTA -1.85538 -2.73348 -2.47134 
45 ENSG00000019186 CYP24A1 6.64018 9.77782 6.26162 
46 ENSG00000170456 DENND5B -5.23767 -5.17718 -3.48743 
47 ENSG00000134757 DSG3 2.31288 6.88777 8.77703 
48 ENSG00000140254 DUOXA1 9.54711 9.16292 7.93566 
49 ENSG00000119718 EIF2B2 1.19938 0.681457 1.28973 
50 ENSG00000145191 EIF2B5 0.600661 0.564016 1.2144 
51 ENSG00000012660 ELOVL5 -5.08761 -5.89612 -7.60296 
52 ENSG00000079819 EPB41L2 -0.672964 -1.32845 -0.321975 
53 ENSG00000134398 ERN2 9.84499 7.58964 0.502074 
54 ENSG00000117036 ETV3 2.70052 3.18012 2.14602 
55 ENSG00000104313 EYA1 7.64586 7.16125 7.43798 
56 ENSG00000196937 FAM3C 1.50418 1.74274 1.90923 
57 ENSG00000152767 FARP1 -2.62667 -3.5426 -3.0495 
58 ENSG00000086570 FAT2 4.43032 7.94218 9.38712 
59 ENSG00000178974 FBXO34 2.30951 1.63828 1.36552 
60 ENSG00000182263 FIGN -2.93936 -3.08247 -1.99938 
61 ENSG00000115226 FNDC4 -7.30821 -6.5816 -7.04702 
62 ENSG00000176920 FUT2 7.68807 6.65781 3.70175 
63 ENSG00000010361 FUZ 1.40519 1.16897 1.17939 
64 ENSG00000183347 GBP6 2.2754 6.14437 7.45772 
65 ENSG00000084734 GCKR -10.7185 -10.3329 -11.2439 
66 ENSG00000174500 GCSAM 3.66306 5.00016 4.05117 
67 ENSG00000167741 GGT6 8.38173 6.74621 6.13143 
68 ENSG00000189280 GJB5 4.2173 5.50757 6.88901 
69 ENSG00000182963 GJC1 0.300494 -0.648348 -2.328 
70 ENSG00000178445 GLDC -9.21808 -11.8325 -9.35116 
71 ENSG00000183098 GPC6 -5.69134 -6.17084 -8.98228 
72 ENSG00000173890 GPR160 5.48111 2.94214 2.59576 
73 ENSG00000130956 HABP4 -1.65346 -3.4378 -1.45223 
74 ENSG00000113070 HBEGF 2.51744 6.93625 4.67341 
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75 ENSG00000196917 HCAR1 7.2173 7.13757 5.84637 
76 ENSG00000164683 HEY1 2.80178 0.684857 5.2667 
77 ENSG00000156510 HKDC1 -0.972524 -3.73895 -4.23489 
78 ENSG00000105996 HOXA2 5.72096 5.68918 4.54647 
79 ENSG00000105997 HOXA3 4.57927 6.73293 6.01831 
80 ENSG00000118960 HS1BP3 -1.39545 -1.62743 -1.41078 
81 ENSG00000030419 IKZF2 3.64571 3.96477 3.00096 
82 ENSG00000145103 ILDR1 7.92229 7.06141 6.24943 
83 ENSG00000115221 ITGB6 6.74292 6.19783 7.42495 
84 ENSG00000173801 JUP 1.36025 1.98285 2.37816 
85 ENSG00000213859 KCTD11 3.65233 4.00698 3.14606 
86 ENSG00000120549 KIAA1217 -0.21553 0.581893 0.780452 
87 ENSG00000179454 KLHL28 0.697186 1.38436 0.862274 
88 ENSG00000133703 KRAS 0.765081 0.988386 1.22788 
89 ENSG00000186081 KRT5 5.78093 7.66791 9.78891 
90 ENSG00000148346 LCN2 6.28174 8.33639 6.16595 
91 ENSG00000259974 LINC00261 -10.9901 -12.983 -14.046 
92 ENSG00000232931 LINC00342 8.34912 6.18784 3.16385 
93 ENSG00000232229 LINC00865 3.66168 2.45745 1.92834 
94 ENSG00000079435 LIPE 8.7409 3.85521 2.55581 
95 ENSG00000176454 LPCAT4 6.08418 6.39268 4.76085 
96 ENSG00000160285 LSS -3.23795 -2.28826 -1.24812 
97 ENSG00000167656 LY6D 6.35121 8.27093 2.87711 
98 ENSG00000013619 MAMLD1 -2.39574 -4.46959 -1.43806 
99 ENSG00000104774 MAN2B1 -0.962583 -1.24939 -1.85552 
100 ENSG00000198909 MAP3K3 -1.71344 -2.68479 -0.90471 
101 ENSG00000129680 MAP7D3 -4.97815 -6.27064 -8.91859 
102 ENSG00000165406 MARCH8 -1.87941 -1.90256 -1.89161 
103 ENSG00000133997 MED6 1.16354 1.3072 1.61473 
104 ENSG00000176624 MEX3C -4.33627 -5.06853 -8.94914 
105 ENSG00000198948 MFAP3L -10.4268 -8.28636 -12.3673 
106 ENSG00000198788 MUC2 6.03995 8.94498 4.38675 
107 ENSG00000176945 MUC20 6.81292 3.99533 -0.829709 
108 ENSG00000145113 MUC4 8.39094 6.88535 3.41174 
109 ENSG00000215182 MUC5AC 9.30152 6.80752 -0.228466 
110 ENSG00000114503 NCBP2 1.2857 1.48054 1.7713 
111 ENSG00000188505 NCCRP1 8.70608 7.32069 0.479353 
112 ENSG00000182636 NDN -1.22045 -1.80513 -5.16089 
113 ENSG00000173848 NET1 1.58196 2.06182 2.43013 
114 ENSG00000204386 NEU1 -1.83373 -2.11503 -1.66592 
115 ENSG00000089723 OTUB2 2.16498 5.4144 5.30582 
116 ENSG00000142623 PADI1 7.06195 6.02811 3.83171 
117 ENSG00000198682 PAPSS2 -5.01815 -5.11279 -6.72876 
118 ENSG00000198807 PAX9 9.84366 8.2648 8.7173 
119 ENSG00000249915 PDCD6 1.30255 1.20496 0.8038 
120 ENSG00000090470 PDCD7 0.526349 1.90138 1.52187 
121 ENSG00000174827 PDZK1 -8.08039 -9.52489 -9.11394 
122 ENSG00000049246 PER3 -3.62109 -4.36849 -5.41498 
123 ENSG00000154864 PIEZO2 -3.97671 -5.84748 -6.64298 
124 ENSG00000081277 PKP1 1.52998 4.5923 8.55219 
125 ENSG00000104368 PLAT 4.48493 8.32242 6.01038 
126 ENSG00000189266 PNRC2 -3.31492 -4.41477 -4.06271 
127 ENSG00000167653 PSCA 11.5416 7.9557 1.22454 
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128 ENSG00000144724 PTPRG -2.40072 -4.5702 -4.34873 
129 ENSG00000106278 PTPRZ1 3.88546 1.93661 8.77178 
130 ENSG00000112531 QKI -2.29834 -1.88325 -1.938 
131 ENSG00000166349 RAG1 3.09727 2.81834 2.43973 
132 ENSG00000079337 RAPGEF3 5.3221 5.24639 2.25839 
133 ENSG00000108352 RAPGEFL1 3.09844 3.97479 3.34882 
134 ENSG00000160439 RDH13 4.00267 2.82134 2.49356 
135 ENSG00000168476 REEP4 3.136 4.04175 3.79 
136 ENSG00000204618 RNF39 7.81211 7.12386 2.63547 
137 ENSG00000263006 ROCK1P1 -1.55749 -3.17191 -1.91296 
138 ENSG00000205293 RP11-1112C15.1 5.98167 6.80322 5.44459 
139 ENSG00000249550 RP11-438N16.1 7.2296 7.31543 4.99993 
140 ENSG00000233901 RP11-65J3.1 2.66168 3.62007 3.06241 
141 ENSG00000235142 RP1-60O19.1 -9.19492 -10.3943 -11.7203 
142 ENSG00000235501 RP4-639F20.1 -3.51849 -4.38445 -4.64336 
143 ENSG00000258545 RP4-755D9.1 8.83201 8.381 6.94735 
144 ENSG00000259153 RP6-65G23.3 3.55104 7.56483 5.55952 
145 ENSG00000215030 RPL13P12 -0.128099 -0.134281 -0.342792 
146 ENSG00000100784 RPS6KA5 1.951 2.5243 2.35138 
147 ENSG00000185924 RTN4RL1 -5.76694 -8.38136 -8.70738 
148 ENSG00000186907 RTN4RL2 -6.25793 -3.80196 -6.27237 
149 ENSG00000196754 S100A2 4.68378 7.50175 9.00635 
150 ENSG00000185033 SEMA4B 2.84415 3.9097 3.06549 
151 ENSG00000057149 SERPINB3 5.19071 8.99174 4.03345 
152 ENSG00000163406 SLC15A2 6.15957 3.92085 4.04967 
153 ENSG00000204385 SLC44A4 9.00878 4.94373 -0.912964 
154 ENSG00000184564 SLITRK6 7.57774 4.19441 7.18078 
155 ENSG00000141646 SMAD4 -2.87796 -3.10818 -3.70125 
156 ENSG00000198732 SMOC1 -9.05928 -9.18828 -8.77733 
157 ENSG00000224078 SNHG14 -3.54699 -5.22555 -6.42603 
158 ENSG00000129194 SOX15 2.45374 6.21233 6.8285 
159 ENSG00000181449 SOX2 6.15933 4.44648 9.96614 
160 ENSG00000204335 SP5 -3.87941 -7.0788 -4.40482 
161 ENSG00000241794 SPRR2A 0.612438 7.15901 5.16385 
162 ENSG00000163209 SPRR3 6.2754 8.55516 7.78921 
163 ENSG00000128039 SRD5A3 3.75925 3.69333 0.215442 
164 ENSG00000249700 SRD5A3-AS1 4.70696 4.57292 0.334964 
165 ENSG00000188529 SRSF10 -4.81383 -4.20586 -2.20995 
166 ENSG00000124783 SSR1 -2.06563 -1.80834 -1.29769 
167 ENSG00000157350 ST3GAL2 -2.51877 -1.75313 -2.14268 
168 ENSG00000165283 STOML2 0.72049 0.770407 1.60217 
169 ENSG00000137868 STRA6 7.23578 8.4395 6.16259 
170 ENSG00000161860 SYCE2 -0.972524 -2.58695 -0.175998 
171 ENSG00000142765 SYTL1 6.42713 6.95691 5.88978 
172 ENSG00000143498 TAF1A 2.53923 3.02592 2.89439 
173 ENSG00000134827 TCN1 9.49695 6.94248 3.23678 
174 ENSG00000159648 TEPP 4.68569 5.31994 1.54647 
175 ENSG00000144115 THNSL2 -7.82271 -8.62978 -9.76315 
176 ENSG00000164180 TMEM161B 1.14026 1.48546 1.033 
177 ENSG00000187049 TMEM216 1.88071 2.1214 2.33677 
178 ENSG00000163472 TMEM79 2.00338 1.98638 2.10539 
179 ENSG00000137648 TMPRSS4 9.56736 9.45437 7.35923 
180 ENSG00000131746 TNS4 4.88177 7.23146 7.96866 
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181 ENSG00000073282 TP63 4.98748 7.33452 8.61017 
182 ENSG00000140391 TSPAN3 4.05598 2.52632 1.62459 
183 ENSG00000100154 TTC28 -5.15532 -6.33162 -6.46499 
184 ENSG00000182247 UBE2E2 -3.36484 -4.64223 -5.55321 
185 ENSG00000135220 UGT2A3 -9.04399 -10.6584 -9.98443 
186 ENSG00000174607 UGT8 6.56016 6.66729 7.28753 
187 ENSG00000147679 UTP23 0.885457 1.72557 1.69229 
188 ENSG00000168140 VASN -2.30035 -2.63041 -3.75115 
189 ENSG00000184056 VPS33B 1.08451 2.23255 1.35281 
190 ENSG00000101443 WFDC2 10.1865 9.29305 5.34805 
191 ENSG00000134744 ZCCHC11 -3.94431 -5.00804 -6.71257 
192 ENSG00000148516 ZEB1 -2.18141 -3.65643 -7.14291 
193 ENSG00000120784 ZFP30 -3.84699 -5.04638 -7.95736 
194 ENSG00000187801 ZFP69B -1.87941 -4.49384 -4.81985 
195 ENSG00000198315 ZKSCAN8 -3.39337 -4.71406 -8.288 
196 ENSG00000125846 ZNF133 1.33383 2.07729 2.02142 
197 ENSG00000168661 ZNF30 -2.23556 -6.49384 -5.23489 
198 ENSG00000181894 ZNF329 -5.25456 -6.52106 -7.65443 
199 ENSG00000177932 ZNF354C -0.585501 -1.96546 -1.91296 
200 ENSG00000161642 ZNF385A 2.87444 4.69218 3.85637 
201 ENSG00000196437 ZNF569 -6.90326 -7.51768 -6.25874 
202 ENSG00000188227 ZNF793 0.197401 -2.26502 -3.91296 
203 ENSG00000223547 ZNF844 -3.95156 -6.45907 -8.59244 
204 ENSG00000121413 ZSCAN18 -3.17246 -5.41138 -8.32236 
205 ENSG00000203995 ZYG11A -5.75388 -5.36831 -3.60686 
      
Unique GenesCCA33(log2FC) 
No. Ensembl GeneID Symbol T P5 P30 
1 ENSG00000226856 AC093901.1 0.561082 0.271033 0.0859771 
2 ENSG00000169129 AFAP1L2 5.66296 5.85383 5.89043 
3 ENSG00000110497 AMBRA1 -0.568686 -3.71779 -3.01329 
4 ENSG00000206560 ANKRD28 0.741587 1.5825 1.65363 
5 ENSG00000152056 AP1S3 5.3555 7.98137 7.03088 
6 ENSG00000144746 ARL6IP5 1.09607 1.95932 1.71753 
7 ENSG00000206190 ATP10A 5.93751 7.11376 6.15111 
8 ENSG00000135407 AVIL -3.09788 -4.32148 -3.115 
9 ENSG00000155096 AZIN1 1.33815 1.66651 2.54332 
10 ENSG00000106635 BCL7B 0.940403 1.33181 0.66853 
11 ENSG00000091317 CMTM6 0.414895 0.33367 0.620144 
12 ENSG00000197813 CTC-301O7.4 -4.40239 -3.03014 -4.63101 
13 ENSG00000105928 DFNA5 0.735112 -2.45898 0.123874 
14 ENSG00000170464 DNAJC18 -0.327557 -0.644011 -0.708182 
15 ENSG00000167968 DNASE1L2 -3.50931 -2.03752 -2.416 
16 ENSG00000178852 EFCAB13 -4.36492 -2.68454 -2.47806 
17 ENSG00000102287 GABRE -1.21215 -2.83366 -4.9002 
18 ENSG00000111846 GCNT2 0.914719 1.89525 2.13101 
19 ENSG00000170604 IRF2BP1 -0.910818 -1.55209 -1.39524 
20 ENSG00000120071 KANSL1 -0.555672 -0.328633 
-
0.00640549 
21 ENSG00000104863 LIN7B -2.00861 -1.28225 -2.12761 
22 ENSG00000238266 LINC00707 6.88301 8.2515 7.33738 
23 ENSG00000088899 LZTS3 -1.18854 -1.42236 -3.15685 
24 ENSG00000078018 MAP2 3.14638 3.83734 3.40553 
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25 ENSG00000143995 MEIS1 -1.55439 -1.91149 -2.18476 
26 ENSG00000203791 METTL10 0.32059 0.735351 0.502806 
27 ENSG00000002079 MYH16 3.15603 4.44791 6.58611 
28 ENSG00000144959 NCEH1 4.5271 6.36807 5.82431 
29 ENSG00000160209 PDXK 2.3648 3.29921 3.67216 
30 ENSG00000172531 PPP1CA 1.12685 1.21244 1.27459 
31 ENSG00000183255 PTTG1IP 1.79231 2.56133 3.04519 
32 ENSG00000137502 RAB30 -1.44561 -0.971586 -2.87168 
33 ENSG00000144118 RALB 1.62669 2.35048 2.01801 
34 ENSG00000108375 RNF43 -0.239609 -0.251694 -3.1745 
35 ENSG00000251003 RP11-152P17.2 -0.701952 -1.13705 -1.93057 
36 ENSG00000234840 RP11-399D6.2 -4.02388 -2.87402 -2.55206 
37 ENSG00000260329 RP11-412D9.4 -2.50931 -2.62248 -3.00096 
38 ENSG00000226824 RP4-756H11.3 -0.583308 0.566555 0.741043 
39 ENSG00000226102 SEPT7P3 -0.106342 -0.137052 0.0774187 
40 ENSG00000042317 SPATA7 -1.72081 -2.23391 -1.568 
41 ENSG00000152582 SPEF2 -1.88416 -2.34727 -0.574812 
42 ENSG00000137767 SQRDL 0.919371 1.36259 0.733205 
43 ENSG00000100321 SYNGR1 -1.76496 -3.05322 -5.63101 
44 ENSG00000104946 TBC1D17 -0.955768 -1.28632 -1.16522 
45 ENSG00000198933 TBKBP1 -0.386856 -2.15995 -2.54422 
46 ENSG00000134490 TMEM241 2.50537 3.55479 3.55544 
47 ENSG00000130598 TNNI2 4.08232 5.8152 6.7532 
48 ENSG00000141510 TP53 -0.579095 -1.9947 -1.58673 
49 ENSG00000165699 TSC1 -0.958727 -0.321877 -0.219319 
50 ENSG00000102904 TSNAXIP1 -2.74148 -3.17658 -7.14003 
51 ENSG00000015532 XYLT2 -0.223905 -0.912558 0.162938 
52 ENSG00000166793 YPEL4 -2.87188 -3.98505 -2.51554 
53 ENSG00000149050 ZNF214 -1.65615 -4.50629 -2.71485 
54 ENSG00000165804 ZNF219 -0.119384 -0.254773 -1.73614 
55 ENSG00000197935 ZNF311 -2.50931 -3.94441 -2.2785 
56 ENSG00000083812 ZNF324 -0.578377 -0.822178 -0.817806 
57 ENSG00000256087 ZNF432 -1.34965 -1.09918 -0.777804 
58 ENSG00000197701 ZNF595 1.8341 2.49522 2.28666 
59 ENSG00000142556 ZNF614 -1.05889 -6.32688 -4.21351 
60 ENSG00000197619 ZNF615 -1.7258 -2.98033 -1.85008 
61 ENSG00000182318 ZSCAN22 -0.778303 -1.25315 -1.19957 
      
Unique GenesHCC9(log2FC) 
No. Ensembl GeneID Symbol T P5 P30 
1 ENSG00000213225 AC018804.7 3.16647 3.38302 3.6791 
2 ENSG00000075340 ADD2 3.72615 0.730814 4.01744 
3 ENSG00000138138 ATAD1 -5.17297 -4.84 -7.11818 
4 ENSG00000105146 AURKC 2.71658 3.73425 3.12263 
5 ENSG00000118276 B4GALT6 2.95968 3.72899 3.64515 
6 ENSG00000273045 C2ORF15 
-
0.0841135 -1.33808 -0.403712 
7 ENSG00000165181 C9orf84 -2.23612 -2.33808 0.0881413 
8 ENSG00000158941 CCAR2 -0.286294 0.201036 0.183907 
9 ENSG00000186567 CEACAM19 -2.60576 -4.31845 -5.61626 
10 ENSG00000111642 CHD4 1.93729 2.64024 2.44673 
11 ENSG00000164695 CHMP4C -0.119077 -1.35855 -2.21361 
12 ENSG00000113946 CLDN16 -3.62843 -3.06743 -3.30418 
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13 ENSG00000109472 CPE 1.26344 2.84605 1.7666 
14 ENSG00000139117 CPNE8 -2.72726 -1.41418 -2.58742 
15 ENSG00000177738 CTD-2201E18.3 2.2407 2.97177 2.68269 
16 ENSG00000273018 CTD-2303H24.2 1.47502 1.27758 0.800702 
17 ENSG00000253982 CTD-2336O2.1 -3.18665 -3.28861 -3.39327 
18 ENSG00000100523 DDHD1 2.35095 3.08995 2.68403 
19 ENSG00000181381 DDX60L -0.887538 2.59536 2.38951 
20 ENSG00000134755 DSC2 -2.55629 -2.86471 -1.80655 
21 ENSG00000134769 DTNA 0.241931 -0.40847 -0.0562486 
22 ENSG00000125971 DYNLRB1 -1.29738 -1.29149 -1.13762 
23 ENSG00000084710 EFR3B 4.20683 6.97253 8.30828 
24 ENSG00000115504 EHBP1 -2.01971 -3.50019 -4.19256 
25 ENSG00000119888 EPCAM 2.55712 -0.451738 -1.21209 
26 ENSG00000198324 FAM109A 1.62866 1.49147 2.06711 
27 ENSG00000183114 FAM43B -0.499151 6.99358 7.65546 
28 ENSG00000168672 FAM84B -1.95583 -1.50686 -2.06898 
29 ENSG00000173295 FAM86B3P -6.71332 -4.60229 -5.9225 
30 ENSG00000066468 FGFR2 -4.19508 -4.4327 -5.92356 
31 ENSG00000136877 FPGS -1.04664 -2.08765 -1.7518 
32 ENSG00000131067 GGT7 -0.870681 -1.33236 -1.74468 
33 ENSG00000173905 GOLIM4 2.51687 0.123506 0.876059 
34 ENSG00000233276 GPX1 -3.52349 -5.26153 -10.3249 
35 ENSG00000181333 HEPHL1 1.71808 5.80403 6.96956 
36 ENSG00000078399 HOXA9 6.84603 7.03696 6.82691 
37 ENSG00000226742 HSBP1L1 -1.92166 -4.02791 -4.29357 
38 ENSG00000126803 HSPA2 2.66605 3.45097 4.20362 
39 ENSG00000003147 ICA1 -3.3557 -6.09707 -8.69322 
40 ENSG00000244242 IFITM10 -3.07627 -4.4654 -4.70903 
41 ENSG00000148798 INA -1.23612 7.43065 8.24566 
42 ENSG00000257093 KIAA1147 -1.40232 -2.47777 -3.35391 
43 ENSG00000137177 KIF13A 0.346726 2.24304 2.50119 
44 ENSG00000166796 LDHC 1.0369 1.18548 1.60752 
45 ENSG00000138131 LOXL4 0.689883 0.805965 -2.87764 
46 ENSG00000148356 LRSAM1 -1.60276 -1.75226 -1.72961 
47 ENSG00000185247 MAGEA11 7.1313 7.99115 8.17295 
48 ENSG00000156009 MAGEA8 7.36973 8.0313 8.11936 
49 ENSG00000185090 MANEAL -4.25848 -3.50247 -2.30196 
50 ENSG00000175130 MARCKSL1 -0.777331 -3.25746 -5.7292 
51 ENSG00000141644 MBD1 -0.696817 -0.414659 -0.549315 
52 ENSG00000014641 MDH1 -5.48611 -5.78072 -9.42238 
53 ENSG00000163975 MFI2 -0.531021 -1.38741 -3.17441 
54 ENSG00000037757 MRI1 -1.63436 -4.49121 -5.27144 
55 ENSG00000173272 MZT2A -0.392692 -0.818495 -0.261443 
56 ENSG00000078177 N4BP2 -2.87323 -2.1998 -2.52614 
57 ENSG00000100285 NEFH 1.68275 6.27387 6.6435 
58 ENSG00000184613 NELL2 7.79262 8.11334 7.16581 
59 ENSG00000107833 NPM3 0.0772155 -1.03051 -0.534446 
60 ENSG00000189223 PAX8-AS1 -3.01256 -0.652557 -0.429929 
61 ENSG00000078674 PCM1 -1.42153 -0.913502 -0.816046 
62 ENSG00000121892 PDS5A -1.49599 -1.98079 -1.98091 
63 ENSG00000162366 PDZK1IP1 1.43848 2.0856 -0.98003 
64 ENSG00000101464 PIGU -0.362334 -0.208151 -0.0832952 
65 ENSG00000057294 PKP2 -2.20558 -2.29707 -2.68552 
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66 ENSG00000110841 PPFIBP1 0.117568 2.28093 2.04913 
67 ENSG00000135406 PRPH 1.34885 7.60443 6.90064 
68 ENSG00000171862 PTEN -4.42956 -5.49941 -8.00756 
69 ENSG00000050628 PTGER3 4.07222 8.02715 8.85003 
70 ENSG00000148334 PTGES2 -0.847132 -0.929812 -1.26917 
71 ENSG00000118849 RARRES1 -1.86999 -3.82993 -4.14068 
72 ENSG00000169733 RFNG -1.78307 -2.67783 -3.00689 
73 ENSG00000225465 RFPL1S -2.58007 1.79245 2.80397 
74 ENSG00000131941 RHPN2 -1.51524 -1.97858 -2.98833 
75 ENSG00000257718 RP11-396F22.1 -4.78044 -4.14544 -4.36307 
76 ENSG00000247903 RP11-421F16.3 -1.68132 -2.97883 -1.95426 
77 ENSG00000259985 RP11-549B18.1 3.01938 3.52982 3.95604 
78 ENSG00000231345 RP11-564C4.6 1.39615 -0.95957 -1.55571 
79 ENSG00000249741 RP11-673E1.3 2.67077 2.90985 1.76621 
80 ENSG00000272005 RP11-91J19.4 -4.08161 -2.20629 -3.75735 
81 ENSG00000272841 RP3-428L16.2 2.26031 5.03944 4.00325 
82 ENSG00000129197 RPAIN -1.09502 -1.56597 -1.36112 
83 ENSG00000220793 RPL21P119 -7.62557 -0.785019 -0.815884 
84 ENSG00000105372 RPS19 -1.03184 -1.3229 -1.93943 
85 ENSG00000081019 RSBN1 -0.594099 -1.3473 -1.29 
86 ENSG00000164764 SBSPON 4.76908 5.3538 3.16906 
87 ENSG00000138623 SEMA7A -0.711026 -1.86274 -2.54694 
88 ENSG00000175793 SFN 4.90087 1.05424 2.77744 
89 ENSG00000111252 SH2B3 1.03569 2.79116 2.48745 
90 ENSG00000116991 SIPA1L2 4.90321 3.70738 4.26464 
91 ENSG00000070915 SLC12A3 2.67077 8.62337 9.35914 
92 ENSG00000214617 SLC6A10P 9.08073 6.50741 6.32846 
93 ENSG00000077935 SMC1B 5.43631 6.00066 6.10829 
94 ENSG00000067221 STOML1 -0.915386 -1.43079 -1.53197 
95 ENSG00000028839 TBPL1 1.58938 0.85938 0.551343 
96 ENSG00000240280 TCAM1P 1.67077 6.11725 5.25807 
97 ENSG00000120889 TNFRSF10B -2.09394 -1.9243 -2.14728 
98 ENSG00000125657 TNFSF9 2.421 7.51102 8.41561 
99 ENSG00000115129 TP53I3 2.37689 2.16102 2.55559 
100 ENSG00000156521 TYSND1 -1.86131 -2.40199 -1.70772 
101 ENSG00000130985 UBA1 0.807591 1.57506 1.43272 
102 ENSG00000078140 UBE2K -2.27226 -2.7344 -2.96828 
103 ENSG00000177414 UBE2U 7.00706 5.55674 6.43864 
104 ENSG00000101019 UQCC1 -1.52864 -0.873413 -0.829397 
105 ENSG00000139190 VAMP1 2.3112 2.48604 1.66081 
106 ENSG00000143951 WDPCP -2.14054 -4.20598 -3.61626 
107 ENSG00000124343 XG -1.18167 3.53323 2.25313 
108 ENSG00000235109 ZSCAN31 4.39964 3.84461 3.30822 
      
Unique GenesHCC16(log2FC)  
No. Ensembl GeneID Symbol T P5  
1 ENSG00000103222 ABCC1 -0.360751 -0.282103  
2 ENSG00000183260 ABHD16B -1.51837 -2.00929  
3 ENSG00000136379 ABHD17C -2.94628 -1.51412  
4 ENSG00000120437 ACAT2 0.958777 0.626383  
5 ENSG00000126705 AHDC1 -0.787993 -0.811939  
6 ENSG00000185567 AHNAK2 -5.31746 -2.62699  
7 ENSG00000161618 ALDH16A1 -1.58743 -3.12952  
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8 ENSG00000178038 ALS2CL -3.06648 -3.19515  
9 ENSG00000138772 ANXA3 -3.53985 -1.02523  
10 ENSG00000142192 APP -3.71471 -3.51217  
11 ENSG00000071205 ARHGAP10 -2.51786 -3.17317  
12 ENSG00000225485 ARHGAP23 -2.24968 -0.971849  
13 ENSG00000142632 ARHGEF19 -2.26301 -2.3878  
14 ENSG00000204959 ARHGEF34P -3.51386 -3.99923  
15 ENSG00000050327 ARHGEF5 -5.38785 -3.04315  
16 ENSG00000072444 ASAH2C -3.53985 3.23947  
17 ENSG00000145246 ATP10D 4.41766 3.17444  
18 ENSG00000174684 B3GNT1 2.16565 1.76668  
19 ENSG00000179913 B3GNT3 -6.16713 -4.12199  
20 ENSG00000182240 BACE2 -2.42927 -2.58114  
21 ENSG00000121753 BAI2 0.267502 3.00452  
22 ENSG00000175866 BAIAP2 -4.97457 -6.50024  
23 ENSG00000226137 BAIAP2-AS1 -3.05443 -2.01671  
24 ENSG00000163093 BBS5 -2.24707 -1.65083  
25 ENSG00000116985 BMP8B -2.39546 -2.63573  
26 ENSG00000169758 C15orf27 6.13787 5.02159  
27 ENSG00000154102 C16orf74 -3.05443 -1.5398  
28 ENSG00000143633 C1orf131 2.35595 1.92572  
29 ENSG00000187642 C1orf170 -1.31746 -0.165407  
30 ENSG00000198715 C1orf85 1.95462 1.82441  
31 ENSG00000197261 C6orf141 -4.43294 -4.08824  
32 ENSG00000182389 CACNB4 8.08128 7.90337  
33 ENSG00000181982 CCDC149 -2.91383 -3.16703  
34 ENSG00000107443 CCNJ -2.50509 -3.22179  
35 ENSG00000105369 CD79A 2.6146 -4.18366  
36 ENSG00000075275 CELSR1 -2.73724 -2.27414  
37 ENSG00000166582 CENPV 2.03547 1.87473  
38 ENSG00000099814 CEP170B -2.62499 -0.883598  
39 ENSG00000189143 CLDN4 -6.01327 -6.20914  
40 ENSG00000154529 CNTNAP3B -4.12481 -3.78012  
41 ENSG00000175029 CTBP2 -2.04028 -1.98705  
42 ENSG00000267575 CTC-459F4.3 
-
0.0735347 -0.728836  
43 ENSG00000118197 DDX59 1.31203 0.487452  
44 ENSG00000153933 DGKE -2.32705 -2.26865  
45 ENSG00000130829 DUSP9 10.0523 5.45901  
46 ENSG00000184349 EFNA5 -2.46946 -2.90237  
47 ENSG00000115211 EIF2B4 1.32893 0.98571  
48 ENSG00000100908 EMC9 -1.71785 -4.75458  
49 ENSG00000173818 ENDOV -2.65059 -1.70231  
50 ENSG00000129595 EPB41L4A -4.17728 -5.00251  
51 ENSG00000110723 EXPH5 -7.5717 -6.64204  
52 ENSG00000092820 EZR -1.24873 -2.28431  
53 ENSG00000184731 FAM110C -7.34884 -8.58911  
54 ENSG00000160752 FDPS 1.5358 1.58957  
55 ENSG00000180263 FGD6 -1.25643 -1.34107  
56 ENSG00000066468 FGFR2 -8.35211 -7.68548  
57 ENSG00000135723 FHOD1 -0.814491 -1.25102  
58 ENSG00000162769 FLVCR1 4.53239 4.29769  
59 ENSG00000198468 FLVCR1-AS1 3.77259 3.95682  
60 ENSG00000186564 FOXD2 -3.94195 -2.42733  
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61 ENSG00000204681 GABBR1 -2.89093 -2.62566  
62 ENSG00000166206 GABRB3 -5.94195 -4.01229  
63 ENSG00000182890 GLUD2 2.23796 3.36154  
64 ENSG00000116906 GNPAT 1.75182 1.51665  
65 ENSG00000147257 GPC3 8.40414 5.74214  
66 ENSG00000152749 GPR180 -2.61797 -4.1707  
67 ENSG00000160360 GPSM1 -2.16743 -1.53323  
68 ENSG00000188290 HES4 -2.13725 -3.00406  
69 ENSG00000029993 HMGB3 -4.11204 -6.29983  
70 ENSG00000113161 HMGCR 2.99151 2.30257  
71 ENSG00000214578 HMGN2P15 3.18504 1.90171  
72 ENSG00000132196 HSD17B7 1.95765 1.61875  
73 ENSG00000164270 HTR4 5.91376 1.69966  
74 ENSG00000164136 IL15 -1.14189 -3.47526  
75 ENSG00000134470 IL15RA -1.96382 -3.28471  
76 ENSG00000100605 ITPK1 -2.85507 -3.02619  
77 ENSG00000096433 ITPR3 -0.344981 0.826181  
78 ENSG00000177807 KCNJ10 0.856159 2.48843  
79 ENSG00000100441 KHNYN -2.47225 -3.66054  
80 ENSG00000120549 KIAA1217 -2.09583 -1.84059  
81 ENSG00000102554 KLF5 -4.10173 -1.22652  
82 ENSG00000167487 KLHL26 -3.68003 -2.55772  
83 ENSG00000119771 KLHL29 -3.87 -2.07464  
84 ENSG00000167767 KRT80 -4.13105 -0.706622  
85 ENSG00000170442 KRT86 -3.19193 -1.5253  
86 ENSG00000126777 KTN1 -1.32664 -1.13136  
87 ENSG00000058085 LAMC2 -4.53985 -2.40856  
88 ENSG00000188636 LDOC1L -2.22092 -1.57973  
89 ENSG00000108679 LGALS3BP -1.79842 -2.98856  
90 ENSG00000237523 LINC00857 -5.27682 -1.3878  
91 ENSG00000137821 LRRC49 -0.95489 -1.49471  
92 ENSG00000124831 LRRFIP1 -1.39137 -1.22609  
93 ENSG00000090006 LTBP4 -4.35917 -5.14073  
94 ENSG00000187123 LYPD6 -3.05443 -3.12476  
95 ENSG00000135525 MAP7 -5.77353 -7.32191  
96 ENSG00000085276 MECOM -1.0179 -1.99138  
97 ENSG00000178053 MLF1 -3.00552 -4.66082  
98 ENSG00000143674 MLK4 -5.32495 -3.98026  
99 ENSG00000115648 MLPH -4.36053 -8.7383  
100 ENSG00000167508 MVD 1.91855 1.94827  
101 ENSG00000157483 MYO1E -2.86301 -3.97715  
102 ENSG00000078177 N4BP2 1.27655 1.16741  
103 ENSG00000050344 NFE2L3 0.811823 0.615953  
104 ENSG00000147862 NFIB -4.79351 -4.03643  
105 ENSG00000167693 NXN -3.34255 -3.46442  
106 ENSG00000145247 OCIAD2 -5.43195 -8.57267  
107 ENSG00000144645 OSBPL10 -1.26043 0.344505  
108 ENSG00000141447 OSBPL1A -2.1346 -3.27532  
109 ENSG00000120327 PCDHB14 -3.19193 -3.26227  
110 ENSG00000078674 PCM1 0.625643 1.96242  
111 ENSG00000106333 PCOLCE 2.57151 1.25852  
112 ENSG00000197461 PDGFA -3.33736 -1.15136  
113 ENSG00000162366 PDZK1IP1 -4.94195 -4.67125  
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114 ENSG00000170525 PFKFB3 -0.771518 -3.70877  
115 ENSG00000107959 PITRM1 -1.82927 -1.19211  
116 ENSG00000184363 PKP3 -3.21792 -3.45819  
117 ENSG00000161714 PLCD3 
-
0.0262289 2.0367  
118 ENSG00000187583 PLEKHN1 -0.147535 1.8976  
119 ENSG00000088970 PLK1S1 1.95973 4.57429  
120 ENSG00000102007 PLP2 
-
0.0386009 -1.37723  
121 ENSG00000196576 PLXNB2 -1.98359 -1.50687  
122 ENSG00000198883 PNMA5 9.47863 8.31221  
123 ENSG00000125534 PPDPF -3.07678 -3.77012  
124 ENSG00000158528 PPP1R9A -2.48739 -3.97276  
125 ENSG00000067606 PRKCZ -4.93217 -9.58747  
126 ENSG00000172382 PRSS27 -3.31746 -1.16541  
127 ENSG00000166450 PRTG 6.62681 6.6664  
128 ENSG00000185920 PTCH1 -1.63494 -2.02721  
129 ENSG00000183134 PTGDR2 5.45096 0.57303  
130 ENSG00000060656 PTPRU -4.90242 -4.84313  
131 ENSG00000171813 PWWP2B -3.00698 -4.99486  
132 ENSG00000124839 RAB17 -8.60132 -8.19773  
133 ENSG00000108352 RAPGEFL1 1.8461 0.859794  
134 ENSG00000172819 RARG -1.85861 -1.25435  
135 ENSG00000146282 RARS2 1.33911 1.05495  
136 ENSG00000100461 RBM23 -3.06197 -4.41692  
137 ENSG00000072422 RHOBTB1 3.9087 2.40671  
138 ENSG00000272327 RP11-1002K11.1 -4.63939 -4.29469  
139 ENSG00000260296 RP11-395I6.3 3.08768 1.58948  
140 ENSG00000205664 RP11-706O15.1 -4.03628 -2.46276  
141 ENSG00000204117 RP4-640H8.2 6.09405 -1.3878  
142 ENSG00000177189 RPS6KA3 1.17684 0.998945  
143 ENSG00000040608 RTN4R -3.79361 -7.14935  
144 ENSG00000163191 S100A11 -0.434296 -1.10439  
145 ENSG00000154447 SH3RF1 -2.1628 -0.303019  
146 ENSG00000185187 SIGIRR -3.41919 -5.29469  
147 ENSG00000197119 SLC25A29 -2.91182 -1.21996  
148 ENSG00000101276 SLC52A3 -0.995532 -1.16541  
149 ENSG00000108576 SLC6A4 4.5997 0.759042  
150 ENSG00000090020 SLC9A1 -0.691856 -0.821274  
151 ENSG00000172123 SLFN12 -1.7325 -1.28088  
152 ENSG00000124107 SLPI -7.86749 -8.5228  
153 ENSG00000227906 SNAP25-AS1 5.88411 3.66082  
154 ENSG00000167780 SOAT2 5.12003 5.06135  
155 ENSG00000168502 SOGA2 -3.97535 -1.1977  
156 ENSG00000124766 SOX4 -3.25724 
-
0.0498778  
157 ENSG00000134278 SPIRE1 -2.83633 -2.63886  
158 ENSG00000144228 SPOPL 1.9966 1.10544  
159 ENSG00000235374 SSR4P1 -4.05443 -4.70973  
160 ENSG00000137868 STRA6 -3.7325 -2.06587  
161 ENSG00000143502 SUSD4 -2.19193 -2.26227  
162 ENSG00000197321 SVIL -3.7747 -2.12258  
163 ENSG00000101190 TCFL5 -2.84798 -3.21377  
164 ENSG00000095627 TDRD1 4.74324 5.37109  
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165 ENSG00000029639 TFB1M 1.28131 1.51698  
166 ENSG00000187720 THSD4 -7.10464 -4.25744  
167 ENSG00000105289 TJP3 -6.00396 -6.33733  
168 ENSG00000104953 TLE6 -4.12481 -5.78012  
169 ENSG00000117500 TMED5 0.568013 0.992343  
170 ENSG00000144120 TMEM177 0.98988 0.694703  
171 ENSG00000106771 TMEM245 3.21037 2.62369  
172 ENSG00000127863 TNFRSF19 5.90548 4.94114  
173 ENSG00000158882 TOMM40L 1.62164 2.21163  
174 ENSG00000115129 TP53I3 2.8356 3.85097  
175 ENSG00000122779 TRIM24 2.2069 2.33593  
176 ENSG00000163462 TRIM46 0.267502 0.727678  
177 ENSG00000099282 TSPAN15 -1.50899 -2.85309  
178 ENSG00000100300 TSPO -1.56516 -1.26697  
179 ENSG00000133985 TTC9 -3.83683 -4.29949  
180 ENSG00000101162 TUBB1 0.621139 3.57156  
181 ENSG00000198680 TUSC1 -4.15876 -4.86653  
182 ENSG00000184787 UBE2G2 -1.43625 -1.46841  
183 ENSG00000154914 USP43 -7.47396 -6.12927  
184 ENSG00000155975 VPS37A 0.364799 1.74255  
185 ENSG00000165171 WBSCR27 -5.43294 -3.50328  
186 ENSG00000188064 WNT7B -2.19193 -3.84723  
187 ENSG00000160062 ZBTB8A -3.05443 -2.97276  
188 ENSG00000159733 ZFYVE28 -3.30235 -4.1503  
189 ENSG00000122515 ZMIZ2 -0.586376 -0.127017  
190 ENSG00000168916 ZNF608 -2.69597 -2.35127  
      
Unique GenesHCC31(log2FC) 
No. Ensembl GeneID Symbol T P5 P30 
1 ENSG00000236078 AC095067.1 2.21046 2.68232 1.64289 
2 ENSG00000008277 ADAM22 -1.0936 
-
0.0336044 -0.737331 
3 ENSG00000102181 CD99L2 1.70832 2.02333 0.236686 
4 ENSG00000176410 DNAJC30 0.541641 -0.372347 0.0931523 
5 ENSG00000178498 DTX3 -1.55346 -1.86868 -3.18325 
6 ENSG00000102034 ELF4 -0.940192 -5.30869 -5.83185 
7 ENSG00000158220 ESYT3 -2.3045 -2.27307 -3.27016 
8 ENSG00000175170 FAM182B -1.24561 0.370786 -0.889335 
9 ENSG00000133136 GNG5P2 1.39381 -1.00773 -0.55415 
10 ENSG00000126945 HNRNPH2 0.704664 0.50155 0.889887 
11 ENSG00000123496 IL13RA2 -2.12007 6.51609 4.6308 
12 ENSG00000187242 KRT12 1.07632 7.95875 11.0274 
13 ENSG00000005893 LAMP2 1.5192 0.346245 -0.565795 
14 ENSG00000198786 MT-ND5 -1.19788 -2.96912 -1.2515 
15 ENSG00000124479 NDP -2.83057 4.69752 3.66321 
16 ENSG00000196865 NHLRC2 -0.847521 -1.04875 -1.82861 
17 ENSG00000125841 NRSN2 -1.44517 -1.69272 -1.78934 
18 ENSG00000255642 PABPC1P4 1.93882 2.50829 1.74716 
19 ENSG00000106443 PHF14 -0.649604 -1.24781 -1.26776 
20 ENSG00000232160 RAP2C-AS1 2.222 2.13632 -0.145173 
21 ENSG00000227354 RBM26-AS1 0.723589 0.147038 0.610534 
22 ENSG00000047936 ROS1 1.84186 6.37259 -1.72584 
23 ENSG00000267390 RP11-635N19.1 -0.151891 -2.88491 -3.26051 
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24 ENSG00000139508 SLC46A3 0.837206 -1.43352 -2.66879 
25 ENSG00000135913 USP37 0.537771 0.692714 -1.07881 
26 ENSG00000165238 WNK2 -4.94604 -4.25926 -3.32674 
27 ENSG00000141040 ZNF287 -3.05296 -2.7585 -6.01862 
28 ENSG00000151789 ZNF385D -2.70504 3.63927 6.19039 
29 ENSG00000197701 ZNF595 0.610005 
-
0.0580574 -1.14415 
30 ENSG00000184635 ZNF93 -0.567533 -2.27307 -2.53319 
      
Unique GenesHCC68(log2FC) 
No. Ensembl GeneID Symbol T P5 P30 
1 ENSG00000232320 AC009299.5 2.10122 1.46892 1.62766 
2 ENSG00000001629 ANKIB1 3.1026 3.72782 3.22252 
3 ENSG00000221838 AP4M1 3.51463 3.09443 2.14973 
4 ENSG00000169188 APEX2 -1.76287 -0.924441 -1.15617 
5 ENSG00000101844 ATG4A -4.20977 -4.17465 -3.61443 
6 ENSG00000106635 BCL7B -1.97821 -1.40823 -1.75998 
7 ENSG00000198908 BHLHB9 -0.443873 -0.704206 -2.69222 
8 ENSG00000157456 CCNB2 2.6365 -1.19018 -0.641596 
9 ENSG00000215039 CD27-AS1 -3.2898 -1.04378 -2.19068 
10 ENSG00000130177 CDC16 -2.43024 -1.4065 -1.57687 
11 ENSG00000181789 COPG1 -0.749147 -0.872021 -0.299222 
12 ENSG00000261780 CTD-2354A18.1 8.22636 9.13313 9.70508 
13 ENSG00000144677 CTDSPL 0.164566 1.50554 1.40524 
14 ENSG00000008283 CYB561 -0.403516 -1.18343 -1.36329 
15 ENSG00000136986 DERL1 -2.74996 -1.47349 -1.53498 
16 ENSG00000088387 DOCK9 -1.43174 -2.56654 -2.74175 
17 ENSG00000132394 EEFSEC -1.35877 -2.23831 -1.47764 
18 ENSG00000118407 FILIP1 3.26772 -3.67912 4.36196 
19 ENSG00000157240 FZD1 4.85771 6.41535 6.35711 
20 ENSG00000198746 GPATCH3 0.683067 0.439833 0.349023 
21 ENSG00000134202 GSTM3 0.954676 -2.93501 -3.87863 
22 ENSG00000110422 HIPK3 -1.80449 -1.71287 -2.29034 
23 ENSG00000106211 HSPB1 -1.29606 -1.4266 -1.77434 
24 ENSG00000063241 ISOC2 -4.82101 -12.5408 -10.2917 
25 ENSG00000184611 KCNH7 3.05154 4.09047 4.4173 
26 ENSG00000104731 KLHDC4 1.96352 0.169901 0.0353021 
27 ENSG00000103550 KNOP1 3.90166 1.89209 2.59138 
28 ENSG00000001631 KRIT1 2.57215 2.57871 1.68 
29 ENSG00000188825 LINC00910 3.39102 2.1928 3.02137 
30 ENSG00000164715 LMTK2 2.92523 2.22792 2.39972 
31 ENSG00000161036 LRWD1 2.87427 1.07596 0.694287 
32 ENSG00000180155 LYNX1 -3.43138 -7.15115 -5.90212 
33 ENSG00000172264 MACROD2 3.07015 4.0427 4.61184 
34 ENSG00000187601 MAGEH1 -4.81471 -6.94951 -5.11553 
35 ENSG00000111196 MAGOHB -1.85033 -1.31743 -1.87813 
36 ENSG00000165175 MID1IP1 -2.45214 -4.68077 -5.37034 
37 ENSG00000123562 MORF4L2 -1.53594 -2.36723 -1.54927 
38 ENSG00000101888 NXT2 -1.99867 -2.18239 -1.72525 
39 ENSG00000138617 PARP16 -2.71223 -2.06442 -1.83045 
40 ENSG00000127980 PEX1 1.28371 1.85911 1.69363 
41 ENSG00000101856 PGRMC1 -4.47208 -3.7759 -5.10689 
42 ENSG00000136147 PHF11 -3.19765 -1.6173 -2.8204 
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43 ENSG00000099256 PRTFDC1 -0.871294 -0.52497 -0.364756 
44 ENSG00000127993 RBM48 2.93348 2.88109 1.76893 
45 ENSG00000013561 RNF14 -1.96562 -1.4791 -1.68148 
46 ENSG00000231841 RP11-206F17.2 5.82915 0.431309 2.26529 
47 ENSG00000261613 RP11-20I23.13 2.738 -3.41787 -6.25631 
48 ENSG00000230291 RP11-244J10.1 -1.30014 -0.113012 0.136012 
49 ENSG00000180211 RP1-278E11.3 -0.443873 0.782781 0.533846 
50 ENSG00000102218 RP2 -2.26255 -1.24626 -1.62896 
51 ENSG00000260121 RP5-1142A6.9 2.4003 -0.219003 -0.715596 
52 ENSG00000235174 RPL39P3 -3.13279 -1.06901 -0.957269 
53 ENSG00000224094 RPS24P8 -2.69442 0.875837 0.840467 
54 ENSG00000185669 SNAI3 2.6365 -0.398766 1.92446 
55 ENSG00000144867 SRPRB -2.09907 -2.10664 -1.38378 
56 ENSG00000235082 SUMO1P3 -0.755817 -0.171801 -0.0972752 
57 ENSG00000133138 TBC1D8B -2.38738 -8.56658 -6.85812 
58 ENSG00000106638 TBL2 -0.34078 -0.753883 -1.09174 
59 ENSG00000172465 TCEAL1 -1.13168 -4.95836 -4.50289 
60 ENSG00000205356 TECPR1 3.28687 1.66775 1.35224 
61 ENSG00000139173 TMEM117 -0.775717 -3.55688 -4.24646 
62 ENSG00000175606 TMEM70 -3.0226 -2.36155 -2.05317 
63 ENSG00000141510 TP53 -2.92574 -2.75179 -3.05502 
64 ENSG00000167614 TTYH1 7.65696 1.12135 5.45784 
65 ENSG00000175063 UBE2C 2.12871 -1.42113 -1.34204 
66 ENSG00000094841 UPRT -1.83619 -1.80107 -1.43041 
67 ENSG00000187555 USP7 -1.25085 -1.02215 -0.590144 
68 ENSG00000078668 VDAC3 -1.39486 -1.32427 -0.931907 
69 ENSG00000131871 VIMP -1.94993 -2.18343 -2.37818 
70 ENSG00000006715 VPS41 1.33392 2.08283 1.65948 
71 ENSG00000177485 ZBTB33 -2.96383 -1.98007 -2.08093 
72 ENSG00000136247 ZDHHC4 -1.7767 -5.39213 -5.39945 
73 ENSG00000063587 ZNF275 -3.37473 -7.20141 -4.84547 
74 ENSG00000169955 ZNF747 -1.57295 -4.31871 -4.99307 
75 ENSG00000196453 ZNF777 -0.540089 -0.537995 -0.723374 
76 ENSG00000198556 ZNF789 3.13825 2.12525 1.68924 
77 ENSG00000197037 ZSCAN25 4.05821 2.36125 1.63658 
 
